Multi-ring fused BTK degradation agent and application thereof in medicine

By developing a multi-cyclic and circular BTK degrader with novel structure, using PROTAC molecular technology to combine ligands to achieve effective degradation of BTK, the problem of insufficient effectiveness of existing BTK inhibitors in the treatment of BTK-related diseases has been solved, and improved Treatment effects and safety.

CN119060070APending Publication Date: 2024-12-03TIBET HAISCO PHARM CO LTD
View PDF 0 Cites 4 Cited by

Patent Information

Application Number
CN202410689187.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-26
Filing Date
2024-05-30
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing BTK inhibitors are difficult to effectively degrade, resulting in poor efficacy in treating BTK-related diseases such as tumors and autoimmune diseases, and insufficient safety and bioavailability.

Method used

Develop a multi-cyclic cyclic BTK degrader with novel structure, combining specific ligands with PROTAC molecular technology to achieve effective degradation of BTK, with good pharmacopoeia and bioavailability.

Benefits of technology

This compound can effectively inhibit or degrade BTK, improve the effectiveness of treating BTK-related diseases, has high safety and good oral performance, and is suitable for the treatment of tumors and autoimmune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004867940530000011
    Figure BDA0004867940530000011
  • Figure BDA0004867940530000012
    Figure BDA0004867940530000012
  • Figure BDA0004867940530000021
    Figure BDA0004867940530000021
Patent Text Reader

Abstract

The invention relates to a polycyclic fused BTK degradation agent and application thereof in medicine, in particular to a compound shown in a general formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, pharmaceutically acceptable salt or eutectic crystal of the compound, an intermediate and a preparation method of the compound, and application of the compound in BTK related diseases such as tumors or autoimmune system diseases. And B-L-K (I).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry and provides a polycyclic BTK degrader and its application in medicine, specifically relates to a compound described by general formula (I) or its stereoisomers, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals, and intermediates and preparation methods thereof, as well as the use of the compound in BTK-related diseases such as tumors or autoimmune system diseases. Background Art

[0002] Bruton's tyrosine kinase (BTK) is a member of the Tec family of non-receptor protein tyrosine kinases and a key regulator in the B cell antigen receptor (BCR) signaling pathway, distributed in the lymphatic system, hematopoiesis and blood system. BTK mutations can cause activation of downstream tumor cell proliferation, differentiation and angiogenesis signaling pathways, leading to X-linked agammaglobulinemia, non-Hodgkin's lymphoma (NHL) and many B cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma and diffuse large B cell lymphoma. BTK is a target with good targeting and safety because it is mainly expressed in B cells and myeloid cells.

[0003] PROTAC (proteolysis targeting chimera) molecules are a class of bifunctional compounds that can simultaneously bind to target proteins and E3 ubiquitin ligases. Such compounds can be recognized by the proteasome of the cell, causing the degradation of the target protein, and can effectively reduce the content of the target protein in the cell. By introducing ligands that can bind to different target proteins into PROTAC molecules, PROTAC technology can be applied to the treatment of various diseases. This technology has also received widespread attention in recent years.

[0004] Therefore, it is necessary to develop new PROTAC drugs that are BTK inhibitors for the treatment of BTK-related tumor diseases. Summary of the invention

[0005] The object of the present invention is to provide a compound with novel structure, good efficacy, high bioavailability, greater safety, and the ability to inhibit or degrade BTK, for the treatment of BTK-related diseases such as autoimmune diseases, inflammatory diseases or cancer.

[0006] The compound of the invention has good pharmacokinetic properties and bioavailability, oral properties and good safety.

[0007] The present invention provides a compound or a stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the compound is selected from the compounds represented by general formula (I),

[0008] BLK(I);

[0009] In some embodiments, the compound represented by general formula (I) is selected from the compound represented by general formula (II),

[0010]

[0011] In some embodiments, the compound represented by general formula (I) or (II) is selected from the compound represented by general formula (III-1) or (III-2),

[0012]

[0013] In some embodiments, the compound represented by the general formula (I), (II), (III-1) or (III-2) is selected from the compound represented by the general formula (IV),

[0014]

[0015] In certain embodiments, B is selected from

[0016] In certain embodiments, B is selected from

[0017] In certain embodiments, B1 is selected from 5-6 membered heterocyclyl;

[0018] In certain embodiments, B1 is selected from 5-6 membered heteroaryl;

[0019] In certain embodiments, B1 is selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl;

[0020] In certain embodiments, L is selected from Its left side is connected to B and its right side is connected to K;

[0021] In certain embodiments, B4 is selected from C 3-8 A monocyclic group, an 8-10-membered bicyclic group, or a 12-15-membered tricyclic group;

[0022] In certain embodiments, B4 is selected from phenyl, 5-6 membered heteroaryl, benzo 5-membered heterocyclic group, benzo 6-membered heterocyclic group, pyrido 5-membered heterocyclic group, pyrido 6-membered heterocyclic group, Selected from aromatic or non-aromatic rings;

[0023] In certain embodiments, B4 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,

[0024] In certain embodiments, Selected from Selected from Selected from Selected from

[0025] In certain embodiments, Selected from

[0026] In certain embodiments, W is selected from 5-6 membered heterocyclyl;

[0027] In certain embodiments, Z2 is selected from CH2, CH, NH or N;

[0028] In certain embodiments, Z2 is selected from CH or N;

[0029] In certain embodiments, K1 is selected from C 3-8 A monocyclic group, an 8-10-membered bicyclic group, or a 12-15-membered tricyclic group;

[0030] In certain embodiments, K1 is selected from phenyl, 5-6 membered heteroaryl, Benzo 5-membered heterocyclic group, benzo 6-membered heterocyclic group;

[0031] In certain embodiments, K1 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,

[0032] In certain embodiments, Selected from Selected from Selected from Selected from

[0033] In certain embodiments, Selected from

[0034] In certain embodiments, Z3 is selected from CH2, CH, NH or N;

[0035] In certain embodiments, Z3 is selected from CH or N;

[0036] In certain embodiments, L1 is selected from -Ak1-, -Cy1-, -Cy1-Ak1-, -Ak1-Cy1-, -Cy1-Ak1-Cy2-, -Cy1-Cy2-Ak1-, -Ak1-Cy1-Cy2-, -Cy1-Ak1-Cy2-, -Cy1-Ak1-Cy2-Ak2-, -Ak1-Cy1-Ak2-Cy2-;

[0037] In certain embodiments, L1 is selected from

[0038] In certain embodiments, Selected from

[0039] In certain embodiments, Ak1 and Ak2 are each independently selected from a bond, C 1-8 Alkylene, C 2-8 Alkenylene, C 2-8 Alkynylidene, O, NR L NR L CO, CO, C≡C, the alkylene, alkenylene, alkynylene are optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0040] In certain embodiments, Ak1 and Ak2 are each independently selected from C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, O, NR L NR L CO, CO, wherein the alkylene, alkenylene, alkynylene is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0041] In certain embodiments, Ak1 and Ak2 are each independently selected from C 1-4 Alkylene, C 2-4 Alkenylene, C 2-4 Alkynylidene, O, NR L NR L CO, CO, wherein the alkylene, alkenylene, alkynylene is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0042] In certain embodiments, Ak1 and Ak2 are each independently selected from methylene, ethylene, vinylene, and ethynylene, wherein the methylene, ethylene, vinylene, and ethynylene are optionally substituted by 1 to 4 selected from deuterium, F, Cl, Br, I, OH, NH2, COOH, CN, =O, 1 to 4 selected from deuterium, F, Cl, Br, I, OH, NH2, COOH, CN, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0043] In certain embodiments, Ak1 and Ak2 are each independently selected from methylene and ethylene;

[0044] In certain embodiments, R L Select from H or C 1-6 alkyl;

[0045] In certain embodiments, R L Select from H or C 1-4 alkyl;

[0046] In certain embodiments, R L is selected from H, methyl or ethyl;

[0047] In certain embodiments, Cy1 and Cy2 are each independently selected from a bond, a 3-7 membered monocyclic heterocyclic group, a 4-12 membered cyclic heterocyclic group, a 5-12 membered spirocyclic heterocyclic group, a 5-12 membered bridged heterocyclic group, a C 3-7, 4-12-membered monocyclic carbocyclic group, 4-12-membered cyclic carbocyclic group, 5-12-membered spirocyclic carbocyclic group, 5-12-membered bridged carbocyclic group, 5-12-membered heteroaryl group or 6-10-membered aryl group, wherein the aryl, heteroaryl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CONH2, CN, NH2, =O, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0048] In certain embodiments, Cy1 and Cy2 are each independently selected from a 3-6 membered monocyclic heterocyclic group, a 4-10 membered cyclic heterocyclic group, a 5-11 membered spirocyclic heterocyclic group, a 5-10 membered bridged heterocyclic group, a C 3-6 4-10 membered monocyclic carbocyclic group, 4-10 membered cyclic carbocyclic group, 5-11 membered spirocyclic carbocyclic group, 5-10 membered bridged carbocyclic group, 5-10 membered heteroaryl group or 6-10 membered aryl group, wherein the aryl, heteroaryl, carbocyclic group or heterocyclic group is selected from 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CONH2, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0049] In certain embodiments, Cy1 and Cy2 are each independently selected from one of the following substituted or unsubstituted groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, phenyl, cyclopropyl-cyclopropyl, cyclopropyl-cyclobutyl, cyclopropyl-cyclopentyl, cyclopropyl-cyclohexyl, cyclobutyl-cyclobutyl, cyclobutyl-cyclopentyl, cyclobutyl-cyclohexyl, cyclopentyl-cyclopentyl, cyclopentyl-cyclohexyl , cyclohexyl and cyclohexyl, cyclopropyl spirocyclopropyl, cyclopropyl spirocyclobutyl, cyclopropyl spirocyclopentyl, cyclopropyl spirocyclohexyl, cyclobutyl spirocyclobutyl, cyclobutyl spirocyclopentyl, cyclobutyl spirocyclohexyl, cyclopentyl spirocyclopentyl, cyclopentyl spirocyclohexyl, cyclohexyl spirocyclohexyl, cyclopropyl and azetidinyl, cyclopropyl and pyrrolidinyl, cyclopropyl and piperidinyl, cyclobutyl and azetidinyl, cyclobutyl and pyrrolidinyl, cyclobutyl and piperidinyl, cyclopentyl and azetidinyl, Cyclopentylpyrrolidinyl, cyclopentylpiperidinyl, cyclohexylazetidinyl, cyclohexylpyrrolidinyl, cyclohexylpiperidinyl, azetidinazetidinyl, azetidinpyrrolidinyl, azetidinpiperidinyl, pyrrolidinazetidinyl, pyrrolidinpyrrolidinyl, pyrrolidinpiperidinyl, piperidinylazetidinyl, piperidinylpyrrolidinyl, piperidinylpiperidinyl, cyclobutylspiroazetidinyl, cyclobutylspiropyrrolidinyl , cyclobutyl spiropiperidinyl, cyclopentyl spiroazetidinyl, cyclopentyl spiropyrrolidinyl, cyclopentyl spiropiperidinyl, cyclohexyl spiroazetidinyl, cyclohexyl spiropyrrolidinyl, cyclohexyl spiropiperidinyl, azetidinyl spiroazetidinyl, azetidinyl spiropyrrolidinyl, azetidinyl spiropiperidinyl, pyrrolidinyl spiroazetidinyl, pyrrolidinyl spiropyrrolidinyl, pyrrolidinyl spiropiperidinyl, piperidinyl spiroazetidinyl, piperidinyl spiropyrrolidinyl, piperidinyl spiropiperidinyl, When substituted, it is optionally replaced by 1 to 4 moieties selected from deuterium, F, Cl, Br, I, OH, NH2, COOH, CONH2, CN, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0050] In certain embodiments, Cy1 and Cy2 are each independently selected from one of the following substituted or unsubstituted groups: When substituted, it is optionally replaced by 1 to 4 deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0051] In certain embodiments, Cy1 and Cy2 are each independently selected from one of the following substituted or unsubstituted groups: When substituted, it is optionally substituted with 1 to 4 deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, CF3, CHF2, CH2F, methyl, ethyl, methoxy, ethoxy, cyclopropyl;

[0052] In certain embodiments, R b1 , R b2 , R b3 , R b4 , R k1 , R k2 , R k3 , R bL , R q Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 4-6 membered carbocyclic group, 4-6 membered heterocyclic group, -OC 3-7 The alkyl and alkoxy, heterocyclic group, and carbocyclic group are optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0053] In certain embodiments, R b1 , R b2 , R b3 , R b4 , R k1 , R k2 , R k3 , R bL , R q Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 4-6 membered carbocyclic group, 4-6 membered heterocyclic group, -OC 3-6The alkyl and alkoxy, heterocyclic group, and carbocyclic group are optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0054] In certain embodiments, R b1 , R b2 , R b3 , R b4 , R k1 , R k2 , R k3 , R bL , R q each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl, cyclobutyl, phenyl, azetidinyl, oxetanyl, pyrrolidinyl, pyrrolyl, pyrazolyl, pyridinyl, -O-cyclopropyl, -O-cyclobutyl, -O-cyclopentyl, -O-cyclohexyl, -O-phenyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl, cyclobutyl, phenyl, azetidinyl, oxetanyl, pyrrolidinyl, pyrrolyl, pyrazolyl, pyridinyl is optionally substituted by 1 to 4 selected from deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0055] In certain embodiments, R b1 , R b2 , R b3 , R b4 , R k1 , R k2 Each is independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl;

[0056] In certain embodiments, R k3 Each is independently selected from H, deuterium, and methyl;

[0057] In certain embodiments, Rq or R bL Each is independently selected from H, deuterium, and methyl;

[0058] In certain embodiments, L is selected from one of the fragments shown in Table A;

[0059] Table A

[0060]

[0061]

[0062]

[0063]

[0064]

[0065] In certain embodiments, L is selected from one of the fragments shown in Table A or one of the stereoisomers of the fragments shown in Table A;

[0066] In certain embodiments, K is selected from

[0067] In certain embodiments, K is selected from

[0068] In certain embodiments, Selected from Selected from Selected from

[0069] In certain embodiments, Q is selected from NR q CO、CONR q 、CO、NR q or key;

[0070] In certain embodiments, Q is selected from NR q CO、CONR q NR q or key;

[0071] In certain embodiments, Q is selected from CONH, NHCO, NH, or a bond;

[0072] In certain embodiments, Z1 is selected from N or CR k2 ;

[0073] In certain embodiments, Z1 is selected from N or CH;

[0074] In certain embodiments, b1, b4 are each independently selected from 0, 1, 2, 3, 4, 5 or 6;

[0075] In certain embodiments, b1, b4 are each independently selected from 0, 1, 2, 3 or 4;

[0076] In certain embodiments, b1, b4 are each independently selected from 0, 1, 2 or 3;

[0077] In certain embodiments, b2 is each independently selected from 0, 1, 2, 3 or 4;

[0078] In certain embodiments, b2 is each independently selected from 0, 1, 2 or 3;

[0079] In certain embodiments, b2 is each independently selected from 0, 1 or 2;

[0080] In certain embodiments, b3 is each independently selected from 0, 1 or 2;

[0081] In certain embodiments, b3 is each independently selected from 0 or 1;

[0082] In certain embodiments, p1 or p2 are each independently selected from 0, 1, 2, 3 or 4;

[0083] In certain embodiments, p1 or p2 are each independently selected from 0, 1, 2 or 3;

[0084] In certain embodiments, R w Selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 4-membered carbocyclic group, 4-6-membered heterocyclic group;

[0085] In certain embodiments, R w Selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, CF3, methyl, ethyl, methoxy, ethoxy, cyclopropyl;

[0086] In certain embodiments, w is selected from 0, 1 or 2;

[0087] In certain embodiments, s is selected from 0 or 1;

[0088] Optionally,

[0089] When K1 is selected from phenyl, pyridyl, benzopyrrolidinyl, B4 is selected from 8-10 membered bicyclic cycloalkyl or 12-15 membered tricyclic cycloalkyl;

[0090] Alternatively, when B4 is selected from phenyl, pyridyl, pyrazolyl, thiazolyl, K1 is selected from 12-15 membered tricyclic annular groups.

[0091] As a first embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0092] B is selected from

[0093] L is selected from Its left side is connected to B and its right side is connected to K;

[0094] K is selected from

[0095] Q is selected from NR q CO、CONR q 、CO、NR q or key;

[0096] B1 is selected from a 5-6 membered heterocyclic group;

[0097] B4 is selected from C 3-8 A monocyclic group, an 8-10-membered bicyclic group, or a 12-15-membered tricyclic group;

[0098] L1 is selected from the group consisting of -Ak1-, -Cy1-, -Cy1-Ak1-, -Ak1-Cy1-, -Cy1-Ak1-Cy2-, -Cy1-Cy2-Ak1-, -Ak1-Cy1-Cy2-, -Cy1-Ak1-Cy2-Ak2-, -Ak1-Cy1-Ak2-Cy2-;

[0099] K1 is selected from C 3-8 A monocyclic group, an 8-10-membered bicyclic group, or a 12-15-membered tricyclic group;

[0100] Z1 is selected from N or CR k2 ;

[0101] Ak1, Ak2 are each independently selected from a bond, C 1-8 Alkylene, C 2-8 Alkenylene, C 2-8 Alkynylidene, O, NR L NR L CO, CO, C≡C, the alkylene, alkenylene, alkynylene are optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, C 1-6Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0102] R L Select from H or C 1-6 alkyl;

[0103] Cy1 and Cy2 are each independently selected from a bond, a 3-7 membered monocyclic heterocyclic group, a 4-12 membered cyclic heterocyclic group, a 5-12 membered spirocyclic heterocyclic group, a 5-12 membered bridged heterocyclic group, a C 3-7 , 4-12-membered monocyclic carbocyclic group, 4-12-membered cyclic carbocyclic group, 5-12-membered spirocyclic carbocyclic group, 5-12-membered bridged carbocyclic group, 5-12-membered heteroaryl group or 6-10-membered aryl group, wherein the aryl, heteroaryl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CONH2, CN, NH2, =O, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0104] R b1 , R b2 , R b3 , R b4 , R k1 , R k2 , R k3 , R bL , R q Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 4-6 membered carbocyclic group, 4-6 membered heterocyclic group, -OC 3-7 The alkyl and alkoxy, heterocyclic group, and carbocyclic group are optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0105] b1 and b4 are each independently selected from 0, 1, 2, 3, 4, 5 or 6;

[0106] b2 are each independently selected from 0, 1, 2, 3 or 4;

[0107] b3 are each independently selected from 0, 1 or 2;

[0108] p1 or p2 are each independently selected from 0, 1, 2, 3 or 4;

[0109] The condition is,

[0110] When K1 is selected from phenyl, pyridyl, benzopyrrolidinyl, B4 is selected from 8-10 membered bicyclic cycloalkyl or 12-15 membered tricyclic cycloalkyl;

[0111] Alternatively, when B4 is selected from phenyl, pyridyl, pyrazolyl, thiazolyl, K1 is selected from 12-15 membered tricyclic annular groups.

[0112] As a second embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0113] B1 is selected from 5-6 membered heteroaryl;

[0114] B4 is selected from phenyl, 5-6 membered heteroaryl, Benzo 5-membered heterocyclic group, benzo 6-membered heterocyclic group, pyrido 5-membered heterocyclic group, pyrido 6-membered heterocyclic group;

[0115] Selected from aromatic or non-aromatic rings;

[0116] W is selected from a 5-6 membered heterocyclic group;

[0117] Z2 is selected from CH2, CH, NH or N;

[0118] K1 is selected from phenyl, 5-6 membered heteroaryl, Benzo 5-membered heterocyclic group, benzo 6-membered heterocyclic group;

[0119] Z3 is selected from CH2, CH, NH or N;

[0120] Ak1 and Ak2 are each independently selected from C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, O, NR L NR L CO, CO, wherein the alkylene, alkenylene, alkynylene is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0121] R L Select from H or C 1-4 alkyl;

[0122] Cy1 and Cy2 are each independently selected from a 3-6 membered monocyclic heterocyclic group, a 4-10 membered cyclic heterocyclic group, a 5-11 membered spirocyclic heterocyclic group, a 5-10 membered bridged heterocyclic group, a C 3-6 4-10 membered monocyclic carbocyclic group, 4-10 membered cyclic carbocyclic group, 5-11 membered spirocyclic carbocyclic group, 5-10 membered bridged carbocyclic group, 5-10 membered heteroaryl group or 6-10 membered aryl group, wherein the aryl, heteroaryl, carbocyclic group or heterocyclic group is selected from 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CONH2, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0123] R b1 , R b2 , R b3 , R b4 , R k1 , R k2 , R k3 , R bL , R q Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 4-6 membered carbocyclic group, 4-6 membered heterocyclic group, -OC 3-6 The alkyl and alkoxy, heterocyclic group, and carbocyclic group are optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0124] The remaining definitions are the same as those of the first embodiment of the present invention.

[0125] As a third embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0126] Ak1 and Ak2 are each independently selected from C 1-4Alkylene, C 2-4 Alkenylene, C 2-4 Alkynylidene, O, NR L NR L CO, CO, wherein the alkylene, alkenylene, alkynylene is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0127] R L is selected from H, methyl or ethyl;

[0128] Cy1 and Cy2 are each independently selected from one of the following substituted or unsubstituted groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, phenyl, cyclopropyl-cyclopropyl, cyclopropyl-cyclobutyl, cyclopropyl-cyclopentyl, cyclopropyl-cyclohexyl, cyclobutyl-cyclobutyl, cyclobutyl-cyclopentyl, cyclobutyl-cyclohexyl, cyclopentyl-cyclopentyl, cyclopentyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclopentyl, cyclopentyl-cyclopentyl, cyclopentyl-cyclohexyl, cyclohex ...hexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohex cyclohexyl, cyclobutylspirocyclobutyl, cyclopropylspirocyclopentyl, cyclopropylspirocyclohexyl, cyclobutylspirocyclobutyl, cyclobutylspirocyclopentyl, cyclobutylspirocyclohexyl, cyclopentylspirocyclopentyl, cyclopentylspirocyclohexyl, cyclohexylspirocyclohexyl, cyclopropylazetidinyl, cyclopropylpyrrolidinyl, cyclopropylpiperidinyl, cyclobutylazetidinyl, cyclobutylpyrrolidinyl, cyclobutylpiperidinyl, cyclopentylazetidinyl, cyclopentyl ...propylazetidinyl, cyclopentylspirocyclohexyl, cyclopropylazetidinyl, cyclopropylpyrrolidinyl, cyclobutylpiperidinyl, cyclopentylazetidinyl, cyclopentylspirocyclohexyl, cyclopropylazetidinyl, cyclopropylpyrrolidinyl, cyclobutylpiperidinyl, cyclopentylazetidinyl, cyclopentylspirocyclohexyl, cyclopropylazetidinyl, cyclopropylpyrrolidinyl, cyclopropylpiperidinyl, cyclopropylspirocyclopentyl, cyclopentylspirocyclohexyl, cyclopropyl pyrrolidinyl, cyclopentylpiperidinyl, cyclohexylazetidinyl, cyclohexylpyrrolidinyl, cyclohexylpiperidinyl, azetidinylazetidinyl, azetidinylpyrrolidinyl, azetidinylpiperidinyl, pyrrolidinylazetidinyl, pyrrolidinylpyrrolidinyl, pyrrolidinylpiperidinyl, piperidinylazetidinyl, piperidinylpyrrolidinyl, piperidinylpiperidinyl, cyclobutylspiroazetidinyl, cyclobutylspiropyrrolidinyl, cyclo butylspiropiperidinyl, cyclopentylspiroazetidinyl, cyclopentylspiropyrrolidinyl, cyclopentylspiropiperidinyl, cyclohexylspiroazetidinyl, cyclohexylspiropyrrolidinyl, cyclohexylspiropiperidinyl, azetidinylspiroazetidinyl, azetidinylspiropyrrolidinyl, azetidinylspiropiperidinyl, pyrrolidinylspiroazetidinyl, pyrrolidinylspiropyrrolidinyl, pyrrolidinylspiropiperidinyl, piperidinylspiroazetidinyl, piperidinylspiropyrrolidinyl, piperidinylspiropiperidinyl, When substituted, it is optionally replaced by 1 to 4 atoms selected from deuterium, F, Cl, Br, I, OH, NH2, CONH2, COOH, CN, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0129] The remaining definitions are the same as those of the first or second embodiment of the present invention.

[0130] As a fourth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0131] B1 is selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl;

[0132] B4 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,

[0133] K1 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,

[0134] Ak1 and Ak2 are each independently selected from methylene, ethylene, vinylene, and ethynylene, wherein the methylene, ethylene, vinylene, and ethynylene are optionally substituted by 1 to 4 selected from deuterium, F, Cl, Br, I, OH, NH2, COOH, CN, =O, 1 to 4 selected from deuterium, F, Cl, Br, I, OH, NH2, COOH, CN, =O, 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0135] Cy1 and Cy2 are each independently selected from one of the following substituted or unsubstituted groups: When substituted, it is optionally replaced by 1 to 4 deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0136] R b1 , R b2 , R b3 , R b4 , R k1 , R k2 , R k3 , R bL , R q each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl, cyclobutyl, phenyl, azetidinyl, oxetanyl, pyrrolidinyl, pyrrolyl, pyrazolyl, pyridinyl, -O-cyclopropyl, -O-cyclobutyl, -O-cyclopentyl, -O-cyclohexyl, -O-phenyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl, cyclobutyl, phenyl, azetidinyl, oxetanyl, pyrrolidinyl, pyrrolyl, pyrazolyl, pyridinyl is optionally substituted by 1 to 4 selected from deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group;

[0137] The remaining definitions are the same as those of the first, second or third embodiment of the present invention.

[0138] As a fifth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0139] L1 is selected from

[0140] Q is selected from NR q CO、CONR q NR q or key;

[0141] Rb1 , R b2 , R b3 , R b4 , R k1 , R k2 Each is independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl;

[0142] R k3 Each is independently selected from H, deuterium, and methyl;

[0143] R q or R bL Each is independently selected from H, deuterium, and methyl;

[0144] The remaining definitions are the same as those of the first, second, third or fourth embodiment of the present invention.

[0145] As a sixth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0146] B is selected from

[0147] L is selected from one of the fragments shown in Table A;

[0148] K is selected from

[0149] As a seventh embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein:

[0150] B is selected from

[0151] L is selected from one of the fragments shown in Table A;

[0152] K is selected from

[0153] As an eighth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or (II) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from the general formula (III-1) or (III-2),

[0154]

[0155] B1, B4, K1, Z1, L1, Q, R b1 , R b2 , R b3 , R b4 , R k1 , R k2 , R bL , b1, b2, b3, b4, p1 or p2 are defined the same as in any one of the first to sixth embodiments of the present invention.

[0156] As a ninth embodiment of the present invention, the compound represented by the aforementioned general formula (III-1) or (III-2) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein:

[0157] B1 is selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl;

[0158] B4 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,

[0159]

[0160] K1 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,

[0161] Z1 is selected from N or CH;

[0162] L1 is selected from

[0163] Q is selected from CONH, NHCO, NH or a bond;

[0164] R b1 , R b2 , R b3 , R b4 , R k1 , R k2Each is independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl;

[0165] R bL Each is independently selected from H, deuterium, and methyl;

[0166] b1, b4 are each independently selected from 0, 1, 2 or 3;

[0167] b2 are each independently selected from 0, 1, 2 or 3;

[0168] b3 are each independently selected from 0, 1 or 2;

[0169] p1 and p2 are each independently selected from 0, 1, 2 or 3.

[0170] As a tenth embodiment of the present invention, the compound represented by the aforementioned general formula (I), (II), (III-1) or (III-2) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, the compound represented by the general formula (I), (II), (III-1) or (III-2) is selected from the compound represented by the general formula (IV), wherein,

[0171]

[0172] R w Selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 4-membered carbocyclic group, 4-6-membered heterocyclic group;

[0173] w is selected from 0, 1 or 2;

[0174] s is selected from 0 or 1;

[0175] The remaining definitions are the same as in any one of the first to fifth embodiments of the present invention.

[0176] As the eleventh embodiment of the present invention, the compound represented by the aforementioned general formula (V) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0177] B1 is selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl;

[0178] R b1 , R b2 , R b3 , R b4 Each is independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl;

[0179] R bL Each is independently selected from H, deuterium, and methyl;

[0180] R w Selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, CF3, methyl, ethyl, methoxy, ethoxy, cyclopropyl;

[0181] w is selected from 0, 1 or 2;

[0182] s is selected from 0 or 1;

[0183] b1, b4 are each independently selected from 0, 1 or 2;

[0184] b2 are each independently selected from 0, 1 or 2;

[0185] b3 are each independently selected from 0, 1 or 2;

[0186] p1 is independently selected from 0, 1 or 2.

[0187] The present invention relates to the following compound or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from the structures shown in Table E-1.

[0188] The present invention relates to a pharmaceutical composition, comprising the above compound or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, and a pharmaceutically acceptable carrier.

[0189] The present invention relates to the use of the above-mentioned compound or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal or the above-mentioned pharmaceutical composition in preparing a drug for inhibiting or degrading BTK.

[0190] The present invention relates to the use of the above-mentioned compound or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals or the above-mentioned pharmaceutical compositions for preparing drugs for treating tumors or autoimmune diseases, wherein the tumor is preferably a relapsed or refractory B-cell malignant tumor.

[0191] The present invention relates to a pharmaceutical composition or pharmaceutical preparation, which comprises a therapeutically effective amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal and a pharmaceutical excipient. The pharmaceutical composition can be in the form of a unit preparation (the amount of the main drug in the unit preparation is also referred to as "preparation specification").

[0192] The present invention also provides a method for treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal or pharmaceutical composition. In some embodiments, the mammal of the present invention includes a human.

[0193] "Effective amount" or "therapeutically effective amount" as used herein refers to administering a sufficient amount of a compound disclosed herein that will alleviate one or more symptoms of the disease or condition (e.g., cancer or autoimmune disease) being treated to some extent. In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired changes in a biological system. For example, an "effective amount" for therapeutic use is the amount of a compound disclosed herein required to provide a clinically significant reduction in disease symptoms.Examples of therapeutically effective amounts include, but are not limited to, 1-1500 mg, 1-1000 mg, 1-800 mg, 1-600 mg, 2-600 mg, 3-600 mg, 4-600 mg, 5-600 mg, 6-600 mg, 10-600 mg, 20-600 mg, 25-600 mg, 30-600 mg, 40-600 mg, 50-600 mg, 60-600 mg, 70-600 mg, 75-600 mg, 80-600 mg, 90-600 mg, 100-600 mg, 200-600 mg, 1-500 mg, 2-500 mg, 3-500 mg g, 4-500mg, 5-500mg, 6-500mg, 10-500mg, 20-500mg, 25-500mg, 30-500mg, 40-500mg, 50-500mg, 60-500mg, 70-500mg, 75-500mg, 80-500mg , 90-500mg, 100-500mg, 125-500mg, 150-500mg, 200-500mg, 250-500mg, 300-500mg, 400-500mg, 5-400mg, 10-400mg, 20-400mg, 25-400mg, 30-400mg, 40-400mg, 50-400mg, 60-400mg, 70-400mg, 75-400mg, 80-400mg, 90-400mg, 100-400mg, 125-400mg, 150-400mg, 200-400mg, 25 0-400mg, 300-400mg, 1-300mg, 2-300mg, 5-300mg, 10-300mg, 20-300mg, 25-300mg, 30-300mg, 40-300mg, 50-300mg, 60-300mg, 70-300mg, 7 5-300mg, 80-300mg, 90-300mg, 100-300mg, 125-300mg, 150-300mg, 200-300mg, 250-300mg, 1-200mg, 2-200mg, 5-200mg, 10-200mg, 20-200 mg, 25-200mg, 30-200mg, 40-200mg, 50-200mg, 60-200mg, 70-200mg, 75-200mg, 80-200mg, 90-200mg, 100-200mg, 125-200mg, 150-200mg;.

[0194] In some embodiments, the pharmaceutical composition includes but is not limited to 1-1500 mg, 1-1000 mg, 1-800 mg, 1-600 mg, 20-400 mg, 25-200 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg g, 95 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 300 mg of a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.

[0195] A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, the therapeutically effective amount preferably being 1-1500 mg, and the disease preferably being a tumor or an autoimmune disease.

[0196] A method for treating a disease in a mammal, the method comprising administering to a subject a drug compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof at a daily dose of 1-1500 mg / day, the daily dose may be a single dose or divided doses, in some embodiments, the daily dose includes but is not limited to 10-1500 mg / day, 10-1000 mg / day, 10-800 mg / day, 25-800 mg / day, 50-800 mg / day, In some embodiments, the daily dose includes but is not limited to 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 200 mg / day, 400 mg / day, 600 mg / day, 800 mg / day.

[0197] The present invention relates to a kit, which may include a composition in a single-dose or multi-dose form, and the kit contains a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and the amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal is the same as its amount in the above-mentioned pharmaceutical composition.

[0198] The amount of the compound of the invention or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal in the present invention is in each case calculated as the free base.

[0199] "Preparation specifications" refers to the weight of the main drug contained in each vial, tablet or other unit preparation.

[0200] The compounds of the present invention can be prepared by the following method:

[0201] General synthesis method 1:

[0202]

[0203] The compound of the general formula (M-1) and the compound of the general formula (M-2) are subjected to coupling reaction to obtain the compound of the general formula (M-3);

[0204] The compound of the general formula (M-3) is oxidized to obtain the compound of the general formula (M-4);

[0205] The general formula compound (M-4) and the general formula compound (M-5) are subjected to a reductive amination reaction to obtain the general formula compound (M-6);

[0206] The compound of the general formula (M-5) and the compound of the general formula (M-7) are coupled to obtain the compound of the general formula (M);

[0207] The remaining groups have the same definitions as in the specification and claims.

[0208] Unless stated otherwise, the terms used in this specification and claims have the following meanings.

[0209] The carbon, hydrogen, oxygen, sulfur, nitrogen or F, Cl, Br, I involved in the groups and compounds of the present invention include their isotopes, and the carbon, hydrogen, oxygen, sulfur or nitrogen involved in the groups and compounds of the present invention are optionally replaced by one or more of their corresponding isotopes, wherein the carbon isotopes include 12 C. 13 C and 14 C, hydrogen isotopes include protium (H), deuterium (D, also called heavy hydrogen), tritium (T, also called super tritium), oxygen isotopes include 16 O.17 O and 18 O, sulfur isotopes include 32 S. 33 S. 34 S and 36 S, isotopes of nitrogen include 14 N and 15 N, fluorine isotopes include 17 F and 19 F, chlorine isotopes include 35 Cl and 37 Isotopes of Cl and bromine include 79 Br and 81 Br.

[0210] "Halogen" refers to F, Cl, Br or I.

[0211] "Halogen substituted" refers to substitution with F, Cl, Br or I, including but not limited to substitution with 1 to 10 substituents selected from F, Cl, Br or I, substitution with 1 to 6 substituents selected from F, Cl, Br or I, preferably substitution with 1 to 4 substituents selected from F, Cl, Br or I. "Halogen substituted" is abbreviated as "halo".

[0212] "Alkyl" refers to a substituted or unsubstituted straight or branched chain saturated aliphatic hydrocarbon group, including but not limited to alkyl groups of 1 to 20 carbon atoms, alkyl groups of 1 to 8 carbon atoms, alkyl groups of 1 to 6 carbon atoms, and alkyl groups of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched chain isomers thereof; the alkyl groups appearing in this article are defined in accordance with this definition. Alkyl groups can be monovalent, divalent, trivalent, or tetravalent.

[0213] "Alkylene" refers to substituted or unsubstituted straight-chain or branched divalent saturated hydrocarbon groups, including -(CH2) v -(v is an integer from 1 to 10), examples of alkylene include but are not limited to methylene, ethylene, propylene and butylene.

[0214] "Cycloalkyl" refers to a substituted or unsubstituted saturated carbocyclic hydrocarbon radical, typically having 3 to 10 carbon atoms, non-limiting examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Cycloalkyl groups appearing herein are defined as above. Cycloalkyl groups may be monovalent, divalent, trivalent or tetravalent.

[0215] "Heterocycloalkyl" refers to a substituted or unsubstituted saturated cyclic hydrocarbon containing heteroatoms, including but not limited to 3 to 10 atoms, 3 to 8 atoms, including 1 to 3 heteroatoms selected from N, O or S, and the selectively substituted N and S in the ring of heterocycloalkyl can be oxidized to various oxidation states. Heterocycloalkyl can be connected to a heteroatom or a carbon atom, and heterocycloalkyl can be connected to an aromatic ring or a non-aromatic ring. Heterocycloalkyl can be connected to a bridge ring or a spiro ring, and non-limiting examples include oxirane, aziridine, oxadiazine, azetidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolane, dioxane, pyrrolidinyl, piperidinyl, imidazolidinyl, oxazolidinyl, oxazolidinyl, morpholinyl, hexahydropyrimidinyl, piperazinyl. Heterocycloalkyl can be monovalent, divalent, trivalent or tetravalent.

[0216] "Alkenyl" refers to a substituted or unsubstituted straight chain or branched unsaturated hydrocarbon group having at least one, typically one, two or three carbon-carbon double bonds, with a backbone of 2 to 10, 2 to 6 or 2 to 4 carbon atoms, examples of alkenyl groups include but are not limited to vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 2- Methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene and 1,4-hexadiene, etc.; the alkenyl groups appearing in this article have the same definition as this definition. The alkenyl group can be monovalent, divalent, trivalent or tetravalent.

[0217] "Alkynyl" refers to substituted or unsubstituted straight and branched unsaturated hydrocarbon groups having at least one, typically one, two or three carbon-carbon triple bonds, with a backbone comprising 2 to 10 carbon atoms, including but not limited to 2 to 6 carbon atoms in the backbone, 2 to 4 carbon atoms in the backbone, examples of alkynyl groups include but are not limited to ethynyl, propargyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 5-pentynyl, 6-pentynyl, 7-pentynyl, 8-pentynyl, 9-pentynyl, 10-pentynyl, 11-pentynyl, 12-pentynyl, 13-pentynyl, 14-pentynyl, 15-pentynyl, 16-pentynyl, 17-pentynyl, 18-pentynyl, 19-pentynyl, 20-pentynyl, 21-pentynyl, 22-pentynyl, 23-pentynyl, 24-pentynyl, 25-pentynyl, 26-pentynyl, 27-pentynyl, 28-pentynyl, 29-pentynyl, 30-pentynyl, 31-pentynyl, 32-pentynyl, 33-pentynyl, 34-pentynyl, 35-pentynyl, 36-pentynyl, 37-pentynyl, 38-pentynyl, 39-pentynyl, 40-pentynyl, 41-pentynyl, 42-pentynyl, 43-pentynyl, 44-pentynyl, 45-pentynyl, 46-pentynyl, 47-pentynyl, 48-pentynyl 1-methyl-1-butynyl, 2-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-1-pentynyl, 2-methyl-1-pentynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 1-octynyl, 3-octynyl, 1-nonynyl, 3-nonynyl, 1-decynyl, 4-decynyl and the like; the alkynyl group may be monovalent, divalent, trivalent or tetravalent.

[0218] The "propynyl group" means 1-propynyl group and 2-propynyl group.

[0219] "Alkoxy" refers to substituted or unsubstituted -O-alkyl. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropyloxy, and cyclobutyloxy.

[0220] "Carbocyclyl" or "carbocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8-membered monocyclic ring, a 4-12-membered bicyclic ring, or a 10-15-membered tricyclic ring system, and the carbocyclyl can be attached to the aromatic or non-aromatic ring, which can be a monocyclic ring, a bridged ring, or a spirocyclic ring. Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl, benzene ring, naphthalene ring, "Carbocyclyl" or "carbocycle" can be monovalent, divalent, trivalent or tetravalent.

[0221] "Heterocyclyl" or "heterocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8 membered monocyclic ring, a 4-12 membered bicyclic ring or a 10-15 membered tricyclic ring system, and contains 1 or more (including but not limited to 2, 3, 4 or 5) heteroatoms selected from N, O or S. The N and S selectively substituted in the heterocyclyl ring can be oxidized to various oxidation states. The heterocyclic group may be connected to a heteroatom or a carbon atom, may be connected to an aromatic ring or a non-aromatic ring, may be connected to a bridged ring or a spiro ring, and non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxhexacyclyl, azepanyl, pyridyl, furanyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, dihydrofuranyl, dihydropyranyl, dithiolanyl, tetrahydrofuranyl, py ... furanyl, tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl, benzimidazolyl, benzopyridinyl, pyrrolopyridinyl, benzodihydrofuranyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyrazinyl, indazolyl, benzothiophenyl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzopyridinyl, benzopyrimidinyl, benzopyrazinyl, piperazinyl, azabicyclo[3.2.1]octyl, azabicyclo[5.2.0]nonanyl, oxatricyclo[5.3.1.1]dodecyl, azaadamantyl, oxaspiro[3.3]heptanyl, "Heterocyclyl" or "heterocycle" may be monovalent, divalent, trivalent or tetravalent.

[0222] "Spirocycle" or "spirocyclyl" refers to a polycyclic group in which substituted or unsubstituted monocyclic rings share one atom (called spiro atom), and the number of ring atoms in the spirocycle system includes but is not limited to 5 to 20, 6 to 14, 6 to 12, 6 to 10, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds, and optionally may contain 1 to 5 selected from N, O or S (=O) n of heteroatoms.

[0223]

[0224] "Spirocycle" or "spirocyclyl" can be monovalent, divalent, trivalent or tetravalent.

[0225] "Parallel ring" or "parallel ring group" refers to a polycyclic group in which each ring in the system shares a pair of adjacent atoms with other rings in the system, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds and may be substituted or unsubstituted, and each ring in the parallel ring system may contain 0 to 5 heteroatoms or groups containing heteroatoms (including but not limited to selected from N, S(=O) n or O, n is 0, 1 or 2). The number of ring atoms in the ring system includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12, 5 to 10. Non-limiting examples include:

[0226]

[0227] "Bicyclic" or "bicyclic group" can be monovalent, divalent, trivalent or tetravalent.

[0228] "Bridged ring" or "bridged ring group" refers to a substituted or unsubstituted polycyclic group containing two atoms that are not directly connected to any two rings, which may contain 0 or more double bonds, and any ring in the bridged ring system may contain 0 to 5 groups selected from heteroatoms or heteroatom-containing groups (including but not limited to N, S(=O)n or O, where n is 0, 1, 2). The number of ring atoms includes but is not limited to 5 to 20, 5 to 14, 5 to 12 or 5 to 10. Non-limiting examples include

[0229] Cubane, adamantane. "Bridged ring" or "bridged ring group" can be monovalent, divalent, trivalent or tetravalent.

[0230] "Carbospirocycle", "spirocarbocyclyl", "spirocarbocyclyl" or "carbospirocyclyl" refers to a "spirocycle" whose ring system consists of only carbon atoms. "Carbospirocycle", "spirocarbocyclyl", "spirocarbocyclyl" or "carbospirocyclyl" appearing in this article has the same definition as spirocycle.

[0231] "Carbocyclic ring", "cyclic carbocyclyl", "cyclic carbocyclyl" or "carbocyclic ring" refers to a "cyclic ring" whose ring system consists of only carbon atoms. "Carbocyclic ring", "cyclic carbocyclyl", "cyclic carbocyclyl" or "carbocyclic ring" appearing in this article have the same definition as cyclic ring.

[0232] "Carbobridge ring", "bridged ring carbocyclic group", "bridged carbocyclic group" or "carbon bridged cyclic group" refers to a "bridged ring" whose ring system consists of only carbon atoms. "Carbobridge ring", "bridged ring carbocyclic group", "bridged carbocyclic group" or "carbon bridged cyclic group" appearing in this article have the same definition as the bridged ring.

[0233] "Heteromonocycle", "monocyclic heterocyclyl" or "heteromonocyclic group" refers to a "heterocyclic group" or "heterocycle" of a monocyclic ring system. The heterocyclic group, "monocyclic heterocyclyl" or "heteromonocyclic group" appearing in this document has the same definition as heterocycle.

[0234] "Heterocyclic ring", "heterocyclic ring group", "cyclic heterocyclic group" or "heterocyclic group" refer to a "cyclic ring" containing a heteroatom. The heterocyclic ring, "heterocyclic ring group", "cyclic heterocyclic group" or "heterocyclic group" appearing in this document have the same definition as cyclic ring.

[0235] "Heterospirocycle", "heterospirocyclyl", "spiro heterocyclyl" or "heterospirocyclyl" refers to a "spirocycle" containing a heteroatom. Heterospirocycle, "heterospirocyclyl", "spiro heterocyclyl" or "heterospirocyclyl" appearing herein have the same definition as spirocycle.

[0236] "Heterobridged ring", "heterobridged ring group", "bridged heterocyclic group" or "heterobridged ring group" refers to a "bridged ring" containing a heteroatom. The heterobridged ring, "heterobridged ring group", "bridged heterocyclic group" or "heterobridged ring group" appearing herein have the same definition as the bridged ring.

[0237] "Aryl" or "aromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group having a single ring or a fused ring, wherein the number of ring atoms in the aromatic ring includes, but is not limited to, 6 to 18, 6 to 12, or 6 to 10 carbon atoms. The aryl ring may be fused to a saturated or unsaturated carbocyclic or heterocyclic ring, wherein the ring connected to the parent structure is the aryl ring, non-limiting examples of which include benzene ring, naphthalene ring, "Aryl" or "aromatic ring" can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the point of attachment is on the aryl ring.

[0238] "Heteroaryl" or "heteroaromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group containing 1 to 5 heteroatoms or groups containing heteroatoms (including but not limited to N, O or S(=O)n, n is 0, 1, 2), and the number of ring atoms in the heteroaromatic ring includes but is not limited to 5 to 15, 5 to 10 or 5 to 6. Non-limiting examples of heteroaryl include but are not limited to pyridyl, furanyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzopyrazole, benzimidazole, benzopyridine, pyrrolopyridine, etc. The heteroaryl ring can be fused to a saturated or unsaturated carbocyclic ring or heterocyclic ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include The heteroaryl groups appearing in this article have the same definition as in this definition. The heteroaryl group can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the attachment site is located on the heteroaryl ring.

[0239] "5-membered ring and 5-membered heteroaromatic ring" refers to a 5-membered fused heteroaromatic ring, at least one of the two rings contains one or more heteroatoms (including but not limited to O, S or N), and the whole group is aromatic. Non-limiting examples include pyrrolopyrrole ring, pyrazolopyrrole ring, pyrazolopyrazole ring, pyrrolofuran ring, pyrazolofuran ring, pyrrolothiophene ring, and pyrazolothiophene ring.

[0240] "5- and 6-membered heteroaromatic ring" refers to a 5- and 6-membered fused heteroaromatic ring, where at least one of the two fused rings contains one or more heteroatoms (including but not limited to O, S or N), and the entire group is aromatic. Non-limiting examples include benzo 5-membered heteroaromatic, 6-membered heteroaromatic ring and 5-membered heteroaromatic ring.

[0241] "Substituted" or "substituted" means substituted by one or more (including but not limited to 2, 3, 4 or 5) substituents, including but not limited to H, F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxyl, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclic, bridged, spiro, cycloalkyl, hydroxyalkyl, =O, carbonyl, aldehyde, carboxylic acid, formate, -(CH2) m -C(=O)-R a 、-O-(CH2) m -C(=O)-R a 、-(CH2) m -C(=O)-NR b R c 、-(CH2) m S(=O) n R a 、-(CH2) m -Alkenyl-R a , OR d or -(CH2) m -alkynyl-R a (wherein m and n are 0, 1 or 2), arylthio, thiocarbonyl, silane or -NR b R c etc., where R b With R c is independently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, R b With R c It can form a five- or six-membered cycloalkyl or heterocyclic group. a With R d Each is independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged, spiro or paracyclic groups.

[0242] “Containing 1 to 5 heteroatoms selected from O, S, and N” means containing 1, 2, 3, 4 or 5 heteroatoms selected from O, S, and N.

[0243] "1 to X substituents selected from..." means substituted by 1, 2, 3...X substituents, where X is selected from any integer between 1 and 10. For example, "1 to 4 R k "Substituted" means replaced by 1, 2, 3 or 4 R k For example, "substituted by 1 to 5 substituents selected from..." means substituted by 1, 2, 3, 4 or 5 substituents selected from..." For example, "the heterobridged ring is optionally substituted by 1 to 4 substituents selected from D or F" means that the heterobridged ring is optionally substituted by 1, 2, 3 or 4 substituents selected from D or F.

[0244] The XY-membered ring (3≤X<Y, Y is any integer between 4 and 12) includes X, X+1, X+2, X+3, X+4...Y-membered rings. The ring includes a heterocyclic ring, a carbocyclic ring, an aromatic ring, an aryl group, a heteroaryl group, a cycloalkyl group, a heteromonocyclic ring, a heterocyclic ring, a heterospirocyclic ring or a heterobridged ring. For example, "a 4-7-membered heteromonocyclic ring" refers to a 4-membered, 5-membered, 6-membered or 7-membered heteromonocyclic ring, and "a 5-10-membered heterocyclic ring" refers to a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered or 10-membered heterocyclic ring.

[0245] "Optional" or "optionally" means that the event or circumstance described later may but need not occur, and the description includes situations where the event or circumstance occurs or does not occur. For example, "alkyl optionally substituted with F" means that alkyl may but need not be substituted with F, and the description includes situations where alkyl is substituted with F and situations where alkyl is not substituted with F.

[0246] "Pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" refers to a salt of the compound of the present invention that retains the biological effectiveness and properties of the free acid or free base, and the free acid is obtained by reacting with a non-toxic inorganic base or organic base, and the free base is obtained by reacting with a non-toxic inorganic acid or organic acid.

[0247] "Pharmaceutical composition" refers to a mixture of one or more compounds of the present invention, or stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals thereof and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients and / or one or more other therapeutic agents.

[0248] "Carrier" refers to a material that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.

[0249] "Excipient" refers to an inert substance added to a pharmaceutical composition to facilitate administration of a compound. Non-limiting examples include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, granulating agents, lubricants, binders, and disintegrants.

[0250] "Prodrug" refers to a compound of the present invention that can be converted into a biologically active compound through in vivo metabolism. The prodrug of the present invention is prepared by modifying the amino or carboxyl group in the compound of the present invention, and the modification can be removed by conventional operations or in vivo to obtain the parent compound. When the prodrug of the present invention is administered to a mammalian subject, the prodrug is cleaved to form a free amino or carboxyl group.

[0251] "Co-crystal" refers to a crystal formed by the active pharmaceutical ingredient (API) and the co-crystal former (CCF) under the action of hydrogen bonds or other non-covalent bonds, in which the pure state of API and CCF are solid at room temperature and there is a fixed stoichiometric ratio between the components. Co-crystal is a multi-component crystal, including binary eutectics formed between two neutral solids and multi-component eutectics formed between neutral solids and salts or solvates.

[0252] "Animal" is meant to include mammals, such as humans, companion animals, zoo animals, and livestock, preferably humans, horses, or dogs.

[0253] "Stereoisomers" refer to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers and conformational isomers.

[0254] "Tautomers" refer to functional group isomers produced by the rapid movement of an atom in a molecule between two positions, such as keto-enol isomerism and amide-imino alcohol isomerism.

[0255] “IC 50 ” is the concentration of a drug or inhibitor required to inhibit a specified biological process (or a component of the process such as an enzyme, receptor, cell, etc.) by half. DETAILED DESCRIPTION

[0256] The following embodiments illustrate the technical solutions of the present invention in detail, but the protection scope of the present invention includes but is not limited to them.

[0257] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or / and mass spectrometry (MS). NMR shifts (δ) were measured in 10 -6The unit of (ppm) is given. NMR measurements were performed using a (Bruker Avance III 400 and Bruker Avance 300) nuclear magnetic spectrometer, the measurement solvents were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), and the internal standard was tetramethylsilane (TMS);

[0258] MS was measured using (Agilent 6120B (ESI) and Agilent 6120B (APCI));

[0259] HPLC determination was performed using an Agilent 1260DAD high pressure liquid chromatograph (Zorbax SB-C18 100×4.6 mm, 3.5 μM);

[0260] Thin layer chromatography silica gel plate using Yantai Huanghai HSGF 254 or Qingdao GF 254 Silica gel plate: The silica gel plate used in thin layer chromatography (TLC) has a specification of 0.15mm-0.20mm, and the specification used for thin layer chromatography separation and purification of products is 0.4mm-0.5mm;

[0261] Column chromatography generally uses Yantai Huanghai Silica Gel 200-300 mesh silica gel as the carrier;

[0262] Boc: tert-butoxycarbonyl;

[0263] Ts: p-toluenesulfonyl;

[0264] Cbz: benzyloxycarbonyl;

[0265] TMS: trimethylsilyl.

[0266] Example 1: Synthesis of Compound 1

[0267]

[0268] Step 1: Synthesis of compound 1B

[0269] Compound 1A (1.0 g, 3.21 mmol), Pd(dppf)Cl2 (0.26 g, 0.32 mmol), biboronic acid pinacol ester (1.22 g, 4.81 mmol) and potassium acetate (0.63 g, 6.42 mmol) were dissolved in 20 mL of 1,4-dioxane and reacted at 90° C. overnight. The residue was concentrated and purified by column chromatography to obtain compound 1B (1.1 g, 95.45%).

[0270] Ms m / z(ESI):360.2[M+H] +

[0271] Step 2: Synthesis of Compound 1C

[0272] Compound 1B (0.85 g, 2.38 mmol), Pd(dppf)Cl2 (0.19 g, 0.23 mmol), intermediate A (1.08 g, 2.62 mmol) and potassium carbonate (0.99 g, 7.16 mmol) were dissolved in 20 mL of 1,4-dioxane and reacted at 80° C. for 2 h. The residue was concentrated and purified by column chromatography to obtain compound 1C (0.6 g, 43.70%).

[0273] Ms m / z(ESI):525.1[M+H] +

[0274] Step 3: Synthesis of Compound 1D

[0275] Compound 1C (0.4 g, 0.76 mmol), Pd(dppf)Cl2 (0.13 g, 0.15 mmol), intermediate 1 (0.37 g, 1.52 mmol) and potassium carbonate (0.32 g, 0.23 mmol) were dissolved in 20 mL of 1,4-dioxane and reacted at 100° C. overnight. The residue was concentrated and purified by column chromatography to obtain compound 1D (220 mg, 48.65%).

[0276] Ms m / z(ESI):596.2[M+H] +

[0277] Step 4: Synthesis of Compound 1E

[0278] The intermediate compound B (63 mg, 0.37 mmol), TCFH (0.21 g, 0.74 mmol), and N-methylimidazole (92.5 mg, 1.11 mmol) were dissolved in 20 mL of DMF, and 1D (0.22 g, 0.37 mmol) was slowly added at room temperature to react overnight. The mixture was extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 1E (130 mg, 46.16%).

[0279] Step 5: Synthesis of Compound 1F

[0280] Compound 1E (130 mg, 0.17 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 1 hour, and concentrated to remove the solvent to obtain crude compound 1F, which was directly used for the next step.

[0281] Step 6: Synthesis of Compound 1G

[0282] The crude compound 1F was dissolved in 15 mL of DCM, and 5 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature. The mixture was stirred for 2 hours, and a certain amount of sodium bicarbonate was added to adjust the pH to greater than 8. The mixture was concentrated, and 5% methanol in dichloromethane solution was added to dissolve the mixture. The filtrate was collected by filtration and concentrated to obtain the crude compound 1G (70 mg), which was directly subjected to the next step without purification.

[0283] Step 7: Synthesis of Compound 7

[0284] Compound 1G (70 mg, 0.13 mmol) and intermediate C (39 mg, 0.43 mmol) (synthesis method, see WO2023023255) were dissolved in 10 mL of chloroform and 2 mL of methanol, stirred at room temperature for 2 hours, sodium triacetylborohydride (55 mg, 0.26 mmol) was slowly added, concentrated, and the residue was purified by column chromatography to obtain compound 1 (20 mg, 19.08%).

[0285] Ms m / z(ESI):807.4[M+H] +

[0286] 1 H NMR (400MHz, CDCl3) δ11.24(s,1H),8.95(s,1H),8.49(s,1H),8.03(s,1H),7.99(d ,1H),7.61–7.48(m,3H),7.20–7.13(m,4H),7.03(s,1H),6.96(d,2H),4.77(d,2H), 3.87–3.81(m,2H),3.78–3.62(m,4H),3.00–2.88(m,2H),2.86–2.70(m,6H),2.56– 2.41(m,5H),2.02–1.94(m,2H),1.88–1.78(m,1H),1.47(s,9H),1.28–1.24(m,2H).

[0287] Example 2: Preparation of Compound 2

[0288]

[0289] Step 1: Preparation of 2A

[0290] 1C (1.1 g, 2.1 mmol) was dissolved in 30 mL of a mixed solvent of 1,4-dioxane and water (v / v) = 5:1, and intermediate D (1.1 g, 2.62 mmol) (synthesis method see WO2022094172), potassium carbonate (870 mg, 6.3 mmol) and Pd(dppf)Cl2 (153 mg, 0.21 mmol) were added, and the mixture was reacted at 80 ° C for 16 h under a nitrogen atmosphere. The reaction system was cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel chromatography (petroleum ether: ethyl acetate (v / v) = 35:65) to obtain 2A (1 g, yield: 61%).

[0291] LCMS m / z=783.3[M+1] +

[0292] Step 3: Preparation of 2B

[0293] 2A (1 g, 1.28 mmol) was dissolved in 30 mL of tetrahydrofuran, and then 5 mL of 4% sodium hydroxide methanol solution was added and reacted at room temperature for 2 h. The reaction system was concentrated under reduced pressure, 20 mL of water was added, filtered, the filter cake was washed with water (5 mL × 2), and the filter cake was dried at 50°C to obtain a crude product 2B (810 mg).

[0294] LCMS m / z=643.1[M+1] +

[0295] Step 4: Preparation of 2C

[0296] The crude product 2B (180 mg) was added to a 50 mL single-mouth bottle, 5 mL of ethyl acetate was added, and 2 mol / L hydrochloric acid ethyl acetate solution (5 mL) was added, and the reaction was carried out at room temperature for 2 h. The reaction system was concentrated under reduced pressure, and dichloromethane (10 mL) and sodium bicarbonate (235 mg) were added. After stirring at room temperature for 30 min, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel chromatography to obtain 2C (55 mg, two-step yield: 36%).

[0297] LCMS m / z=543.1[M+1] +

[0298] Step 5: Preparation of Compound 2

[0299] 2C (55 mg, 0.1 mmol) was added to a 50 mL single-mouth bottle, and dichloromethane (10 mL) and ethanol (2 mL), intermediate C (31 mg, 0.103 mmol) and 0.04 mL acetic acid were added. After stirring at room temperature for 4 h, sodium triacetoxyborohydride (43 mg, 0.2 mmol) was added and reacted at room temperature for 2 h. The reaction system was concentrated under reduced pressure, water (50 mL) was added, and the mixture was extracted with a mixed solvent of dichloromethane and isopropanol (v / v) = 10:1 (20 mL×3). The organic phase was washed with a saturated sodium chloride aqueous solution (20 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by Prep-TLC (dichloromethane ether: methanol (v / v) = 10:1) to obtain a crude product. The crude product was prepared by Prep-HPLC (instrument: WATERS AUTOP preparative liquid; chromatographic column: SunFire@PrepC18 (19×250nm); mobile phase A: acetonitrile; mobile phase B: water (containing 5mmol / L ammonium acetate); gradient elution: mobile phase A content is 10-70%; flow rate: 17mL / min; column temperature: room temperature; detection wavelength: 210nm; the sample is dissolved in DMF and filtered with a 0.45um filter to prepare a sample solution; elution time: 15min), and lyophilized to obtain compound 2 (25mg, yield: 30%).

[0300] LCMS m / z=415.0[M / 2+1] +

[0301] 1 H NMR (400MHz, CDCl3) δ11.16(br.s,1H),8.91(s,1H),8.22(s,1H),7.56–7.47(m,2H),7.44–7.32(s ,3H),7.24–7.20(m,1H),7.19–7.12(m,2H),6.99–6.91(m,2H),6.79(s,1H),6.71(s,1H),4.25–4. 07(m,3H),3.91–3.79(m,3H),3.76–3.64(m,4H),3.00–2.90(m,2H),2.86–2.70(m,6H),2.58–2.40 (m,6H),2.27(s,3H),1.97–1.88(m,2H),1.85–1.77(m,1H),1.49–1.35(m,2H),1.29–1.21(m,6H).

[0302] Example 3: Preparation of Compound 3

[0303]

[0304] Referring to the synthetic route and operation method of Example 2, compound 3 (12 mg) was obtained.

[0305] LCMS m / z=828.8[M+1] +

[0306] 1 H NMR(400MHz, CDCl3)δ11.62(s,1H),8.94(s,1H),8.64(s,1H),7.57–7.47(m,3H),7.44–7.33 (m,2H),7.21–7.09(m,3H),7.00–6.91(m,2H),6.79(s,1H),6.71(s,1H),4.24–4.05(m,3H), 3.92–3.79(m,3H),3.77–3.55(s,4H),2.99–2.88(m,2H),2.87–2.67(m,6H),2.59–2.38(m,5 H),2.27(s,3H),2.02–1.90(m,2H),1.88–1.74(m,1H),1.48–1.34(m,2H),1.31–1.22(m,6H).

[0307] Example 4: Preparation of Compound 4

[0308]

[0309] Step 1: Preparation of chiral isomers 4a-1 and 4a-2

[0310] 4a (synthesis method see WO2022007866) was subjected to chiral separation. The chiral separation method is as follows:

[0311] 1. Instrument: SFC Prep 150AP; Chromatographic column: Daicel AD-H (19 mm × 250 mm).

[0312] 2. Dissolve the sample in methanol and filter it with a 0.45 μm filter to prepare a sample solution.

[0313] 3. Preparative chromatographic conditions: a. The mobile phase consists of A and B system: mobile phase A: CO2; mobile phase B: methanol; b. Isocratic elution, mobile phase B content is 25%; c. Flow rate is 40mL / min.

[0314] Peak time: chiral isomer 4a-1: 4.65 min, chiral isomer 4a-2: 5.85 min.

[0315] The chiral isomer 1 and the chiral isomer 2 of compound 4a are respectively one of the isomers of structure 4a-1 or 4a-2.

[0316] Step 2: Preparation of 4b

[0317] The intermediate 4a-2 (1.5 g, 7.9 mmol) was dissolved in 40 ml of dichloromethane, and triethylamine (2.4 g, 23.7 mmol) and di-tert-butyl dicarbonate (2.6 g, 11.85 mmol) were added, and stirred at room temperature overnight. The reaction solution was washed twice with 0.5 N dilute hydrochloric acid (20 mL × 2), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated and purified by silica gel column chromatography to obtain 4b (1 g, yield: 45.5%).

[0318] LCMS m / z=289.1[M+1] +

[0319] Step 3: Preparation of 4c

[0320] 4b (1 g, 3.5 mmol) was dissolved in acetonitrile (30 ml), and N-bromosuccinimide (0.68 g, 3.85 mmol) was added. The mixture was stirred at room temperature for 1 h. After the solvent was removed by concentration under reduced pressure, the crude product was separated and purified by silica gel column chromatography to obtain 4c (1.1 g, yield: 86.6%).

[0321] LCMS m / z=367.5[M+1] +

[0322] Step 4: Preparation of 4D

[0323] 4c (1.1 g, 3 mmol) was dissolved in dioxane (30 ml), and diboric acid pinacol ester (1.1 g, 4.5 mmol), potassium acetate (882 mg, 9 mmol), Pd (dppf) Cl2 (218 mg, 0.3 mmol) were added. The atmosphere was replaced with nitrogen three times, and the oil bath was heated to 100°C for 16 hours. After cooling to room temperature, 50 mL of water and 50 mL of ethyl acetate were added to the reaction solution, and the liquid was separated. The aqueous phase was extracted with ethyl acetate (50 mL), and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column chromatography to obtain 4d (0.78 g, yield: 65%).

[0324] LCMS m / z=415.3[M+1] +

[0325] Step 5: Preparation of 4e

[0326] Intermediate A (0.7 g, 1.7 mmol) was dissolved in 20 mL of a mixed solvent of dioxane and water (dioxane: water (v / v) = 5:1), 4d (775 mg, 1.87 mmol), potassium carbonate (704 mg, 5.1 mmol), Pd(dppf)Cl2 (123 mg, 0.17 mmol) were added, and nitrogen was replaced three times. The oil bath was heated to 80 ° C for 16 h, and the crude product was concentrated under reduced pressure and purified by silica gel chromatography to obtain 4e (0.73 g) (yield = 75.5%).

[0327] LCMS m / z=580.1[M+1] +

[0328] Step 6: Preparation of 4f

[0329] 4e (0.73 g, 1.3 mmol) was dissolved in 30 ml of a mixed solvent of dioxane and water (dioxane: water (v / v) = 5:1), and intermediate D (655 mg, 1.56 mmol), potassium carbonate (538 mg, 3.9 mmol), and Pd(dppf)Cl2 (94 mg, 0.13 mmol) were added. The mixture was replaced with nitrogen three times, and the mixture was heated in an oil bath to 100°C for 16 h. The solvent was removed by concentration under reduced pressure, and the crude product was separated and purified by silica gel chromatography to obtain 4f (660 mg) (yield = 62.6%).

[0330] LCMS m / z=838.1[M+1] +

[0331] Step 7: Preparation of 4g

[0332] 4f (660 mg, 0.79 mmol) was dissolved in 20 ml of tetrahydrofuran, and then a 4% sodium hydroxide methanol solution (4 ml) was added, and the mixture was stirred at room temperature for 2 h. The solvent was removed by concentration under reduced pressure, and water (20 ml) was added for filtration. The filter cake was washed twice with water, and then dried at 50°C for 16 h to obtain 4g (410 mg) (yield = 76.7%).

[0333] LCMS m / z=698.1[M+1] +

[0334] Step 8: 4h preparation

[0335] 4g (150mg, 0.22mmol) was added to a 50ml single-mouth bottle, and then ethyl acetate (8ml) was added, and a solution of hydrogen chloride in ethyl acetate (8ml, 4N) was added, and the mixture was stirred at room temperature for 2h, and the solvent was removed by concentration under reduced pressure, and dichloromethane (20ml) and sodium bicarbonate (235mg, 2.8mmol) were added and stirred at room temperature for 30 minutes, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel chromatography to obtain 4h (100mg) (yield = 78.1%)

[0336] LCMS m / z=598.1[M+1] +

[0337] Step 9: Preparation of compound 4

[0338] 4h (50 mg, 0.084 mmol) was added to a 50 ml single-mouth bottle, followed by the addition of dichloromethane (10 ml), ethanol (2 ml), intermediate C (26 mg, 0.084 mmol), and acetic acid (2 drops). The mixture was stirred at room temperature for 4 h, and then sodium triacetylborohydride (36 mg, 0.168 mmol) was added and the mixture was stirred at room temperature for 2 h. After the mixture was concentrated under reduced pressure to remove the solvent, water (50.0 ml) was added, and a mixed solvent of dichloromethane and isopropanol (dichloromethane ether: isopropanol (v / v) = 10:1) was added and extracted three times (20 ml × 3). The organic phase was washed twice with saturated brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product which was separated and purified by Prep-TLC to obtain compound 4 (27 mg) (yield = 36.9%).

[0339] LCMS m / z=881.1[M-1] -

[0340] Example 5: Preparation of Compound 5

[0341]

[0342] Using 4a-1 as the starting material and referring to the synthetic route and operation method of Example 4, compound 5 (20 mg) was obtained.

[0343] LCMS m / z=881.1[M-1] -

[0344] Example 6: Synthesis of Compound 6

[0345]

[0346] Step 1: Synthesis of compound 6B

[0347] Compound 4a-2 (3 g, 15.93 mmol) and triethylamine (4.84 g, 47.79 mmol) were dissolved in 25 mL of DCM, and di-tert-butyl dicarbonate was slowly added at 0° C. The mixture was stirred at room temperature for 2 hours, extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 6B (4.2 g, 91.3%).

[0348] LCMS m / z=289.2[M+H] +

[0349] Step 2: Synthesis of compound 6C

[0350] Compound 6B (3 g, 10.4 mmol) was dissolved in 25 mL of DCM, and NBS (1.85 g, 10.4 mmol) was slowly added at 0°C. The mixture was stirred overnight at room temperature, extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 6C (3.1 g, 81.2%).

[0351] LCMS m / z=367.1[M+H] +

[0352] Step 3: Synthesis of compound 6D

[0353] Compound 6C (2 g, 5.45 mmol), Pd(dppf)Cl2 (0.45 g, 0.55 mmol), pinacol diboron (1.66 g, 6.54 mmol) and potassium acetate (1.6 g, 16.35 mmol) were dissolved in 20 mL of 1,4-dioxane and reacted overnight at 90° C. Silica gel was directly added to the sample and the sample was purified by column chromatography to obtain compound 6D (1.6 g, 70.85%).

[0354] Ms m / z(ESI):415.2[M+H] +

[0355] Step 4: Synthesis of compound 6E

[0356] Compound 6D (1 g, 2.38 mmol), Pd(dppf)Cl2 (0.19 g, 0.23 mmol), intermediate A (1.08 g, 2.62 mmol) and potassium carbonate (0.99 g, 7.16 mmol) were dissolved in 20 mL of 1,4-dioxane and reacted at 80°C overnight. Silica gel was directly added to the sample and purified by column chromatography to obtain compound 6E (1.1 g, 79.67%).

[0357] Ms m / z(ESI):580.1[M+H] +

[0358] Step 5: Synthesis of compound 6F

[0359] Compound 6E (1.1 g, 1.90 mmol), Pd(dppf)Cl2 (0.16 g, 0.19 mmol), intermediate 1 (0.7 g, 2.85 mmol) and potassium carbonate (0.79 g, 5.7 mmol) were dissolved in 20 mL of 1,4-dioxane and reacted at 100°C overnight. Silica gel was directly added to the sample and the sample was purified by column chromatography to obtain compound 6F (945 mg, 74.81%).

[0360] Ms m / z(ESI):665.2[M+H] +

[0361] Step 6: Synthesis of Compound 6G

[0362] Compound intermediate B (0.15 g, 0.88 mmol), TCFH (0.49 g, 1.76 mmol), N-methylimidazole 1 (0.22 g, 2.64 mmol) were dissolved in 20 mL of DMF, and 6F (0.64 g, 0.97 mmol) was slowly added at room temperature to react overnight. The reaction was extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 6G (400 mg, 55.64%).

[0363] Ms m / z(ESI):817.3[M+H] +

[0364] Step 7: Synthesis of compound 6H

[0365] Compound 6G (0.4 g, 0.49 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 1 hour, concentrated to remove the solvent, and the crude residue 6H was directly used in the next step.

[0366] Step 8: Synthesis of compound 6I

[0367] The crude compound 6H was dissolved in 15 mL of DCM, and 5 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature. The mixture was stirred for 2 hours, and a saturated aqueous sodium bicarbonate solution was added to adjust the pH to about 8. The mixture was concentrated and dissolved in 5% methanol in dichloromethane. The filtrate was collected by filtration and concentrated to obtain the crude compound 6I (200 mg), which was directly subjected to the next step.

[0368] Step 9: Synthesis of compound 6

[0369] Compound 6I (0.2 g, 0.35 mmol) and intermediate C (0.13 g, 0.43 mmol) were dissolved in 10 mL of chloroform and 2 mL of methanol, and stirred at room temperature for 2 hours. Sodium triacetylborohydride (0.15 g, 0.71 mmol) was slowly added, and silica gel was directly added to stir the sample. Compound 6 (20 mg, 6.63%) was obtained by separation and purification by column chromatography.

[0370] Ms m / z(ESI):862.3[M+H] +

[0371] 1 H NMR(400MHz,DMSO-d6)δ12.43(s,1H),10.26(s,1H),9.54–9.47(m,1H),8.73(s,1H),8.09–8.03(m,2H),7.74–7.6 8(m,1H),7.68–7.64(m,1H),7.46–7.41(m,1H),7.17–7.10(m,3H),6.97–6.89(m,3H),4.57–4.51(m,2H),3.93–3. 85(m,1H),3.73–3.64(m,4H),3.10–3.03(m,1H),2.97–2.83(m,3H),2.79–2.61(m,6H),2.48(s,3H),2.24–2.16(m ,2H),2.13–2.04(m,1H),1.99–1.90(m,1H),1.87–1.77(m,3H),1.75–1.59(m,2H),1.44(s,9H),1.29–1.20(m,2H).

[0372] Example 7: Preparation of Compound 7

[0373]

[0374] Step 1: Preparation of 7B

[0375] Suspend (methoxymethyl)triphenylphosphonium chloride (21.49 g, 62.59 mmol) in 250 ml dry tetrahydrofuran, cool to 0°C under nitrogen protection, slowly drop potassium tert-butoxide solution (1M in THF), (66.76 ml, 66.76 mmol) and continue stirring for 10 minutes after addition, then warm to room temperature for reaction for 1 hour, add raw material 7A (10.0 g, 41.84 mmol), stir for 10 minutes after addition, and then react at 70°C for 2 hours. Cool to room temperature, add 150 ml of water and 200 ml of ethyl acetate, separate the liquids, wash the organic layer twice with saturated sodium chloride solution (150 ml×2), dry over anhydrous sodium sulfate, filter, concentrate the filtrate under reduced pressure, and separate and purify the crude product with silica gel chromatography to obtain 7B (6.6 g, yield: 60%)

[0376] LCMS m / z=268.1[M+1] +

[0377] Step 2: Preparation of 7C

[0378] 7B (6.6 g, 24.7 mmol) was dissolved in 150 ml of a mixed solvent of acetonitrile and water (acetonitrile / water (v / v) = 5:1), and then trifluoroacetic acid (2.5 ml) was added, and the reaction was stirred at room temperature for 12 hours. Solid sodium bicarbonate was added to adjust the pH of the system to weak alkalinity, and the system was concentrated. The residual liquid was extracted three times with ethyl acetate (50 ml × 3), and the organic phases were combined and washed twice with saturated brine (50 ml × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography to obtain 7C (6 g, yield: 96.7%)

[0379] Step 3: Preparation of 7D

[0380] Dissolve 7C (6 g, 23.7 mmol) in methanol (150 ml), cool to 0°C in an ice-water bath, and then add sodium borohydride (1.26 g, 23.7 mmol) in batches. React at room temperature for 1 hour. Concentrate the reaction solution, and purify the crude product with a silica gel column to obtain 7D (5.6 g, yield: 93.3%)

[0381] LCMS m / z=256.1[M+1] +

[0382] Step 4: Preparation of 7E

[0383] 7D (5.6 g, 21.96 mmol) was dissolved in dichloromethane (60 ml) and then trifluoroacetic acid (15 ml) was added and reacted at room temperature for 4 hours. After concentration under reduced pressure, dichloromethane (100 ml) was added and the mixture was washed twice with saturated sodium bicarbonate solution (60 ml×2). The organic phase was dried over anhydrous sodium sulfate and concentrated and purified on a silica gel column (petroleum ether / ethyl acetate to obtain 7E (2 g, yield: 58.8%).

[0384] LCMS m / z=156.1[M+1] +

[0385] Step 5: Preparation of 7F

[0386] 7E (2 g, 12.9 mmol) was dissolved in DMF (30 ml), p-fluoronitrobenzene (1.82 g, 12.9 mmol) and potassium carbonate (3.56 g, 25.8 mmol) were added, and the mixture was heated to 80°C in an oil bath for 16 h. The reaction system was cooled to room temperature, 200 mL of water was added, and the mixture was extracted with ethyl acetate (80 mL×3). The organic phase was washed with saturated brine three times (50 mL×3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by silica gel chromatography to obtain 7F (1.1 g, yield: 31.4%).

[0387] LCMS m / z=277.1[M+1] +

[0388] Step 6: Preparation of 7G

[0389] 7F (1.1 g, 3.98 mmol) was dissolved in a mixed solvent of dichloromethane and methanol (40 ml) (DCM:MeOH (v / v) = 1:4), palladium carbon (0.5 g, 10%) was added, and the mixture was reacted at room temperature for 16 h under a hydrogen balloon atmosphere. The reaction system was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product 7G (0.92 g).

[0390] LCMS m / z=247.1[M+1] +

[0391] Step 7: Preparation of 7H

[0392] The above crude product 7G (0.92 g, 3.7 mmol) and acrylic acid (0.8 g, 11.1 mmol) were added to 20 mL of toluene and reacted at 90°C for 12 h. The reaction system was cooled to room temperature, 12 mL of acetic acid and urea (1.1 g, 18.5 mmol) were added, and the reaction was continued at 110°C for 16 h. The reaction system was cooled to room temperature, added to 50 mL of water, extracted with ethyl acetate (50 mL×3), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was separated and purified by silica gel chromatography to obtain 7H (510 mg, yield: 35.4%).

[0393] LCMS m / z=386.2[M+1] +

[0394] Step 8: Preparation of 7I

[0395] 7H (0.51 g, 1.32 mmol) was dissolved in dilute hydrochloric acid (20 ml, 2 M), and heated to 90°C in an oil bath for 12 h. The reaction system was cooled to 0°C and the pH was adjusted to 7.5 with sodium hydroxide aqueous solution (1 N). The solid precipitated and was filtered. The filter cake was dried under reduced pressure to obtain 7I (0.3 g, yield: 66.1%).

[0396] LCMS m / z=344.2[M+1] +

[0397] Step 9: Preparation of 7J

[0398] The above 7I (0.3 g, 0.87 mmol) was dissolved in DMSO (10 ml), and then 2-iodoacylbenzoic acid (365 mg, 1.3 mmol) was added, and the reaction was carried out at room temperature for 12 h. Water (100 ml) was added to the reaction system, and then extracted with dichloromethane three times (80 mL×3), the organic phase was washed with saturated brine three times (60 mL×3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography to obtain compound 7J (150 mg, yield: 50.1%).

[0399] LCMS m / z=342.2[M+1] +

[0400] Step 10: Preparation of compound 7

[0401] 7J (30 mg, 0.088 mmol) was added to a 50 ml single-mouth bottle, followed by the addition of dichloromethane (10 ml), ethanol (2 ml), 2C (48 mg, 0.088 mmol), and acetic acid (1 drop). The mixture was stirred at room temperature for 4 h, and then sodium triacetylborohydride (37 mg, 0.176 mmol) was added and the mixture was stirred at room temperature for 2 h. After the mixture was concentrated under reduced pressure to remove the solvent, water (50.0 ml) was added, and a mixed solvent of dichloromethane and isopropanol (dichloromethane ether: isopropanol (v / v) = 10:1) was added and extracted three times (20 ml × 3). The organic phase was washed twice with saturated brine (20 ml × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product which was separated and purified by Prep-TLC to obtain compound 7 (20 mg) (yield = 26.3%).

[0402] LCMS m / z=434.9[M+1] / 2 +

[0403] 1 H NMR (400MHz, CDCl3) δ11.30(s,1H),8.95(s,1H),8.53(s,1H),7.56–7.47(m,2H),7.44–7.34(m,2H ),7.20–7.14(m,2H),7.13–7.08(s,1H),6.98–6.91(m,2H),6.79(s,1H),6.72–6.68(m,1H),4.29–4 .06(m,3H),3.92–3.59(m,5H),3.23–3.14(m,2H),3.12–3.05(m,2H),3.03–2.63(m,8H),2.57–2.4 6(m,4H),2.27(s,3H),2.17–2.07(m,2H),1.85–1.78(m,2H),1.72–1.55(m,5H),1.28–1.21(m,6H).

[0404] Example 8: Synthesis of Compound 8

[0405]

[0406] Using 4a-1 as the starting material and referring to the synthetic route and experimental operation method of compound 6, compound 8 (45 mg, 16%) was obtained.

[0407] Ms m / z(ESI):862.3[M+H] +

[0408] 1 H NMR(400MHz,DMSO-d6)δ12.41(s,1H),10.23(s,1H),9.51–9.44(m,1H),8.73(s,1H),8.08–8.02(m, 2H),7.71(d,1H),7.65(s,1H),7.47–7.40(m,1H),7.17–7.10(m,3H),6.96–6.87(m,3H),4.55(d,2H) ,3.92–3.83(m,1H),3.73–3.64(m,4H),3.11–3.01(m,1H),2.98–2.61(m,9H),2.48(s,3H),2.25–2. 16(m,2H),2.12–2.02(m,1H),2.00–1.91(m,1H),1.87–1.59(m,5H),1.44(s,9H),1.30–1.17(m,2H).

[0409] Example 9: Synthesis of Compound 9

[0410]

[0411] Step 1: Synthesis of compound 9B

[0412] Compound 9A (1 g, 3.77 mmol) was placed in a sealed tube, 40 mL of ultra-dry tetrahydrofuran was added to dissolve, the system was placed in an ice bath for 10 min, and then borane dimethyl sulfide tetrahydrofuran solution (18.85 mL, 37.7 mmol, 2 mmol / L) was added, the system was heated to 70 degrees to react overnight after replacing the gas, 1N hydrochloric acid was added to the system to adjust the pH to about 2-3, and heating at 70 degrees was continued for 2 hours. The pH was adjusted to greater than 8 with saturated sodium bicarbonate, EA was extracted, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 9B (0.4 g, 42%).

[0413] LCMS m / z=251.1[M+H] +

[0414] Step 2: Synthesis of compound 9C

[0415] Compound 9B (0.4 g, 1.59 mmol) and triethylamine (0.44 mL, 3.19 mmol) were dissolved in 5 mL of DCM, and di-tert-butyl dicarbonate was slowly added at 0° C. The mixture was stirred at room temperature for 2 hours, extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 9C (0.486 g, 89%).

[0416] LCMS m / z=351.2[M+H] +

[0417] Step 3: Synthesis of compound 9D

[0418] Compound 9C (0.96 g, 1.39 mmol), Pd(dppf)Cl2 (0.1 g, 0.14 mmol), biboronic acid pinacol ester (0.71 g, 2.78 mmol) and potassium acetate (0.41 g, 4.17 mmol) were dissolved in 10 mL of 1,4-dioxane and reacted at 90° C. overnight. Silica gel was directly added to the sample and the sample was purified by column chromatography to obtain compound 9D (0.27 g, 50%).

[0419] Ms m / z(ESI):399.2[M+H] +

[0420] Step 4: Synthesis of compound 9E

[0421] Compound 9D (0.27 g, 0.68 mmol), Pd(dppf)Cl2 (50 mg, 0.07 mmol), intermediate A (0.43 g, 1.02 mmol) and potassium carbonate (0.19 g, 1.36 mmol) were dissolved in 10 mL of 1,4-dioxane and 1 mL of water, and reacted at 80°C overnight. Silica gel was directly added to the sample, and the sample was purified by column chromatography to obtain compound 9E (0.26 g, 90%).

[0422] Ms m / z(ESI):564.1[M+H] +

[0423] Step 5: Synthesis of Compound 9F

[0424] Compound 9E (0.26 g, 0.46 mmol), Pd(dppf)Cl2 (34 mg, 0.05 mmol), intermediate D (0.39 g, 0.92 mmol) and potassium carbonate (0.19 g, 1.38 mmol) were dissolved in 10 mL of 1,4-dioxane and 1 ml of water, and reacted at 100° C. overnight. Silica gel was directly added to the sample, and the sample was purified by column chromatography to obtain compound 9F (0.23 mg, 60%).

[0425] Ms m / z(ESI):822.2[M+H] +

[0426] Step 6: Synthesis of compound 9H

[0427] Compound 9F (0.23 g, 0.28 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 1 hour, concentrated, and directly carried out to the next step to obtain crude compound 9H (0.26 g).

[0428] Step 8: Synthesis of Compound 9I

[0429] The crude compound 9H was dissolved in 10 mL of DCM, and 3 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature. The mixture was stirred for 2 hours, and sodium bicarbonate was added to adjust the pH to alkaline. The organic solvent was directly dried, and a 5% methanol solution in dichloromethane was added to dissolve the mixture. The filtrate was collected by filtration to obtain compound 9I (0.18 g). The mixture was directly subjected to the next step without purification.

[0430] Step 11: Synthesis of compound 9

[0431] Compound 9I (0.18 g crude, 0.28 mmol) and intermediate C (0.12 g, 0.42 mmol) were dissolved in 10 mL chloroform and 2 mL methanol, stirred at room temperature for 2 hours, sodium triacetylborohydride (0.19 g, 0.56 mmol) was slowly added, silica gel was directly added to stir the sample, and the compound (28 mg, 11%) was obtained by column chromatography purification.

[0432] Ms m / z(ESI):867.3[M+H] +

[0433] Synthesis of intermediates E-1 and E-2:

[0434]

[0435]

[0436] Step 1: Preparation of compounds Ea and Eb

[0437] The intermediate E (2.8 g, 13.58 mmol) (synthesis method reference Bioorganic & Medicinal Chemistry Letters, 2016, 26, 5877-5882) was dissolved in dichloromethane (50 mL), and Boc2O (5.93 g, 27.17 mmol) and DMAP (3.32 g, 27.18 mmol) were added, and the reaction was carried out at room temperature for 16 h. The reaction system was washed with 0.5 mol / L hydrochloric acid (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (ethyl acetate: petroleum ether (v / v) = 0: 1-1: 9) to obtain a racemic mixture of Ea and Eb (3.4 g, yield: 82%).

[0438] The racemic mixture of Ea and Eb is subjected to chiral separation, and the chiral separation method is as follows:

[0439] 1. Instrument: SFC Prep 150AP; Chromatographic column: Daicel IC-H (19 mm × 250 mm).

[0440] 2. Dissolve the sample in methanol and filter it with a 0.45 μm filter to prepare a sample solution.

[0441] 3. Preparative chromatographic conditions: a. The mobile phase consists of A and B system: mobile phase A: CO2; mobile phase B: methanol / isopropanol (v / v) = 1:1; b. Isocratic elution, mobile phase B content is 20%; c. Flow rate is 40 mL / min.

[0442] Peak time: chiral isomer 1 (compound Ea): 5.7 min, chiral isomer 2 (compound Eb): 6.47 min.

[0443] According to the MicroED structure determination of compound Eb-1, compound Ea is of R configuration and compound Eb is of S configuration.

[0444] LCMS m / z=307.3[M+1] + .

[0445] Step 2: Preparation of Eb-1

[0446] Eb (1.4 g, 4.57 mmol) was dissolved in acetonitrile (50 mL), and NBS (0.81 g, 4.55 mmol) was added, and the reaction was carried out at room temperature for 1 h. The reaction system was concentrated under reduced pressure, and the crude product was separated and purified by silica gel column chromatography (ethyl acetate: petroleum ether (v / v) = 0:1-1:9) to obtain Eb-1 (1.6 g, yield: 92%).

[0447] LCMS m / z=385.3[M+1] + .

[0448] The compound Eb-1 was determined to be S-configuration by MicroED structure analysis.

[0449] Step 3: Preparation of Eb-2

[0450] Eb-1 (1.6 g, 4.16 mmol), intermediate Ea-A (3.46 g, 8.29 mmol), Pd(dppf)Cl2·DCM (0.34 g, 0.42 mmol) and cesium carbonate (2.70 g, 8.3 mmol) were added to a reaction flask, 1,4-dioxane (50 mL) and water (5 mL) were added, and the mixture was reacted at 100°C for 20 h under a nitrogen atmosphere. The reaction system was cooled to room temperature, 50 mL of water and 50 mL of ethyl acetate were added, the aqueous phase was extracted with ethyl acetate (50 mL), the organic phase was washed with 30 mL of saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 1:0-9:1) to obtain Eb-2 (1.4 g, yield: 56%).

[0451] Step 4: Preparation of Eb-3

[0452] Eb-2 (1.4 g, 2.35 mmol) was dissolved in THF (50 mL), 10% palladium on carbon (1.25 g) was added, and the mixture was reacted at 45°C under a hydrogen balloon atmosphere for 20 h. The reaction system was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel chromatography (MeOH:DCM (v / v) = 0:1-5:95) to obtain Eb-3 (0.85 g, yield: 87%).

[0453] LCMS m / z=418.1[M+1] + .

[0454] Step 5: Preparation of E-2

[0455] Eb-3 (620 mg, 1.49 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (3 mL) was added, and the reaction was allowed to react at room temperature for 3 h. The reaction system was concentrated under reduced pressure, 5 mL of dichloromethane and 1 mL of triethylamine were added, and the reaction was concentrated under reduced pressure to obtain a crude product of Eb-3 (460 mg).

[0456] LCMS m / z=318.3[M+1] + .

[0457]

[0458] Step 2: Preparation of Ea-1

[0459] Ea (1.8 g, 5.88 mmol) was dissolved in acetonitrile (50 mL), and NBS (1.05 g, 5.90 mmol) was added, and the reaction was carried out at room temperature for 1 h. The reaction system was concentrated under reduced pressure, and the crude product was separated and purified by silica gel column chromatography (ethyl acetate: petroleum ether (v / v) = 0:1-1:9) to obtain Ea-1 (1.6 g, yield: 71%).

[0460] LCMS m / z=385.3[M+1] + .

[0461] Step 3: Preparation of Ea-2

[0462] Ea-1 (0.77 g, 2.0 mmol), intermediate Ea-A (1.67 g, 4.0 mmol) (synthesis method see WO2022235945), Pd (dppf) Cl2·DCM (0.16 g, 0.20 mmol) and cesium carbonate (1.30 g, 4.0 mmol) were added to a reaction flask, 1,4-dioxane (30 mL) and water (3 mL) were added, and the reaction was carried out at 100 ° C for 20 h under a nitrogen atmosphere. The reaction system was cooled to room temperature, 50 mL of water and 50 mL of ethyl acetate were added, the aqueous phase was extracted with 50 mL of ethyl acetate, the organic phase was washed with 30 mL of saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 1:0-9:1) to obtain Ea-2 (0.70 g, yield: 59%).

[0463] Step 4: Preparation of Ea-3

[0464] Ea-2 (0.70 g, 1.18 mmol) was dissolved in THF (20 mL), 10% palladium carbon (0.63 g) was added, and the mixture was placed under a hydrogen balloon atmosphere at 45°C for 20 h. The reaction system was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel chromatography (MeOH:DCM (v / v) = 0:1-5:95) to obtain Ea-3 (0.25 g, yield: 51%).

[0465] LCMS m / z=418.1[M+1] + .

[0466] Step 5: Preparation of E-1

[0467] Ea-3 (250 mg, 0.6 mmol) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (2 mL) was added, and the reaction was carried out at room temperature for 3 h. The reaction system was concentrated under reduced pressure, 5 mL of dichloromethane and 1 mL of triethylamine were added, and the reaction was concentrated under reduced pressure to obtain a crude product E-1 (190 mg).

[0468] LCMS m / z=318.3[M+1] + .

[0469] Synthesis of Intermediate F

[0470]

[0471] Step 1: Preparation of F-2

[0472] F-1 (1.28 g, 3.48 mmol) (synthesis method see Bioorg. Med. Chem. Lett. 2016, 26, 5877-5882), cesium carbonate (2.27 g, 6.97 mmol), palladium acetate (0.16 g, 0.71 mmol), XantPhos (0.20 g, 0.35 mmol) and F-1A (0.89 g, 4.91 mmol) were added to a 1,4-dioxane solution (40 mL) and reacted at 105 ° C for 3 h under a nitrogen atmosphere. The reaction system was cooled to room temperature, water (100 mL) was added, and it was extracted with ethyl acetate (80 mL×3), and the organic phase was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 1:0-7:3) to obtain F-2 (1.30 g, yield: 80%).

[0473] LCMS m / z=468.4[M+1] + .

[0474] Step 2: Preparation of F-3

[0475] F-2 (1.30 g, 2.78 mmol) was added to methanol (10 mL), and 10% palladium carbon (1.33 g) and ammonium acetate (1.32 g, 17.13 mmol) were added, and the mixture was reacted at room temperature for 12 h under a hydrogen balloon atmosphere. The reaction system was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate (v / v) = 1:0-1:1) to obtain F-3 (0.76 g, yield: 90%).

[0476] LCMS m / z=304.4[M+1] + .

[0477] Step 3: Preparation of F-4

[0478] F-3 (0.76 g, 2.55 mmol), ethyl acrylate (0.75 g, 7.49 mmol) and DIPEA (0.97 g, 7.50 mmol) were added to ethanol (50 mL) in sequence and reacted at 100°C for 48 h. The reaction system was cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (methanol / dichloromethane (v / v) = 0:1-6:94) to obtain F-4 (0.70 g, yield: 68%).

[0479] LCMS m / z=404.2[M+1] + .

[0480] Step 4: Preparation of F-5

[0481] F-4 (700 mg, 1.74 mmol) and DIPEA (671 mg, 5.19 mmol) were added to tetrahydrofuran (20 mL), triphosgene (565 mg, 1.90 mmol) was slowly added, and the mixture was reacted at room temperature for 1 h. Ammonia water (5 mL) was added to the reaction system, and the mixture was reacted at 50 °C for 2 h. The reaction system was cooled to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 2). The organic phase was concentrated under reduced pressure, and the crude product was separated and purified by silica gel chromatography (methanol / dichloromethane (v / v) = 0:1-1:9) to obtain F-5 (700 mg, yield: 90%).

[0482] Step 5: Preparation of Intermediate F

[0483] F-5 (0.70 g, 1.57 mmol) was added to acetonitrile (30 mL), and then a 40% benzyltrimethylammonium hydroxide methanol solution (2 mL) was added, and the reaction was carried out at 60° C. for 2 h. The reaction system was cooled to room temperature, concentrated under reduced pressure, and the crude product was separated and purified by silica gel column chromatography (methanol / dichloromethane (v / v) = 0:1-8:92) to obtain intermediate F (530 mg, yield: 84%).

[0484] LCMS m / z=401.4[M+1] + .

[0485] Example 10: Synthesis of Compound 10

[0486]

[0487] Step 1: Synthesis of compound 10B

[0488] Compound 10A (2.7 g, 10.0 mmol), Pd(dppf)Cl2 (0.82 g, 1.0 mmol), biboronic acid pinacol ester (5.08 g, 20.0 mmol) and potassium acetate (2.94 g, 30 mmol) were dissolved in 100 mL of 1,4-dioxane and reacted at 90° C. overnight. The residue was concentrated and purified by column chromatography to obtain compound 10B (2.5 g, 78.86%).

[0489] Ms m / z(ESI):318.2[M+H] + .

[0490] Step 2: Synthesis of Compound 10C

[0491] Compound 10B (2.5 g, 7.88 mmol), Pd(dppf)Cl2 (0.64 g, 0.78 mmol), intermediate A (3.29 g, 7.88 mmol) and potassium carbonate (2.17 g, 15.76 mmol) were dissolved in 100 mL of 1,4-dioxane and 20 mL of water and reacted at 80° C. for 2 h. The residue was concentrated and purified by column chromatography to obtain compound 10C (1.81 g, 47.71%).

[0492] Ms m / z(ESI):483.1[M+H] + .

[0493] Step 3: Synthesis of compound 10D

[0494] Compound 10C (1.5 g, 3.11 mmol), Pd(dppf)Cl2 (0.25 g, 0.31 mmol), intermediate 1 (0.77 g, 3.11 mmol) and potassium carbonate (0.86 g, 6.22 mmol) were dissolved in 50 mL of 1,4-dioxane and 10 mL of water and reacted at 100° C. overnight. The residue was concentrated and purified by column chromatography to obtain compound 10D (1.21 g, 68.57%).

[0495] Ms m / z(ESI):568.2[M+H] + .

[0496] Step 4: Synthesis of compound 10E

[0497] Compound intermediate B (0.36 g, 2.12 mmol), TCFH (1.19 g, 4.24 mmol), and N-methylimidazole (0.52 g, 6.36 mmol) were dissolved in 50 mL of DMF, and 10D (1.21 g, 2.12 mmol) was slowly added at room temperature to react overnight. The reaction was extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 10E (900 mg, 59.14%).

[0498] Step 5: Synthesis of Compound 10F

[0499] Compound 10E (900 mg, 1.25 mmol) was dissolved in 10 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 1 hour, and concentrated to remove the solvent to obtain crude compound 10F, which was directly used for the next step.

[0500] Step 6: Synthesis of Compound 10G

[0501] The crude compound 10F (250 mg, 0.43 mmol) was dissolved in 15 mL DMSO, and IBX (482 mg, 1.72 mmol) was added at room temperature. The mixture was stirred for 16 hours, quenched with water, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 10G (200 mg, 80.27%).

[0502] Ms m / z(ESI):578.2[M+H] + .

[0503] Step 7: Synthesis of compound 10

[0504] Compound 10G (29 mg, 0.10 mmol) and intermediate E-1 (16 mg, 0.10 mmol) were dissolved in 10 mL of chloroform and 2 mL of methanol, 1 drop of acetic acid was added, stirred at room temperature for 2 hours, sodium triacetylborohydride (55 mg, 0.26 mmol) was slowly added, concentrated, and the residue was purified by column chromatography to obtain compound 10 (5 mg, 11.33%).

[0505] Ms m / z(ESI):880.5[M+H] + .

[0506] 1 H NMR(400MHz, CD3OD+CDCl3(10:1))δ8.68(s,1H),7.91–7.84(m,2H),7.77–7.70(m,2H),7.51 (d,1H),7.03(d,2H),6.92(s,1H),6.76(d,1H),6.52(d,1H),4.75–4.65(m,2H),3.87–3.73(m ,3H),3.69–3.59(m,1H),3.08–2.93(m,2H),2.92–2.73(m,5H),2.70–2.60(m,3H),2.51(s,3 H),2.31–2.06(m,5H),1.96–1.84(m,3H),1.82–1.65(m,2H),1.47(s,9H),1.43–1.25(m,3H).

[0507] Example 11: Synthesis of Compound 11

[0508]

[0509] Step 1: Synthesis of compound 11B

[0510] 10C (1.1 g, 2.28 mmol) was dissolved in 30 mL of a mixed solvent of 1,4-dioxane and water (v / v) = 5:1, and intermediate D (1.15 g, 2.74 mmol), potassium carbonate (950 mg, 6.84 mmol) and Pd(dppf)Cl2 (190 mg, 0.23 mmol) were added, and the mixture was reacted at 100°C for 16 h under a nitrogen atmosphere. The reaction system was cooled to room temperature, concentrated under reduced pressure, and the crude product was separated and purified by silica gel chromatography to obtain 11B (1.1 g, yield: 65.12%).

[0511] LCMS m / z=741.3[M+1] +

[0512] Step 2: Synthesis of compound 11C

[0513] 11B (1 g, 1.28 mmol) was dissolved in 20 mL of tetrahydrofuran, and then 10 mL of 4% sodium hydroxide methanol solution was added and reacted at room temperature for 4 h. The reaction system was concentrated under reduced pressure, 20 mL of water was added, filtered, the filter cake was washed with water (5 mL × 2), and the filter cake was dried at 50°C to obtain a crude product 11C (600 mg).

[0514] LCMS m / z=601.2[M+1] +

[0515] Step 3: Synthesis of compound 11D

[0516] 11C (1 g, 1.28 mmol) was dissolved in 20 mL DMSO, and then IBX (1 g, 1.28 mmol) was added, and the nitrogen was replaced 3 times, and the reaction was carried out at room temperature for 12 h. 20 mL of water was added, and the filter cake was filtered, and the filter cake was washed with water (5 mL×2), and the filter cake was dried at 50°C to obtain a crude product 11D (500 mg).

[0517] LCMS m / z=599.3[M+1] +

[0518] Step 4: Synthesis of compound 11

[0519] Compound 11D (190 mg, 0.32 mmol) and intermediate E-2 (100 mg, 0.32 mmol) were dissolved in 10 mL of chloroform and 2 mL of methanol, stirred at room temperature for 2 hours, sodium triacetylborohydride (140 mg, 0.66 mmol) was slowly added, concentrated, and the residue was purified by column chromatography to obtain compound 11 (20 mg, 6.94%).

[0520] LCMS m / z=900.2[M+1] +

[0521] 1 H NMR(400MHz,DMSO-d6)δ12.49(s,1H),10.76(s,1H),8.76(s,1H),7.79(d,2H),7.51–7.39(m,3H ),7.00(d,2H),6.79(d,1H),6.66–6.56(m,2H),6.50(s,1H),4.25–4.09(m,3H),3.89–3.67(m,5H ),3.01–2.85(m,3H),2.82–2.64(m,5H),2.63–2.54(m,3H),2.54–2.45(m,1H),2.45–2.39(m,2H) ,2.24–2.11(m,5H),2.10–1.99(m,2H),1.99–1.71(m,6H),1.65–1.51(m,1H),1.28–1.13(m,8H).

[0522] Example 12: Synthesis of Compound 12

[0523]

[0524] Referring to the synthetic route and experimental operation method of compound 11, compound 12 (15 mg) was obtained

[0525] LCMS m / z=900.90[M+1] +

[0526] 1 H NMR(400MHz,DMSO-d6)δ12.49(s,1H),10.76(s,1H),8.76(s,1H),7.79(d,2H),7.51–7.37(m,3H ),7.00(d,2H),6.79(d,1H),6.67–6.56(m,2H),6.50(s,1H),4.24–4.08(m,3H),3.90–3.68(m,5H ),3.01–2.84(m,3H),2.82–2.64(m,5H),2.63–2.54(m,3H),2.54–2.45(m,1H),2.44–2.39(m,2H) ,2.23–2.16(m,2H),2.16–2.00(m,5H),1.99–1.71(m,6H),1.65–1.52(m,1H),1.27–1.13(m,8H).

[0527] Example 13: Synthesis of Compound 13

[0528]

[0529] Step 1: Synthesis of compound 13B

[0530] Compound 13A (2 g, 8.65 mmol) was placed in a sealed tube, 20 mL of ultra-dry tetrahydrofuran was added to dissolve, the system was placed in an ice bath for 10 min, and then borane dimethyl sulfide tetrahydrofuran solution (17.3 mL, 34.6 mmol, 2 mmol / L) was added, the system was heated to 70°C for overnight reaction after replacing the gas, 1N hydrochloric acid was added to the system to adjust the pH to about 2-3, and heating at 70°C was continued for 2 hours. The pH was adjusted to greater than 8 with saturated sodium bicarbonate, EA was extracted, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 13B (1.4 g, 74.51%).

[0531] LCMS m / z=218.2[M+H] +

[0532] Step 2: Synthesis of compound 13C

[0533] Compound 13B (1.4 g, 6.45 mmol) and triethylamine (2.68 mL, 19.35 mmol) were dissolved in 20 mL of DCM, and di-tert-butyl dicarbonate was slowly added at 0° C. The mixture was stirred at room temperature for 2 hours, extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 13C (1.8 g, 87.94%).

[0534] LCMS m / z=318.1[M+H] +

[0535] Step 3: Synthesis of compound 13D

[0536] Compound 13C (1.4 g, 6.45 mmol) was dissolved in 20 mL of methanol, and 10% palladium carbon was slowly added at room temperature. The mixture was stirred at room temperature for 2 hours, filtered through celite, and the filtrate was collected to obtain compound 13D (1.4 g, 85.92%).

[0537] LCMS m / z=288.1[M+H] +

[0538] Step 4: Synthesis of compound 13E

[0539] Compound 13D (1.4 g, 4.87 mmol) was placed in a sealed tube, 15 mL of ethanol was added to dissolve, the system was placed in an ice bath, and then methyl acrylate (1.26 g, 14.61 mmol) and DIPEA (1.89 g, 14.61 mmol) were added in sequence. After replacing the gas, the system was heated to 100 degrees to react overnight, extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 13E (1.2 g, 65.98%).

[0540] LCMS m / z=374.2[M+H] +

[0541] Step 5: Synthesis of Compound 13F

[0542] Compound 13E (1.2 g, 3.21 mmol) was placed in a 100 mL flask, and 20 mL of ethanol was added to dissolve it. Then bromoacetonitrile (0.68 g, 6.42 mmol) and sodium bicarbonate (1.35 g, 16.05 mmol) were added in sequence. The mixture was reacted at room temperature overnight, extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 13F (0.95 g, 74.27%).

[0543] LCMS m / z=399.2[M+H] +

[0544] Step 6: Synthesis of Compound 13G

[0545] Compound 13F (0.95 g, 2.38 mmol) was placed in a 100 mL flask, 15 mL of toluene was added to dissolve, and then acetaldehyde oxime (0.42 g, 7.14 mmol) and indium trichloride (0.16 g, 0.71 mmol) were added in sequence. After replacing the gas, the system was heated to 120 degrees to react overnight, extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 13G (0.75 g, 75.67%).

[0546] LCMS m / z=417.3[M+H] +

[0547] Step 7: Synthesis of compound 13H

[0548] Compound 13G (0.75 g, 1.8 mmol) was placed in a 100 mL flask, 10 mL THF was added to dissolve, and then benzyltrimethylammonium hydroxide (0.9 g, 5.4 mmol) was added in sequence. After replacing the gas, the mixture was reacted at room temperature for 2 hours, extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 13H (0.41 g, 59.25%).

[0549] LCMS m / z=385.1[M+H] +

[0550] Step 8: Synthesis of Compound 13I

[0551] Compound 13H (0.75 g, 1.8 mmol) was dissolved in 10 mL DCM, 3 mL TFA was slowly added at room temperature, and the mixture was stirred for 2 hours. The organic solvent was directly dried to obtain compound 13I (0.28 g), which was directly carried out to the next step without purification.

[0552] Step 9: Synthesis of compound 13

[0553] Compound 11D (209 mg, 0.35 mmol) and 13I (100 mg, 0.35 mmol) were dissolved in 10 mL of chloroform and 2 mL of methanol, stirred at room temperature for 2 hours, sodium triacetylborohydride (150 mg, 0.71 mmol) was slowly added, concentrated, and the residue was purified by column chromatography to obtain compound 13 (14 mg, 4.61%).

[0554] LCMS m / z=867.3[M+1] +

[0555] 1 H NMR(400MHz,DMSO-d6)δ12.49(s,1H),10.23(s,1H),8.76(s,1H),7.79(d,2H),7 .52–7.30(m,5H),7.08–6.95(m,3H),6.59(s,1H),6.50(s,1H),6.19(s,1H),4.24 –4.02(m,5H),3.89–3.69(m,7H),3.00–2.89(m,2H),2.84–2.68(m,4H),2.62–2. 53(m,2H),2.45–2.36(m,4H),2.14(s,3H),1.93–1.78(m,3H),1.32–1.14(m,8H).

[0556] Example 14: Synthesis of Compound 14

[0557]

[0558] Referring to the synthetic route and experimental operation method of compound 13, compound 14 (15 mg) was obtained

[0559] LCMS m / z=846.50[M+1] +

[0560] 1 H NMR (400MHz, DMSO-d6) δ12.47(s,1H),10.23(s,1H),9.47(t,1H),8.74(s,1H),8.11–8. 01(s,2H),7.88(d,2H),7.47–7.31(m,3H),7.19(s,1H),7.07–6.97(m,3H),6.20(s,1H) ,4.55(d,2H),4.12–4.01(m,2H),3.91–3.71(m,6H),3.02–2.89(m,2H),2.85–2.68(m,4 H),2.48(s,3H),2.45–2.38(m,2H),1.91–1.80(m,3H),1.44(s,9H),1.33–1.19(m,2H).

[0561] Example 15: Synthesis of Compound 15

[0562]

[0563] Step 1: Synthesis of compound 15A

[0564] Dissolve the intermediate compound F (40 mg, 0.01 mmol) in 2 mL of dichloromethane and 0.5 ml of trifluoroacetic acid, and stir at room temperature for 1 hour. Concentrate under reduced pressure to obtain a crude compound 15A (40 mg). Use it directly in the next step.

[0565] Step 2: Synthesis of compound 15

[0566] Compound 15A (40 mg) was dissolved in 5 ml of DMAc, 10G (58 mg, 0.01 mmol) and 1 drop of acetic acid were added, and the mixture was stirred at room temperature for 1 hour. Sodium triacetoxyborohydride (64 mg, 0.03 mmol) was added and the mixture was stirred for 16 hours. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and subjected to column chromatography to obtain compound 15 (15 mg, 17.42%).

[0567] LCMS m / z=863.4[M+1] +

[0568] 1H NMR(400MHz,DMSO-d6)δ12.46(s,1H),10.19(s,1H),9.46(t,1H),8.74(s,1H),8.09–8.02(m,2H),7.88(d ,2H),7.47–7.42(m,1H),7.18(s,1H),7.02(d,2H),6.94(dd,1H),6.88(d,1H),6.81(d,1H),4.55(d,2H), 3.90–3.71(m,3H),3.66(t,2H),2.99–2.86(m,3H),2.85–2.70(m,3H),2.70–2.57(m,4H),2.48(s,3H),2. 25–2.16(m,2H),2.13–2.02(m,1H),1.89–1.71(m,5H),1.69–1.56(m,1H),1.44(s,9H),1.29–1.15(m,2H).

[0569] Example 16: Synthesis of Compound 16

[0570]

[0571] Referring to the synthetic route and experimental operation method of compound 10, compound 16 (15 mg) was obtained.

[0572] LCMS m / z=879.2[M+1] +

[0573] 1 H NMR(400MHz,DMSO-d6)δ12.46(s,1H),10.75(s,1H),9.46(t,1H),8.74(s,1H),8.10–8.01(m ,2H),7.88(d,2H),7.44(d,1H),7.18(s,1H),7.02(d,2H),6.79(d,1H),6.62(d,1H),4.55(d ,2H),3.91–3.76(m,3H),3.75–3.66(m,1H),3.01–2.84(m,3H),2.83–2.54(m,6H),2.48(s,3 H),2.24–2.00(m,4H),1.99–1.71(m,6H),1.66–1.52(m,1H),1.44(s,9H),1.30–1.14(m,3H).

[0574] Example 17: Synthesis of Compound 17

[0575]

[0576] Step 1: Synthesis of compound 17A

[0577] Compound intermediate 5c (1.5 g, 4.08 mmol), Pd(dppf)Cl2 (0.33 g, 0.41 mmol), pinacol diboron (1.55 g, 6.12 mmol) and potassium acetate (1.2 g, 12.24 mmol) were dissolved in 30 mL of 1,4-dioxane and reacted overnight at 90° C. The mixture was concentrated under reduced pressure, and the residue was concentrated under reduced pressure on silica gel, and the residue was purified by silica gel column chromatography to obtain compound 17A (1.22 g, 72.17%).

[0578] Ms m / z(ESI):415.3[M+H] +

[0579] Step 2: Synthesis of compound 17B

[0580] Compound 17A (1.22 g, 2.94 mmol), Pd(dppf)Cl2 (0.24 g, 0.29 mmol), intermediate A (1.23 g, 2.94 mmol) and potassium carbonate (1.22 g, 8.82 mmol) were dissolved in 30 mL of 1,4-dioxane and reacted at 80° C. overnight. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to obtain compound 17B (0.5 g, 29.32%).

[0581] Ms m / z(ESI):580.1[M+H] +

[0582] Step 3: Synthesis of compound 17C

[0583] Compound 17B (0.5 g, 0.86 mmol), Pd(dppf)Cl2 (0.07 g, 0.086 mmol), intermediate 1 (0.32 g, 1.12 mmol) and potassium carbonate (0.36 g, 2.58 mmol) were dissolved in 10 mL of 1,4-dioxane and reacted at 100° C. for 2 hours. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to obtain compound 17C (190 mg, 33.23%).

[0584] Ms m / z(ESI):665.3[M+H] +

[0585] Step 4: Synthesis of compound 17D

[0586] The compound intermediate G (0.15 g, 0.87 mmol) was dissolved in 5 mL of dichloromethane, and TCFH (0.39 g, 2.61 mmol) was added dropwise under ice bath. After the addition was completed, the mixture was heated to room temperature and stirred for 30 minutes. Under ice bath, the reaction solution was added dropwise to 17C (0.19 g, 0.29 mmol) and triethylamine (0.44 g, 4.35 mmol) dissolved in 5 mL of dichloromethane. The mixture was reacted at room temperature for 2 hours, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 17D (110 mg, 46.43%).

[0587] Step 5: Synthesis of compound 17E

[0588] Compound 17D (0.11 g, 0.13 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 1 hour, concentrated to remove the solvent, and the crude residue 17E was directly used in the next step.

[0589] Step 6: Synthesis of Compound 17F

[0590] The crude compound 17E was dissolved in 6 mL of DCM, and 2 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature. The mixture was stirred for 2 hours, and a saturated aqueous sodium bicarbonate solution was added to adjust the pH to about 8. The mixture was concentrated and dissolved in 5% methanol in dichloromethane. The filtrate was collected by filtration and concentrated to obtain the crude compound 17F (75 mg), which was directly used for the next step.

[0591] Step 7: Synthesis of compound 17

[0592] Compound 17F (75 mg, 0.13 mmol) and intermediate C (39 mg, 0.13 mmol) were dissolved in 5 mL 1,2-dichloroethane and 1 mL methanol, stirred at room temperature for 2 hours, sodium triacetyl borohydride (55 mg, 0.26 mmol) was slowly added, stirred at room temperature for overnight reaction, concentrated, the residue was dissolved in acetonitrile and water, and purified by Pre-HPLC (instrument and preparation column: SHIMADZU LC-20AP was used to prepare the liquid phase, the preparation column model was Phenomenex C18, 5 μm, inner diameter * length = 19 mm * 150 mm). Preparation method: The reaction solution was filtered with a 0.45 μm filter membrane to prepare a sample solution. Mobile phase system: acetonitrile / water (containing 10 Mm ammonium carbonate). Gradient elution method: Acetonitrile was gradient eluted from 32% to 62% (elution time 15 min). After freeze-drying, compound 17 (10 mg, 8.92%) was obtained.

[0593] Ms m / z(ESI):862.3[M+H] +

[0594] 1H NMR(400MHz,CD3OD)δ8.68(s,1H),7.96–7.89(m,2H),7.64–7.57(m,1H),7.56–7.50(m,2H),7 .23–7.15(m,2H),7.05–6.98(m,2H),6.98–6.91(m,2H),4.70(s,2H),3.95–3.87(m,1H),3.80 (t,2H),3.75–3.67(m,2H),3.16–2.88(m,5H),2.86–2.70(m,5H),2.54(s,3H),2.41–2.24(m, 3H),2.06–1.98(m,2H),1.96–1.87(m,2H),1.86–1.70(m,2H),1.42(s,9H),1.33–1.28(m,2H).

[0595] Example 18: Synthesis of Compound 18

[0596]

[0597] Step 1: Synthesis of compound 18A

[0598] Compound 17B (0.7 g, 1.21 mmol), Pd(dppf)Cl2 (0.1 g, 0.12 mmol), intermediate 2 (0.47 g, 1.57 mmol) and potassium carbonate (0.5 g, 3.63 mmol) were dissolved in 10 mL of 1,4-dioxane and reacted overnight at 100° C. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to obtain compound 18A (421 mg, 52.34%).

[0599] Ms m / z(ESI):679.3[M+H] +

[0600] Step 2: Synthesis of compound 18B

[0601] The compound intermediate G (0.32 g, 1.86 mmol) was dissolved in 5 mL of dichloromethane, and TCFH (0.83 g, 5.58 mmol) was added dropwise under ice bath. After the addition was completed, the mixture was heated to room temperature and stirred for 30 minutes. Under ice bath, the reaction solution was added dropwise to 18A (421 mg, 0.62 mmol) and triethylamine (0.94 g, 9.30 mmol) dissolved in 5 mL of dichloromethane. The mixture was reacted at room temperature for 2 hours, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 18B (323 mg, 62.69%).

[0602] Step 3: Synthesis of compound 18C

[0603] Compound 18B (0.32 g, 0.39 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 1 hour, and concentrated to remove the solvent. The crude residue 18C was used directly in the next step.

[0604] Step 4: Synthesis of compound 18D

[0605] The crude compound 18C was dissolved in 6 mL of DCM, and 2 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature. The mixture was stirred for 2 hours, and a saturated aqueous sodium bicarbonate solution was added to adjust the pH to about 8. The mixture was concentrated and dissolved in 5% methanol in dichloromethane. The filtrate was collected by filtration and concentrated to obtain the crude compound 18D (190 mg), which was directly subjected to the next step.

[0606] Step 5: Synthesis of compound 18

[0607] Compound 18D (190 mg, 0.32 mmol) and intermediate C (96 mg, 0.32 mmol) were dissolved in 10 mL 1,2-dichloroethane and 2 mL methanol, stirred at room temperature for 2 hours, sodium triacetyl borohydride (140 mg, 0.64 mmol) was slowly added, stirred at room temperature for overnight reaction, concentrated, the residue was dissolved in acetonitrile and water, and purified by Pre-HPLC (instrument and preparation column: SHIMADZU LC-20AP preparation liquid phase, preparation column model is Phenomenex C18, 5 μm, inner diameter * length = 19 mm * 150 mm). Preparation method: The reaction solution was filtered with a 0.45 μm filter membrane to prepare a sample solution. Mobile phase system: acetonitrile / water (containing 10 Mm ammonium carbonate). Gradient elution method: acetonitrile gradient elution from 32% to 62% (elution time 15 min). After freeze-drying, compound 18 (30 mg, 26.77%) was obtained.

[0608] Ms m / z(ESI):876.4[M+H] +

[0609] 1H NMR(400MHz,CD3OD)δ8.67(s,1H),8.03–7.87(m,2H),7.65(d,1H),7.62–7.56(m,1H),7.55–7.48(m,1H ),7.26–7.14(m,2H),7.06–6.98(m,2H),6.99–6.88(m,2H),5.52(q,1H),3.94–3.84(m,1H),3.80(t,,2H ),3.76–3.66(m,2H),3.14–2.87(m,5H),2.84–2.69(m,5H),2.59(s,3H),2.34(d,2H),2.30–2.20(m,1H) ,2.04–1.97(m,2H),1.95–1.86(m,2H),1.83–1.70(m,2H),1.63(d,3H),1.41(s,9H),1.35–1.27(m,2H).

[0610] Example 19: Synthesis of Compound 19

[0611]

[0612] Step 1: Synthesis of compound 19B

[0613] Compound 19A (10.0 g, 44.83 mmol), 4-hydroxymethylpiperidine (6.2 g, 53.80 mmol) and potassium carbonate (18.59 g, 134.49 mmol) were dissolved in 100 mL of ACN and reacted at 90° C. overnight. The residue was concentrated and purified by column chromatography to obtain compound 19B (12.1 g, 84.82%).

[0614] Ms m / z(ESI):319.2[M+H] +

[0615] Step 2: Synthesis of compound 19C

[0616] Compound 19B (4.5 g, 14.30 mmol), Pd(dppf)Cl2 (0.97 g, 1.19 mmol), intermediate A (5.0 g, 11.92 mmol) and potassium carbonate (4.94 g, 35.76 mmol) were dissolved in 60 mL of 1,4-dioxane and 6 mL of water and reacted at 80° C. for 12 h. The residue was concentrated and purified by column chromatography to obtain compound 19C (3.4 g, 58.94%).

[0617] Ms m / z(ESI):484.1[M+H] +

[0618] Step 3: Synthesis of compound 19D

[0619] Compound 19C (1.1 g, 2.27 mmol), Pd(dppf)Cl2 (0.19 g, 0.23 mmol), intermediate 1 (0.62 g, 2.52 mmol) and potassium carbonate (1.1 g, 7.96 mmol) were dissolved in 20 mL of 1,4-dioxane and 2 mL of water and reacted at 100° C. for 2 hours. The residue was concentrated and purified by column chromatography to obtain compound 19D (900 mg, 69.72%).

[0620] Ms m / z(ESI):569.2[M+H] +

[0621] Step 4: Synthesis of compound 19E

[0622] The compound intermediate G (320 mg, 1.90 mmol) was dissolved in 10 mL of DCM, 1-chloro-N,N,2-trimethylpropyleneamine (630 mg, 4.74 mmol) was slowly added at 0 degrees Celsius, the temperature was raised to room temperature and stirred for 30 minutes, the above liquid was slowly added to a dichloromethane mixed solution of 19D (0.9 g, 1.58 mmol) and triethylamine (480 mg, 4.74 mmol) at room temperature, and the reaction was allowed to proceed for 2 hours. The reaction was extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 19E (505 mg, 44.34%).

[0623] Ms m / z(ESI):721.2[M+H] +

[0624] Step 5: Synthesis of Compound 19F

[0625] Compound 19E (500 mg, 0.69 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 2 hours, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 19F (300 mg, 74.87%).

[0626] Step 6: Synthesis of Compound 19G

[0627] Compound 19F (300 mg, 0.52 mmol) was dissolved in 10 mL DMSO solution, and IBX (730 mg, 2.6 mmol) was added at room temperature under nitrogen protection, and stirred for 12 hours. The reaction was extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 19G (210 mg, 69.79%).

[0628] Step 7: Synthesis of compound 19

[0629] 19G (100 mg, 0.17 mmol) was added to a 50 mL single-mouth bottle, and 1,2-dichloroethane (5 mL) and methanol (5 mL), intermediate E-1 (81 mg, 0.26 mmol) and 0.04 mL acetic acid were added. After stirring at room temperature for 4 h, sodium triacetoxyborohydride (43 mg, 0.2 mmol) was added and reacted at room temperature for 2 h. The reaction system was concentrated under reduced pressure, water (50 mL) was added, and the mixture was extracted with a mixed solvent of dichloromethane and isopropanol (v / v) = 10:1 (20 mL×3), and the organic phase was washed with a saturated sodium chloride aqueous solution (20 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by Prep-TLC to obtain compound 19 (20 mg, 13.37%).

[0630] Ms m / z(ESI):880.2[M+H] +

[0631] 1 H NMR(400MHz,CD3OD)δ8.71(s,1H),8.61(d,1H),8.01(dd,1H),7.95–7.90(m,2H),7.54(d,1H),7.0 2(s,1H),6.92(d,1H),6.81(d,1H),6.57(d,1H),4.70(s,2H),4.46–4.35(m,2H),3.85(dd,1H),3. 74–3.67(m,1H),3.10–2.90(m,5H),2.88–2.58(m,5H),2.58(s,3H),2.35–2.29(m,2H),2.27–2.16 (m,2H),2.14–1.99(m,2H),1.96–1.86(m,4H),1.77–1.55(m,1H),1.42(s,9H),1.36–1.19(m,2H).

[0632] Example 20: Synthesis of Compound 20

[0633]

[0634] Step 1: Synthesis of compound 20A

[0635] Compound 19C (2.7 g, 5.58 mmol), Pd(dppf)Cl2 (0.19 g, 0.23 mmol), intermediate 2 (1.75 g, 6.70 mmol) and potassium carbonate (2.7 g, 19.53 mmol) were dissolved in 30 mL of 1,4-dioxane and 3 mL of water and reacted at 100° C. for 2 hours. The residue was concentrated and purified by column chromatography to obtain compound 20A (1.9 g, 58.43%).

[0636] Ms m / z(ESI):582.2[M+H] +

[0637] Step 2: Synthesis of compound 20B

[0638] The compound intermediate G (699 mg, 4.11 mmol) was dissolved in 10 mL of DCM, 1-chloro-N,N,2-trimethylpropyleneamine (550 mg, 4.11 mmol) was slowly added at 0 degrees Celsius, the temperature was raised to room temperature and stirred for 30 minutes, the above liquid was slowly added to a mixed solution of 20A (0.9 g, 1.58 mmol) and triethylamine (420 mg, 4.11 mmol) in dichloromethane at room temperature, and the mixture was reacted for 2 hours. The reaction was extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 20B (600 mg, 59.60%).

[0639] Ms m / z(ESI):735.3[M+H] +

[0640] Step 3: Synthesis of Compound 20C

[0641] Compound 20B (500 mg, 0.68 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 2 hours, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 20C (320 mg, 65.62%).

[0642] Step 4: Synthesis of compound 20D

[0643] Compound 20C (320 mg, 0.54 mmol) was dissolved in 10 mL DMSO solution, and IBX (760 mg, 2.7 mmol) was added under nitrogen protection at room temperature and stirred for 12 hours. The mixture was extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 20D (285 mg, 89.05%).

[0644] Step 5: Synthesis of compound 20

[0645] Referring to the synthesis method of compound 19, the target compound 20 (15 mg, 12.91%) was obtained.

[0646] Ms m / z(ESI):894.2[M+H] +

[0647] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.60(d,1H),8.01(dd,1H),7.96–7.90(m,2H),7.66(d,1 H),7.02(s,1H),6.91(d,1H),6.80(d,1H),6.57(d,1H),5.52(q,1H),4.44–4.36(m,2H),3.8 4(dd,1H),3.73–3.66(m,1H),3.09–2.91(m,5H),2.88–2.63(m,5H),2.59(m,3H),2.33–2.02 (m,5H),1.98–1.85(m,5H),1.76–1.67(m,1H),1.63(d,3H),1.41(s,9H),1.33–1.18(m,2H).

[0648] Example 21: Synthesis of Compound 21

[0649]

[0650] Using 4c as the starting material, referring to the synthesis methods of intermediate F and compound 15, the target compound 21 (16 mg, 10.73%) was obtained.

[0651] Ms m / z(ESI):877.2[M+H] +

[0652] 1 H NMR(400MHz,CD3OD)δ8.71(s,1H),8.61(d,1H),8.01(dd,1H),7.97–7.89(m,2H) ,7.66(d,1H),7.04–6.97(m,2H),6.95–6.82(m,3H),5.54(q,1H),4.44–4.36(m, 2H),3.85–3.68(m,3H),3.09–2.66(m,11H),2.59(s,3H),2.35–2.16(m,3H),2.0 2–1.86(m,4H),1.79–1.67(m,1H),1.63(d,3H),1.41(s,9H),1.29–1.19(m,2H).

[0653] Example 22: Synthesis of Compound 22

[0654]

[0655] Referring to the synthesis method of compound 19, the target compound 22 (13 mg, 8.72%) was obtained.

[0656] Ms m / z(ESI):877.1[M+H] +

[0657] 1 H NMR(400MHz,CD3OD)δ8.73(s,1H),8.65(d,1H),8.05(dd,1H),7.99–7.92(m,2H) ,7.68(d,1H),7.07–7.01(m,2H),6.99–6.86(m,3H),5.56(q,1H),4.48–4.41(m, 2H),3.90–3.68(m,3H),3.19–2.71(m,11H),2.61(s,3H),2.41–2.33(m,3H),2.0 1–1.90(m,4H),1.83–1.71(m,1H),1.65(d,3H),1.50(s,9H),1.40–1.26(m,2H).

[0658] Example 23: Synthesis of Compound 23

[0659]

[0660] Step 1: Synthesis of compound 23C

[0661] Intermediate B (0.35 g, 2.08 mmol), TCFH (0.73 g, 2.5 mmol), N-methylimidazole (0.36 g, 4.4 mmol) and 20 mL CH3CN were added to a reaction tube, and compound 20A (0.93 g, 2.08 mmol) was slowly added at room temperature to react overnight. The reaction solution was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate and chromatographed on a silica gel column to obtain compound 23C (298 mg, 20%).

[0662] Step 2: Synthesis of compound 23D

[0663] Compound 23C (0.26 g, 0.35 mmol) and 2 mL of 4% NaOH methanol solution were added to a reaction tube and reacted at room temperature for 1 hour. The reaction solution was directly concentrated and purified by silica gel column chromatography to obtain compound 23D (200 mg, 89%).

[0664] Step 3: Synthesis of compound 23E

[0665] Compound 23D (200 mg, 0.34 mmol) was dissolved in 3 mL DMSO, IBX (0.47 g, 1.68 mmol) was added and reacted at room temperature for 4 hours. The reaction solution was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate and chromatographed on a silica gel column to obtain compound 23E (165 mg, 83%).

[0666] Step 4: Synthesis of compound 23

[0667] Referring to the synthetic route and experimental operation method of compound 10, compound 23 (47 mg, 39%) was obtained.

[0668] LCMS m / z=894.5[M+1] +

[0669] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.61(d,1H),8.01(dd,1H),7.97–7.89(m,2H),7.66(d,1H),7.02(s, 1H),6.91(d,1H),6.80(d,1H),6.57(d,1H),5.54(q,1H),4.39(d,2H),3.84(dd,1H),3.69(d,1H),3.10 –2.90(m,5H),2.88–2.74(m,2H),2.74–2.63(m,3H),2.59(s,3H),2.32–2.26(m,2H),2.24–2.15(m,2H) ,2.14–2.05(m,1H),1.97–1.86(m,5H),1.77–1.66(m,1H),1.63(d,3H),1.48(s,9H),1.36–1.19(m,2H).

[0670] Example 24: Synthesis of Compound 24

[0671]

[0672] Using 5c ​​as the starting material, referring to the synthesis methods of intermediate F and compound 15, the target compound 24 (43 mg, 37%) was obtained.

[0673] LCMS m / z=877.4[M+1] +

[0674] 1H NMR(400MHz,CD3OD)δ8.70(s,1H),8.61(d,1H),8.01(dd,1H),7.96–7.90(m,2H), 7.65(d,1H),7.04–6.97(m,2H),6.95–6.89(m,2H),6.85(d,1H),5.54(q,1H),4.40 (d,2H),3.85–3.72(m,3H),3.07–2.67(m,11H),2.59(s,3H),2.37–2.16(m,3H),2 .02–1.86(m,4H),1.79–1.68(m,1H),1.62(d,3H),1.48(s,9H),1.36–1.19(m,2H).

[0675] Example 25: Synthesis of Compound 25

[0676]

[0677] Using intermediate 20D and E-2 as raw materials, referring to the synthesis of compound 10, compound 25 (48 mg, 40%) was obtained.

[0678] LCMS m / z=894.5[M+1] +

[0679] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.60(d,1H),7.99(dd,1H),7.97–7.88(m,2H),7.6 5(d,1H),7.01(s,1H),6.89(d,1H),6.80(d,1H),6.56(d,1H),5.52(q,1H),4.38(d,2H ),3.84(dd,1H),3.68(d,1H),3.07–2.89(m,5H),2.87–2.62(m,5H),2.30–2.05(m,5H ),1.98–1.84(m,5H),1.74–1.66(m,1H),1.63(d,3H),1.41(s,9H),1.30–1.15(m,2H).

[0680] Example 26: Synthesis of Compound 26

[0681]

[0682] Referring to the synthetic route and experimental operation method of compound 10, compound 26 (40 mg, 34%) was obtained.

[0683] LCMS m / z=877.4[M+1]+

[0684] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.61(d,1H),8.00(dd,1H),7.96–7.89(m,2H), 7.66(d,1H),7.04–6.96(m,2H),6.95–6.88(m,2H),6.85(d,1H),5.52(q,1H),4.40 (d,2H),3.82–3.74(m,3H),3.07–2.68(m,10H),2.59(s,3H),2.35–2.17(m,3H),2 .00–1.85(m,5H),1.80–1.70(m,1H),1.63(d,3H),1.41(s,9H),1.33–1.17(m,2H).

[0685] Preparation of Example 27:

[0686]

[0687] Step 1: Synthesis of compound 27B

[0688] Compound 4c (0.50 g, 1.36 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.11 g, 0.13 mmol), biboronic acid pinacol ester (0.51 g, 2.02 mmol) and potassium acetate (0.27 g, 2.75 mmol) were dissolved in 15 mL of 1,4-dioxane and reacted at 90°C for 16 h under a nitrogen atmosphere. The reaction was cooled to room temperature, and silica gel was directly added to mix the sample, and compound 27B (0.33 g, 58.56%) was obtained by column chromatography purification.

[0689] LCMS m / z=415.2[M+H] +

[0690] Step 2: Synthesis of compound 27C

[0691] Compound 27B (0.33 g, 0.80 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.098 g, 0.12 mmol), intermediate A (0.37 g, 0.88 mmol) and potassium carbonate (0.22 g, 1.60 mmol) were dissolved in a mixed solvent of 15 mL of 1,4-dioxane and 2 mL of water, and reacted at 80°C for 16 h under a nitrogen atmosphere. The reaction was cooled to room temperature, and silica gel was directly added to stir the sample, and purified by column chromatography to obtain compound 27C (0.20 g, 43.10%).

[0692] LCMS m / z=580.2[M+H] +

[0693] Step 3: Synthesis of compound 27D

[0694] Compound 27C (0.20 g, 0.34 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.042 g, 0.051 mmol), intermediate E (0.12 g, 0.46 mmol) and potassium carbonate (0.094 g, 0.68 mmol) were dissolved in a mixed solvent of 10 mL of 1,4-dioxane and 1 mL of water, and reacted at 100° C. for 2 h under a nitrogen atmosphere. The reaction was cooled to room temperature, and silica gel was directly added to stir the sample, and compound 27D (0.12 g, 51.99%) was obtained by column chromatography purification.

[0695] LCMS m / z=679.2[M+H] +

[0696] Step 4: Synthesis of compound 27E

[0697] 3-tert-Butyl-1,2,4-oxadiazole-5-carboxylic acid (0.072 g, 0.54 mmol) was dissolved in 6 mL of dry dichloromethane. 1-Chloro-N,N,2-trimethylpropyleneamine (0.14 g, 1.08 mmol) was slowly added dropwise at 0°C under a nitrogen atmosphere. After completion of the addition, the mixture was reacted at room temperature for 1 h. Under a nitrogen atmosphere, the reaction solution was slowly added dropwise to 5 mL of dry dichloromethane containing compound 27D (0.12 g, 0.18 mmol) and triethylamine (0.055 g, 0.54 mmol) at 0°C. The mixture was reacted at room temperature for 1 h. 8 mL of water was added, the liquids were separated, the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was chromatographed on a silica gel column (PE:EA=2:1) ​​to obtain compound 27E (65 mg, 43.46%).

[0698] LCMS m / z=831.1[M+H] +

[0699] Step 5: Synthesis of compound 27F

[0700] Compound 27E (65 mg, 0.078 mmol) was dissolved in 15 mL of 4% sodium hydroxide methanol solution, stirred at room temperature for 1 h, and the solvent was directly dried without purification to proceed to the next step to obtain compound 27F.

[0701] LCMS m / z=691.4[M+H] +

[0702] Step 6: Synthesis of compound 27G

[0703] The crude compound 27F was dissolved in 5 mL of DCM, and 1 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature and stirred for 2 h. After the reaction was completed, a certain amount of sodium bicarbonate was added to adjust the pH to alkaline. The organic solvent was directly spin-dried, and 5% methanol in dichloromethane solution was added to dissolve it. The filtrate was collected by filtration to obtain compound 27G (43 mg), which was directly carried out to the next step without purification.

[0704] LCMS m / z=591.4[M+H] +

[0705] Step 9: Synthesis of compound 27

[0706] Compound 27G (0.043 g, 0.073 mmol) and intermediate C (0.033 g, 0.11 mmol) were dissolved in a mixed solvent of 5 mL 1,2-dichloroethane and 1 mL methanol, and 1 drop of glacial acetic acid was added. The mixture was stirred at room temperature for 2 h, and sodium triacetylborohydride (0.046 g, 0.22 mmol) was slowly added. The mixture was reacted at room temperature for 16 h. Silica gel was directly added to the mixture and the mixture was purified by column chromatography to obtain compound 27 (8 mg, 12.51%).

[0707] LCMS m / z=876.4[M+H] +

[0708] 1 H NMR(400MHz,CD3OD)δ8.67(s,1H),7.96–7.88(m,2H),7.65(d,1H),7.62–7.57(m,1H),7.54–7.49( m,1H),7.22–7.15(m,2H),7.04–6.98(m,2H),6.97–6.90(m,2H),5.52(q,1H),3.92–3.85(m,1H),3. 80(t,2H),3.74–3.67(m,2H),3.18–2.93(m,4H),2.92–2.69(m,6H),2.59(s,3H),2.32(d,2H),2.2 7–2.16(m,1H),2.04–1.86(m,4H),1.83–1.70(m,2H),1.63(d,3H),1.42(s,9H),1.35–1.27(m,2H).

[0709] Example 28: Synthesis of Compound 28

[0710]

[0711] Using 23E as starting material and referring to the synthesis of compound 19, compound 28 (16 mg) was prepared.

[0712] LCMS m / z=894.5[M+H] +

[0713] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.61(d,1H),8.01(dd,1H),7.96–7.89(m,2H),7.65(d,1H),7 .02(s,1H),6.91(d,1H),6.80(d,1H),6.57(d,1H),5.53(q,1H),4.44–4.36(m,2H),3.84(dd,1H) ,3.72–3.65(m,1H),3.08–2.89(m,5H),2.87–2.61(m,5H),2.58(s,3H),2.31–2.26(m,2H),2.24– 2.05(m,3H),1.96–1.85(m,5H),1.76–1.65(m,1H),1.62(d,3H),1.48(s,9H),1.28–1.17(m,2H).

[0714] Example 29: Synthesis of Compound 29

[0715]

[0716] Using Eb-1 as the raw material, refer to the synthesis process of Example 27 and synthesize compound 29 (33 mg)

[0717] LCMS m / z=894.5[M+H] +

[0718] 1 H NMR(400MHz,CD3OD)δ8.71(s,1H),7.94–7.87(m,2H),7.66(d,1H),7.47(d,1H),7.23–7.15(m ,2H),7.04–6.96(m,3H),6.70(d,1H),5.52(q,1H),3.84–3.77(m,3H),3.74–3.67(m,2H),3.22 –3.11(m,1H),3.06–2.68(m,9H),2.58(s,3H),2.36–2.28(m,2H),2.25–2.15(m,1H),2.05–1. 96(m,2H),1.96–1.87(m,2H),1.84–1.69(m,2H),1.62(d,3H),1.41(s,9H),1.39–1.31(m,2H).

[0719] Preparation of Example 30:

[0720]

[0721] Using Ea-1 as the starting material and referring to the synthesis of compound 27, compound 30 (90 mg) was prepared.

[0722] LCMS m / z=894.5[M+H] +

[0723] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),7.95–7.87(m,2H),7.66(d,1H),7.47(d,1H),7.22–7. 15(m,2H),7.04–6.97(m,3H),6.70(d,1H),5.52(q,1H),3.83–3.76(m,3H),3.74–3.65(m, 2H),3.21–3.12(m,1H),3.06–2.67(m,9H),2.58(s,3H),2.36–2.28(m,2H),2.23–2.12(m ,1H),2.05–1.85(m,4H),1.82–1.68(m,2H),1.62(d,3H),1.41(s,9H),1.39–1.30(m,2H).

[0724] Intermediate H Synthesis

[0725]

[0726] Step 1: Preparation of H-1

[0727] Ea-1 (5.0 g, 12.98 mmol), benzophenone imine (3.05 mL, 3.29 g, 18.17 mmol), cesium carbonate (9.30 g, 28.56 mmol), palladium acetate (583 mg, 2.6 mmol), XANT PHOS (751 mg, 1.3 mmol) were added to a dioxane solution (100 mL) and reacted at 100 ° C for 16 h under a nitrogen atmosphere. The reaction solution was cooled to room temperature, and the solid was removed by diatomaceous earth filtration. The filter cake was washed with dichloromethane, and the organic phase was collected and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 1 / 5) to obtain H-1 (5.6 g, yield: 89%).

[0728] LCMS m / z=486.3[M+H] +

[0729] Step 2: Preparation of H-2

[0730] H-1 (5.6 g, 11.53 mmol) was added to methanol (200 mL), palladium carbon (3.0 g, wt% = 10%), ammonium acetate (5.6 g, 72.6 mmol), and hydrogen atmosphere (balloon pressure) was reacted at room temperature for 16 h. The mixture was filtered through diatomaceous earth, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 1 / 1) to obtain H-2 (3.6 g, yield: 97%).

[0731] LCMS m / z=322.3[M+H] +

[0732] Step 3: Preparation of H-3

[0733] H-2 (3.6 g, 11.2 mmol), ethyl acrylate (3.36 g, 33.60 mmol) and N,N-diisopropylethylamine (4.34 g, 33.60 mmol) were added to ethanol (100 mL) in sequence, and the temperature was raised to 100°C for 72 h. The mixture was concentrated under reduced pressure, and the residue was separated and purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 1 / 20) to obtain H-3 (3.0 g, yield: 64%).

[0734] LCMS m / z=422.3[M+H] +

[0735] Step 4: Preparation of H-4

[0736] H-3 (1.0 g, 2.37 mmol) and N,N-diisopropylethylamine (0.92 g, 7.11 mmol) were added to tetrahydrofuran (30 mL), and then triphosgene (0.77 g, 2.61 mmol) was slowly added and reacted at room temperature for 1 h. Ammonia water (9 mL) was added, and the temperature was raised to 50 ° C and the reaction was continued for 2 h. The reaction solution was diluted with 100 mL of ethyl acetate, and the organic phase was washed with water 3 times, washed with saturated sodium chloride once, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 1 / 15) to obtain H-4 (1.0 g, yield: 91%).

[0737] LCMS m / z=465.3[M+H] +

[0738] Step 5: Preparation of H-5

[0739] H-4 (1.0 g, 2.15 mmol) was added to acetonitrile (20 mL), and then benzyltrimethylammonium hydroxide 40% methanol solution (2.5 mL, 6.45 mmol) was added, and the temperature was raised to 60°C for 2 h. Silica gel was added, and the mixture was concentrated under reduced pressure. The residue was separated and purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 1 / 15) to obtain H-5 (0.69 g, yield: 77%).

[0740] LCMS m / z=363.2[M-55] +

[0741] Step 6: Preparation of intermediate H

[0742] H-5 (0.5 g, 1.19 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (5 mL) was added, and the mixture was stirred at room temperature for 1 h. The reaction solution was concentrated under reduced pressure to remove trifluoroacetic acid, and 10 mL of dichloromethane and 1 mL of isopropanol were added to dissolve the residue. The sodium carbonate aqueous solution was adjusted to alkalinity, and the mixture was extracted 3 times with dichloromethane / isopropanol (v / v) = 10 / 1. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate H (0.37 g, yield: 97%).

[0743] LCMS m / z=319.2[M+H] +

[0744] Intermediate I Synthesis:

[0745]

[0746] Step 1: Preparation of I-1

[0747] Eb-1 (6.29 g, 16.32 mmol), benzophenone imine (4.14 g, 22.85 mmol), cesium carbonate (10.63 g, 32.64 mmol), palladium acetate (0.73 g, 3.26 mmol), XANT PHOS (0.94 g, 1.63 mmol) were added to a dioxane solution (100 mL) and reacted at 105 ° C for 16 h under a nitrogen atmosphere. The reaction solution was cooled to room temperature, filtered through diatomaceous earth to remove the solid, the filter cake was washed with dichloromethane, the organic phase was collected, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 1 / 5) to obtain I-1 (6.94 g, yield: 87%).

[0748] LCMS m / z=486.2[M+H] +

[0749] Step 3: Preparation of I-2

[0750] I-1 (6.94 g, 14.29 mmol) was added to methanol (200 mL), palladium carbon (6.92 g, wt% = 10%), ammonium acetate (6.79 g, 88.03 mmol), and hydrogen atmosphere (balloon pressure) was reacted at room temperature for 12 h. The reaction solution was filtered through diatomaceous earth, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 1 / 1) to obtain I-2 (4.15 g, yield: 90%).

[0751] LCMS m / z=322.2[M+H] +

[0752] Step 4: Preparation of I-3

[0753] I-2 (4.15 g, 12.91 mmol), ethyl acrylate (3.88 g, 38.73 mmol) and N,N-diisopropylethylamine (5.01 g, 38.73 mmol) were added to ethanol (60 mL) in sequence, and the temperature was raised to 100°C for 72 h. The mixture was concentrated under reduced pressure, and the residue was separated and purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 1 / 20) to obtain I-3 (3.91 g, yield: 71%).

[0754] LCMS m / z=422.3[M+H] +

[0755] Step 5: Preparation of I-4

[0756] I-3 (0.50 g, 1.19 mmol) and N,N-diisopropylethylamine (0.46 g, 3.56 mmol) were added to tetrahydrofuran (20 mL), and then triphosgene (0.39 g, 1.31 mmol) was slowly added and reacted at room temperature for 1 h. Ammonia water (5 mL) was added, and the temperature was raised to 50 ° C and the reaction was continued for 2 h. The reaction solution was diluted with 100 mL of ethyl acetate, the organic phase was washed with water 3 times, washed with saturated sodium chloride once, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 1 / 15) to obtain I-4 (0.46 g, yield: 83%).

[0757] LCMS m / z=465.3[M+H] +

[0758] Step 6: Preparation of I-5

[0759] I-4 (0.46 g, 1.00 mmol) was added to acetonitrile (10 mL), and then benzyltrimethylammonium hydroxide 40% methanol solution (1.2 mL) was added, and the temperature was raised to 60°C for 2 h. Silica gel was added, and the mixture was concentrated under reduced pressure. The residue was separated and purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 1 / 15) to obtain I-5 (0.21 g, yield: 50%).

[0760] Step 7: Preparation of Intermediate I

[0761] I-5 (0.21 g, 0.50 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (5 mL) was added, and the mixture was stirred at room temperature for 1 h. The reaction solution was concentrated under reduced pressure to remove trifluoroacetic acid, and 10 mL of dichloromethane and 1 mL of isopropanol were added to dissolve the residue. The sodium bicarbonate aqueous solution was adjusted to alkalinity, and the mixture was extracted 3 times with dichloromethane / isopropanol (v / v) = 10 / 1. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate I (0.158 g).

[0762] LCMS m / z=319.2[M+H] +

[0763] Preparation of Example 31:

[0764]

[0765] Compound 20D (150 mg, 0.25 mmol), 4 mL 1,2-dichloroethane, 2 mL methanol and two drops of acetic acid were added to 120 mg of the crude intermediate H in sequence and stirred at room temperature for one hour, then sodium triacetoxyborohydride (161 mg, 0.76 mmol) was added to the reaction solution and stirred overnight. The reaction mixture was filtered and concentrated to obtain a crude compound 31, which was then purified by silica gel column chromatography to obtain a yellow solid 31 (190 mg).

[0766] LCMS m / z=895.3[M+H] +

[0767] 1H NMR(400MHz,CD3OD)δ8.70(s,1H),8.61(d,1H),8.00(dd,1H),7.96–7.90(m,2H), 7.66(d,1H),7.01(s,1H),6.91(t,2H),6.64(d,1H),5.56–5.48(m,1H),4.39(d,2 H),3.75–3.67(m,3H),3.14–3.04(m,1H),3.03–2.84(m,6H),2.78(t,3H),2.71–2 .64(m,1H),2.59(s,3H),2.26(d,2H),2.21–2.12(m,1H),1.96–1.86(m,4H),1.77–

[0768] 1.68(m,1H),1.63(d,3H),1.41(s,9H),1.27–1.23(m,2H).

[0769] Example 32 Preparation:

[0770]

[0771] Step 1: Preparation of 32A

[0772] Ea-1 (7.00 g, 18.17 mmol) and 70 mL of tetrahydrofuran were added to the reaction bottle under nitrogen atmosphere, and 2.5 mol / L n-butyl lithium in n-hexane solution (14.50 mL, 36.25 mmol) was slowly added dropwise at -78°C. After stirring for 1.5 h at -78°C, carbon dioxide was replaced three times, and the system temperature was controlled to be below -40°C under a carbon dioxide balloon atmosphere for 0.5 h. The reaction system was restored to room temperature, 20 mL of ethyl acetate was added, the pH was adjusted to 2 with 1 mol / L hydrochloric acid, and extracted with ethyl acetate (30 mL×3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was separated and purified by silica gel chromatography (petroleum ether / ethyl acetate (v / v) = 10:1-2:1) to obtain 32A (2.4 g, yield: 38%).

[0773] 1 H NMR(400MHz,DMSO-d6)δ7.42(d,1H),6.64(d,1H),4.00–3.82(m,3H),3.23–3.09(m,1H),3.08–2.90(m ,1H),2.90–2.77(m,1H),2.76–2.60(m,3H),2.05–1.90(m,1H),1.65–1.50(m,1H),1.49–1.35(m,9H).

[0774] Step 2: Preparation of intermediate 32B

[0775] 32A (0.21 g, 0.50 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (5 mL) was added, and the mixture was stirred at room temperature for 1 h. The reaction solution was concentrated under reduced pressure to remove trifluoroacetic acid, and 10 mL of dichloromethane and 1 mL of isopropanol were added to dissolve the residue. The sodium bicarbonate aqueous solution was adjusted to alkalinity, and the mixture was extracted 3 times with dichloromethane / isopropanol (v / v) = 10 / 1. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 32B (0.158 g).

[0776] LCMS m / z=319.2[M+H]+

[0777] Step 3: Preparation of intermediate 32C

[0778] 32C (146 mg) was synthesized from 20D by referring to the method of compound 31.

[0779] LCMS m / z=827.5[M+H] +

[0780] Step 4: Preparation of compound 32

[0781] Intermediate 32C (146 mg, 0.18 mmol) was dissolved in 2 mL DMF, and HOBt (24 mg, 0.18 mmol), EDCI (34 mg, 0.18 mmol) and NMI (34 mg, 0.54 mmol) were added thereto in sequence, followed by stirring at room temperature for one hour. Compound 32D (59 mg, 0.36 mmol) was then added to the reaction solution, and stirring continued for two hours. The reaction solution was then extracted three times with ethyl acetate, and the obtained organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product of the target product 32, which was purified by silica gel column chromatography to obtain a yellow solid 32 (56 mg, 34%).

[0782] LCMS m / z=937.5[M+H] +

[0783] Example 33 Preparation:

[0784]

[0785] Referring to the synthetic method of compound 31, compound 33 (20 mg) was prepared.

[0786] LCMS m / z=881.4[M+H] +

[0787] Example 34: Synthesis of Compound 34

[0788]

[0789] Intermediate G was used to replace intermediate B, and compound 34 (20 mg) was prepared by referring to the synthetic method of compound 1.

[0790] Ms m / z(ESI):807.4[M+H] +

[0791] 1 H NMR(400MHz,CD3OD)δ8.74(s,1H),7.98–7.92(m,2H),7.69-7.65(m,2H),7.55(d,1H),7.22–7.12(m,4H),7.01(d,2H),4.70(s,2H),3.83–3.77 (m,2H),3.75–3.66(m,4H),3.06–2.98(m,2H),2.85–2.69(m,6H),2.54( s,3H),2.47(d,2H),1.99–1.82(m,3H),1.42(s,9H),1.39–1.31(m,2H).

[0792] Example 35: Synthesis of Compound 35

[0793]

[0794] Step 1: Synthesis of compound 35B

[0795] Compound 35A (3.78 g, 10.01 mmol), Pd(dppf)Cl2 (0.68 g, 0.83 mmol), intermediate A (3.5 g, 8.34 mmol) and potassium carbonate (3.46 g, 25.02 mmol) were dissolved in 50 mL of 1,4-dioxane and 5 mL of water and reacted at 80° C. for 12 h. The residue was concentrated and purified by column chromatography to obtain compound 35B (3.1 g, 68.45%).

[0796] Ms m / z(ESI):543.1[M+H] +

[0797] Step 2: Synthesis of compound 35C

[0798] Compound 35B (1.4 g, 2.58 mmol), Pd(dppf)Cl2 (0.21 g, 0.26 mmol), intermediate 2 (0.81 g, 3.1 mmol) and potassium carbonate (1.07 g, 7.74 mmol) were dissolved in 30 mL of 1,4-dioxane and 3 mL of water and reacted at 100° C. overnight. The residue was concentrated and purified by column chromatography to obtain compound 35C (900 mg, 54.36%).

[0799] Ms m / z(ESI):628.2[M+H] +

[0800] Step 3: Synthesis of compound 35D

[0801] Compound intermediate B (178.68 mg, 1.05 mmol), TCFH (0.39 g, 1.4 mmol), and N-methylimidazole (170 mg, 2.1 mmol) were dissolved in 20 mL of DMF, and 35D (0.45 g, 0.7 mmol) was slowly added at room temperature to react overnight. The mixture was extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 35D (310 mg, 55.78%).

[0802] Step 4: Synthesis of compound 35E

[0803] Compound 35D (310 mg, 0.39 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 1 hour, and concentrated to remove the solvent to obtain crude compound 35E, which was directly used for the next step.

[0804] Step 5: Synthesis of compound 35F

[0805] The crude compound 35E was dissolved in 15 mL of DCM, and 5 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature. The mixture was stirred for 2 hours, and a certain amount of sodium bicarbonate was added to adjust the pH to greater than 8. The mixture was concentrated and dissolved in 5% methanol in dichloromethane. The filtrate was collected by filtration and concentrated to obtain the crude compound 35F, which was directly used for the next step without purification.

[0806] Step 6: Synthesis of compound 35

[0807] Compound 35F (220 mg, 0.40 mmol) and intermediate C (140 mg, 0.46 mmol) were dissolved in 10 mL 1,2-dichloroethane and 5 mL methanol, stirred at room temperature for 2 hours, and sodium triacetyl borohydride (55 mg, 0.26 mmol) was slowly added, and reacted at room temperature for 2 hours. After concentration, the crude product was prepared by Prep-HPLC (instrument: WATERS AUTOP preparative liquid phase; chromatographic column: SunFire@PrepC18 (19×250 nm); mobile phase A: acetonitrile; mobile phase B: water (containing 0.1% ammonium acetate); gradient elution: mobile phase A content is 10-70%; flow rate: 17 mL / min; column temperature: room temperature; detection wavelength: 210 nm; the sample was dissolved in DMF and filtered with a 0.45 um filter head to prepare a sample solution; elution time: 15 min), and lyophilized to obtain compound 35 (40 mg, 11.92%).

[0808] Ms m / z(ESI):839.2[M+H] +

[0809] 1 H NMR(400MHz,CD3OD)δ8.75(s,1H),7.99–7.91(m,2H),7.66(d,1H),7.54(s,1H) ,7.47(d,1H),7.22–7.16(m,3H),7.01(d,2H),5.54(q,1H),3.80(t,2H),3.74–3 .66(m,4H),3.05–2.99(m,2H),2.84–2.71(m,6H),2.60(s,3H),2.50(d,2H),1.9 8–1.91(m,2H),1.90–1.82(m,1H),1.63(d,3H),1.48(s,9H),1.44–1.34(m,2H).

[0810] Example 36: Synthesis of Compound 36

[0811]

[0812] Intermediate G was used to replace intermediate B, and compound 36 was prepared by referring to the synthesis method and experimental operation of compound 35 to obtain 35 mg of product.

[0813] Ms m / z(ESI):839.2[M+H] +

[0814] 1H NMR(400MHz,CD3OD)δ8.75(s,1H),7.99–7.91(m,2H),7.66(d,1H),7.54(s,1 H),7.47(d,1H),7.22–7.15(m,3H),7.01(d,2H),5.52(q,1H),3.80(t,2H),3 .75–3.66(m,4H),3.05–2.98(m,2H),2.83–2.70(m,6H),2.60(s,3H),2.50(d ,2H),1.98–1.91(m,2H),1.89–1.81(m,1H),1.63(d,3H),1.45–1.35(m,11H).

[0815] Example 37: Synthesis of Compound 37

[0816]

[0817] Intermediate B was substituted for intermediate G, and intermediate H was substituted for intermediate E-1. Referring to the synthetic route and experimental operation method of compound 19, compound 37 (15 mg) was obtained.

[0818] LCMS m / z=880.4[M+H] +

[0819] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.61(d,1H),8.00(dd,1H),7.95–7.89(m,2H),7.53(d, 1H),7.01(s,1H),6.91(dd,2H),6.64(d,1H),4.70(s,2H),4.39(d,2H),3.71(t,3H),3.14– 3.05(m,1H),3.02–2.82(m,6H),2.78(t,3H),2.72–2.62(m,1H),2.53(s,3H),2.27(d,2H) ,2.20–2.13(m,1H),1.95–1.87(m,4H),1.76–1.64(m,1H),1.49(s,9H),1.30–1.21(m,2H).

[0820] Example 38: Synthesis of Compound 38

[0821]

[0822] Using intermediate 20D and intermediate I as raw materials, referring to the synthesis of compound 10, compound 38 (48 mg) was obtained

[0823] LCMS m / z=895.5[M+H] +

[0824] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.61(d,1H),8.01(dd,1H),7.96–7.89(m,2H),7.66(d, 1H),7.02(s,1H),6.92(dd,2H),6.66(d,1H),5.52(q,1H),4.40(d,2H),3.77–3.67(m,3H), 3.14–2.86(m,7H),2.78(t,3H),2.72–2.64(m,1H),2.59(s,3H),2.31(d,2H),2.26–2.16( m,1H),1.96–1.89(m,4H),1.75–1.67(m,1H),1.63(d,3H),1.41(s,9H),1.31–1.24(m,2H).

[0825] Example 39: Synthesis of Compound 39

[0826]

[0827] Step 1: Synthesis of compound 39B

[0828] 39A (5.00 g, 14.43 mmol), 2-fluoro-3-bromopyridine (5.08 g, 28.87 mmol), Pd(OAc)2 (1.30 g, 5.79 mmol), N,N-diisopropylethylamine (5.59 g, 43.25 mmol) and X-Phos (2.75 g, 5.77 mmol) were dissolved in 50 mL of N,N-dimethylformamide and reacted at 95 °C for 16 h under nitrogen protection. Water (100 mL) was added and extracted with ethyl acetate (100 mL x 2). The organic phases were combined, washed with saturated brine (100 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography to obtain compound 39B (3.20 g, yield 50%).

[0829] Ms m / z(ESI):442.0[M+H] +

[0830] Step 2: Synthesis of compound 39C

[0831] Compound 39B (3.20 g, 7.25 mmol) and 10% palladium on carbon (0.82 g) were dissolved in 50 mL of methanol and reacted at room temperature overnight under a hydrogen atmosphere. The mixture was directly filtered and the filtrate was concentrated under reduced pressure to obtain compound 39C (1.57 g, 100%).

[0832] Ms m / z(ESI):310.1[M+H] +

[0833] Step 3: Synthesis of compound 39D

[0834] Compound 39C (2.90 g, 9.37 mmol) and potassium carbonate (0.36 g, 2.60 mmol) were dissolved in 50 mL of dimethyl sulfoxide and reacted at room temperature for 16 hours. Water (100 mL) was added and extracted with ethyl acetate (100 mL×2). The organic phases were combined, washed with saturated brine (100 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography to obtain compound 39D (2.70 g).

[0835] Ms m / z(ESI):290.1[M+H] +

[0836] Step 4: Synthesis of compound 39E

[0837] Compound 39D (2.20 g, 7.60 mmol) and N-bromosuccinimide (1.49 g, 8.37 mmol) were dissolved in 30 mL of N,N-dimethylformamide and reacted at room temperature for 2 hours. Water (50 mL) was added and extracted with ethyl acetate (50 mL×2). The organic phases were combined, washed with saturated brine (50 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography to obtain compound 39D (2.70 g, 96%).

[0838] Steps 5 to 11: Synthesis of compound 39

[0839] Using compound 39E as the starting material, compound 39 (20 mg) was obtained by referring to the synthetic method of compound 17.

[0840] Ms m / z(ESI):439.3[1 / 2M+H] +

[0841] 1H NMR(400MHz,CD3OD)δ8.70(s,1H),8.45(d,1H),7.99–7.89(m,2H),7.76–7.71(m,1H),7.65(d,1H),7.2 4–7.14(m,2H),7.04–6.98(m,3H),5.52(q,1H),4.74–4.68(m,1H),3.80(t,2H),3.75–3.67(m,2H),3.47 –3.42(m,1H),3.09–3.01(m,2H),3.00–2.83(m,3H),2.82–2.68(m,4H),2.59(s,3H),2.36–2.30(m,2H) ,2.21–2.01(m,2H),1.96–1.87(m,3H),1.83–1.69(m,2H),1.63(d,3H),1.42(s,9H),1.40–1.34(m,2H).

[0842] Example 40: Synthesis of Compound 40

[0843]

[0844] Compound 40 was obtained by using compound 40A as the starting material and referring to the synthetic method of compound 39.

[0845] Ms m / z(ESI):877.4[M+H] +

[0846] 1 H NMR (400MHz, CD3OD) δ8.70(s,1H),8.45(d,1H),7.97–7.89(m,2H),7.77–7.72(m,1H),7.65(d,1H),7.22–7. 16(m,2H),7.04–6.97(m,3H),5.52(q,1H),4.74–4.67(m,1H),3.80(t,2H),3.76–3.67(m,2H),3.49–3.40(m , 1H), 3.07–3.00 (m, 2H), 3.00–2.83 (m, 3H), 2.82–2.69 (m, 4H), 2.59 (s, 3H), 2.34–2.30 (m, 2H), 2.21–2.02 (m, 2H), 1.96–1.88 (m, 3H), 1.85–1.69 (m, 2H), 1.63 (d, 3H), 1.42 (s, 9H), 1.40–1.34 (m, 2H). Example 41: Synthesis of Compound 41

[0847]

[0848] Step 1: Synthesis of compound 41A

[0849] Compound 35B (1.4 g, 2.58 mmol), Pd(dppf)Cl2 (0.21 g, 0.26 mmol), intermediate 1 (0.77 g, 3.30 mmol) and potassium carbonate (1.07 g, 7.74 mmol) were dissolved in 30 mL of 1,4-dioxane and 3 mL of water and reacted at 100° C. overnight. The residue was concentrated and purified by column chromatography to obtain compound 41A (1.1 g, 67.92%).

[0850] Ms m / z(ESI):614.2[M+H] +

[0851] Step 2: Synthesis of compound 41B

[0852] Intermediate B (600 mg, 3.53 mmol), compound 41A (1.1 g, 1.79 mmol), and N-methylimidazole (430 mg, 5.24 mmol) were dissolved in 20 mL of DMF, and TCFH (0.98 g, 3.49 mmol) was slowly added at room temperature and reacted overnight. The mixture was diluted with water, extracted with ethyl acetate, and the organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and the residue was purified by column chromatography to obtain compound 41B (710 mg, 51.95%).

[0853] Step 3: Synthesis of compound 41C

[0854] Compound 41B (710 mg, 0.91 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 1 hour, and concentrated to remove the solvent to obtain crude compound 41C, which was directly used for the next step.

[0855] Step 4: Synthesis of compound 41D

[0856] The crude compound 41C was dissolved in 15 mL of DCM, and 5 mL of 4N hydrochloric acid 1,4-dioxane solution was slowly added at room temperature. The mixture was stirred for 2 hours, and a certain amount of sodium bicarbonate was added to adjust the pH to greater than 8. The mixture was concentrated and dissolved in 5% methanol in dichloromethane. The filtrate was collected by filtration and concentrated to obtain the crude compound 41D, which was directly subjected to the next step without purification.

[0857] Step 6: Synthesis of compound 41

[0858] Compound 41D (250 mg, 0.46 mmol) and intermediate C (150 mg, 0.50 mmol) were dissolved in 10 mL 1,2-dichloroethane and 5 mL methanol, stirred at room temperature for 2 hours, sodium triacetyl borohydride (290 mg, 1.37 mmol) was slowly added, and reacted at room temperature for 2 hours. After concentration, the crude product was prepared by Prep-HPLC (instrument: WATERS AUTOP preparative liquid phase; chromatographic column: SunFire@PrepC18 (19×250 nm); mobile phase A: acetonitrile; mobile phase B: water (containing 0.1% ammonium acetate); gradient elution: mobile phase A content is 10-70%; flow rate: 17 mL / min; column temperature: room temperature; detection wavelength: 210 nm; the sample was dissolved in DMF and filtered with a 0.45 um filter head to prepare a sample solution; elution time: 15 min), and lyophilized to obtain compound 41 (45 mg, 11.77%).

[0859] Ms m / z(ESI):825.2[M+H] +

[0860] 1 H NMR(400MHz,DMSO-d6)δ12.62(s,1H),10.23(s,1H),9.49(t,1H),8.82(s,1H),8 .12–8.05(m,2H),7.78–7.71(m,2H),7.50–7.42(m,2H),7.13(d,2H),6.93(d,2H) ,4.56(d,2H),3.73–3.66(m,4H),3.60(s,2H),3.28(s,3H),2.97–2.87(m,2H),2. 76–2.63(m,6H),2.42(d,2H),1.88–1.76(m,3H),1.44(s,9H),1.33–1.19(m,2H).

[0861] Example 42: Synthesis of Compound 42

[0862]

[0863] Intermediate G was used to replace intermediate B, and compound 42 was prepared by referring to the synthesis method and experimental operation of compound 41 to obtain 41 mg of product.

[0864] Ms m / z(ESI):825.2[M+H] +

[0865] 1H NMR(400MHz,DMSO-d6)δ12.67(s,1H),10.23(s,1H),9.89(t,1H),8.82(s,1H),8 .13–8.04(m,2H),7.77–7.71(m,2H),7.51–7.45(m,2H),7.13(d,2H),6.93(d,2H) ,4.57(d,2H),3.74–3.67(m,4H),3.60(s,2H),3.28(s,3H),2.97–2.88(m,2H),2. 75–2.65(m,6H),2.42(d,2H),1.88–1.78(m,3H),1.38(s,9H),1.28–1.23(m,2H).

[0866] Example 43: Synthesis of Compound 43

[0867]

[0868] Step 1: Preparation of 43B

[0869] 43A (48 g, 198.90 mmol) was dissolved in 300 mL of tetrahydrofuran, and pyridine (23.60 g, 298.35 mmol) and acetic anhydride (26.40 g, 258.57 mmol) were added in sequence, and the mixture was reacted at 80°C for 16 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was chromatographed on a silica gel column to obtain 43B (46 g, yield 81.62%).

[0870] Ms m / z(ESI):228.1[M+H-56] +

[0871] Step 2: Preparation of 43C

[0872] 43B (20 g, 70.58 mmol) was dissolved in 80 mL of dichloromethane, and 30 mL of trifluoroacetic acid was added, and the mixture was reacted at room temperature for 3 hours. After concentration under reduced pressure, the crude product 43C (12 g, yield 92.78%) was obtained, which was used for the next step without purification.

[0873] Ms m / z(ESI):184.3[M+H] +

[0874] Step 3: Preparation of 43D

[0875] The crude product 43C (10 g, 54.68 mmol) was dissolved in 80 mL of acetonitrile, and the intermediate 19A (10 g, 44.83 mmol) and potassium carbonate (12.39 g, 89.66 mmol) were added, and the mixture was reacted at 80°C for 16 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was chromatographed on a silica gel column to obtain 43D (10 g, yield 57.75%).

[0876] Ms m / z(ESI):305.2[M+H] +

[0877] Step 4: Preparation of 43E

[0878] 43D (5 g, 16.44 mmol) was dissolved in a mixed solvent of 40 mL 1,4-dioxane and 4 mL water, and intermediate A (7.59 g, 18.08 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (2.01 g, 2.47 mmol), potassium carbonate (4.54 g, 32.88 mmol) were added in sequence, and reacted at 90°C for 16 hours under a nitrogen atmosphere. The reaction was cooled to room temperature, filtered through diatomaceous earth, washed with ethyl acetate, and the filtrate was collected and concentrated under reduced pressure. The residue was chromatographed on a silica gel column to obtain 43E (4.1 g, yield: 45.18%).

[0879] Ms m / z(ESI):552.5[M+H] +

[0880] Step 5: Preparation of 43F

[0881] 43E (3.2 g, 5.80 mmol) was dissolved in a mixed solvent of 40 mL 1,4-dioxane and 4 mL water, and intermediate 2 (1.97 g, 7.54 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.71 g, 0.87 mmol), potassium carbonate (1.6 g, 11.6 mmol) were added in sequence, and reacted at 100°C for 3 hours under a nitrogen atmosphere. The reaction was cooled to room temperature, concentrated under reduced pressure, and the residue was chromatographed on a silica gel column to obtain 43F (2.2 g, yield: 58.32%).

[0882] Ms m / z(ESI):651.1[M+H] +

[0883] Step 6: Preparation of 43G

[0884] 43F (2.2 g, 3.38 mmol) was dissolved in 20 mL of dichloromethane, and intermediate G (1.14 g, 6.67 mmol), N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (1.9 g, 6.67 mmol), and N-methylimidazole (0.83 g, 10.14 mmol) were added in sequence, and the mixture was reacted at room temperature for 16 hours. After concentration under reduced pressure, the residue was chromatographed on a silica gel column to obtain 43G (1.3 g, yield: 47.89%).

[0885] Ms m / z(ESI):803.1[M+H] +

[0886] Step 7: Preparation of 43H

[0887] 43G (1.3 g, 1.62 mmol) was dissolved in 8 mL of 4% NaOH-MeOH solution and reacted at room temperature for 1 hour. After reduced pressure concentration, the residue was chromatographed on a silica gel column to obtain 43H (570 mg, yield 56.72%).

[0888] Ms m / z(ESI):621.1[M+H] +

[0889] Step 8: Preparation of 43I

[0890] 43H (0.57 g, 0.92 mmol) was dissolved in 8 mL of dimethyl sulfoxide, and 2-iodoacylbenzoic acid (0.52 g, 1.84 mmol) was added, and the mixture was reacted at room temperature for 16 hours. Water (15 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (15 mL×2). The ethyl acetate layers were combined, and the ethyl acetate layers were washed with water (15 mL×2) and a saturated aqueous solution of NaCl (15 mL) in sequence. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was chromatographed on a silica gel column to obtain 43I (0.37 g, yield 65.12%).

[0891] Ms m / z(ESI):619.1[M+H] +

[0892] Step 9: Preparation of compound 43

[0893] 43I (0.12 g, 0.19 mmol) was dissolved in 10 mL of N,N-dimethylacetamide, and intermediate 33B (91 mg, 0.29 mmol) and 4 drops of glacial acetic acid were added in sequence, and the mixture was reacted at room temperature for 30 min. Sodium triacetoxyborohydride (160 mg, 0.76 mmol) was added in batches, and the mixture was reacted at room temperature for 16 hours. Water (15 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (15 mL×2). The ethyl acetate layers were combined, and the ethyl acetate layers were washed with water (15 mL×2) and a saturated aqueous solution of NaCl (15 mL) in sequence. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was chromatographed on a silica gel column to obtain compound 43 (43 mg, yield 24.15%).

[0894] Ms m / z(ESI):921.6[M+H] +

[0895] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.61(d,1H),8.00(dd,1H),7.99–7.89(m,2H),7.66(d,1H),7.02(s,1H),6. 92(dd,2H),6.66(d,1H),5.52(q,1H),3.81–3.68(m,3H),3.66–3.61(m,2H),3.59–3.53(m,2H),3.10–3.00(m,2 H),2.97–2.91(m,1H),2.90–2.85(m,2H),2.83–2.75(m,3H),2.73–2.64(m,1H),2.59(s,3H),2.19–2.10(m,2H ),2.09–2.00(m,1H),1.99–1.91(m,1H),1.89–1.84(m,1H),1.81–1.69(m,5H),1.68–1.60(m,5H),1.41(s,9H).

[0896] Example 44: Synthesis of Compound 44

[0897]

[0898] Step 1: Synthesis of compound 44A

[0899] Compound 43E (3.0 g, 5.44 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (0.40 g, 0.54 mmol), intermediate 1 (2.02 g, 8.16 mmol) and potassium carbonate (1.88 g, 13.60 mmol) were dissolved in 20 mL of 1,4-dioxane and 2 mL of water, and reacted at 100° C. for 2 hours. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 44A (1.5 g, 43.31%).

[0900] Ms m / z(ESI):637.2[M+H] +

[0901] Step 2: Synthesis of compound 44B

[0902] Compound 44A (1.50 g, 2.35 mmol), intermediate B (800 mg, 4.70 mmol), and N-methylimidazole (579 mg, 7.05 mmol) were dissolved in 10 mL of DCM. N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (1.32 g, 4.70 mmol) was slowly added at 0°C. The mixture was heated to room temperature and stirred for 12 h. The mixture was concentrated and the residue was purified by column chromatography to obtain compound 44B (600 mg, 32.24%).

[0903] Ms m / z(ESI):789.3[M+H] +

[0904] Step 3: Synthesis of compound 44C

[0905] Compound 44B (600 mg, 0.76 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 2 hours, diluted with water, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 44C (300 mg, 65.01%).

[0906] Step 4: Synthesis of compound 44D

[0907] Compound 44C (300 mg, 0.50 mmol) was dissolved in 10 mL DMSO solution, and IBX (730 mg, 2.6 mmol) was added under nitrogen protection, and stirred at room temperature for 12 hours, diluted with water, extracted with ethyl acetate, washed with saturated sodium chloride, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 44D (220 mg, 66.66%).

[0908] Step 6: Synthesis of compound 44

[0909] 44D (100 mg, 0.17 mmol) was added to a 50 mL single-mouth bottle, 1,2-dichloroethane (5 mL) and methanol (5 mL) were added, and then compound 31B (81 mg, 0.26 mmol) and 0.04 mL acetic acid were added. After stirring at room temperature for 4 h, sodium triacetoxyborohydride (43 mg, 0.2 mmol) was added and reacted at room temperature for 2 h. The reaction system was concentrated under reduced pressure, water (50 mL) was added, and the mixture was extracted with a mixed solvent of dichloromethane and isopropanol (v / v) = 10:1 (20 mL×3), and the organic phase was washed with a saturated sodium chloride aqueous solution (20 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 44 (10 mg, 6.69%).

[0910] Ms m / z(ESI):454.8[M / 2+H] +

[0911] 1 H NMR(400MHz,DMSO-d6)δ12.54(s,1H),10.33(s,1H),9.47(t,1H),8.80–8.71(m,2H),8.17–8.01(m, 3H),7.44(d,1H),7.25(s,1H),6.99–6.88(m,2H),6.72(d,1H),4.60–4.51(m,2H),3.81–3.72(m,1H) ,3.66–3.56(m,4H),3.56–3.47(m,2H),3.03–2.93(m,1H),2.92–2.81(m,2H),2.79–2.64(m,5H),2. 64–2.56(m,1H),2.48(s,3H),2.08–1.98(m,2H),1.93–1.82(m,2H),1.70–1.49(m,8H),1.44(s,9H).

[0912] Example 45: Synthesis of Compound 45

[0913]

[0914] Referring to the preparation method of compound 43, compound 45 (10 mg) was prepared by substituting 31B for 33B.

[0915] Ms m / z(ESI):921.4[M+H] +

[0916] 1H NMR(400MHz,DMSO-d6)δ12.54(s,1H),10.32(s,1H),9.91(d,1H),8.83–8.70(m,2H),8.19–7 .91(m,3H),7.66(d,1H),7.26(s,1H),7.01–6.87(m,2H),6.72(d,1H),5.46–5.29(m,1H),3. 82–3.72(m,1H),3.67–3.48(m,6H),3.03–2.93(m,1H),2.92–2.81(m,2H),2.80–2.64(m,5H) ,2.63–2.53(m,4H),2.07–1.97(m,2H),1.94–1.82(m,2H),1.69–1.49(m,11H),1.37(s,9H).

[0917] Example 46: Synthesis of Compound 46

[0918]

[0919] Referring to the preparation method of compound 44, 33B was used to replace 31B to prepare compound 46 (7 mg)

[0920] Ms m / z(ESI):907.2[M+H] +

[0921] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.61(d,1H),8.01(dd,1H),7.95–7.89(m,2H),7.53(d,1H),7.02( s,1H),6.93(dd,2H),6.67(d,1H),4.70(s,2H),3.86–3.76(m,1H),3.74–3.68(m,2H),3.67–3.61(m,2 H),3.60–3.53(m,2H),3.12–3.02(m,2H),3.01–2.85(m,3H),2.85–2.76(m,3H),2.73–2.64(m,1H),2 .53(s,3H),2.20–2.06(m,3H),2.01–1.92(m,1H),1.87–1.75(m,3H),1.75–1.61(m,5H),1.49(s,9H).

[0922] Example 47: Synthesis of Compound 47

[0923]

[0924] Step 1: Preparation of 47B

[0925] 47A (20 g, 78.32 mmol) was dissolved in 200 mL of tetrahydrofuran, and pyridine (18.59 g, 234.96 mmol) and acetic anhydride (12 g, 117.48 mmol) were added in sequence, and the mixture was reacted at 80°C for 16 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was chromatographed on a silica gel column to obtain 47B (21 g, yield 90.16%).

[0926] Ms m / z(ESI):242.1[M+H-56] +

[0927] Step 2: Preparation of 47C

[0928] 47B (21 g, 70.61 mmol) was dissolved in 50 mL of dichloromethane, and 30 mL of trifluoroacetic acid was added, and the mixture was reacted at room temperature for 3 hours. After concentration under reduced pressure, the crude product 47C (13.5 g, yield 96.9%) was obtained, which was used for the next step without purification.

[0929] Ms m / z(ESI):198.1[M+H] +

[0930] Step 3: Preparation of 47D

[0931] The crude product 47C (13.2 g, 67.27 mmol) was dissolved in 80 mL of acetonitrile, and the intermediate 19A (15 g, 67.27 mmol) and potassium carbonate (27.89 g, 201.81 mmol) were added, and the mixture was reacted at 80°C for 16 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was chromatographed on a silica gel column to obtain 47D (19 g, yield 88.77%).

[0932] Ms m / z(ESI):319.2[M+H] +

[0933] Step 4: Preparation of 47E

[0934] 47D (15 g, 47.14 mmol) was dissolved in a mixed solvent of 200 mL 1,4-dioxane and 40 mL water, and intermediate A (19.78 g, 47.14 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (3.85 g, 4.71 mmol), potassium carbonate (13.03 g, 94.28 mmol) were added in sequence, and reacted at 90°C for 16 hours under a nitrogen atmosphere. The reaction was cooled to room temperature, filtered through diatomaceous earth, washed with ethyl acetate, and the filtrate was collected and concentrated under reduced pressure. The residue was chromatographed on a silica gel column to obtain 47E (13 g, yield: 48.72%).

[0935] Ms m / z(ESI):566.2[M+H] +

[0936] Step 5: Synthesis of Compound 47F

[0937] Compound 47E (8 g, 14.3 mmol), Pd(dppf)Cl2 (1.15 g, 1.41 mmol), intermediate 1 (6.98 g, 28.26 mmol) and potassium carbonate (8.79 g, 63.65 mmol) were dissolved in 40 mL of 1,4-dioxane and 5 mL of water, and reacted at 100° C. for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 47F (5.1 g, 55.45%).

[0938] Ms m / z(ESI):651.2[M+H] +

[0939] Step 6: Synthesis of Compound 47G

[0940] Compound intermediate B (630 mg, 3.68 mmol) and 47F (1.2 g, 1.84 mmol) were dissolved in 10 mL of DMF, triethylamine (930 mg, 9.2 mmol) was slowly added, T3P (1.17 g, 3.68 mmol) was slowly added at room temperature, and the mixture was reacted for 2 hours. The mixture was diluted with water, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 47G (780 mg, 52.38%).

[0941] Ms m / z(ESI):803.3[M+H] +

[0942] Step 7: Synthesis of compound 47H

[0943] Compound 47G (780 mg, 0.95 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 2 hours, concentrated under reduced pressure, and the residue was diluted with ethyl acetate, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 47H (520 mg, 85.8%).

[0944] Step 8: Synthesis of compound 47I

[0945] Compound 47H (520 mg, 0.68 mmol) was dissolved in 10 mL DMSO solution, and IBX (760 mg, 2.72 mmol) was added at room temperature under nitrogen protection, stirred for 12 hours, diluted with water, extracted with ethyl acetate, and the organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 47I (410 mg, 79.05%).

[0946] Step 9: Synthesis of compound 47

[0947] 47I (200 mg, 0.32 mmol) was added to a 50 mL single-mouth bottle, 1,2-dichloroethane (5 mL) and methanol (5 mL), intermediate 31B (81 mg, 0.26 mmol) and 0.04 mL acetic acid were added, and after stirring at room temperature for 1 h, sodium triacetoxyborohydride (200 mg, 0.96 mmol) was added, and the reaction was carried out at room temperature for 12 h. The reaction system was concentrated under reduced pressure, water (50 mL) was added, and the mixture was extracted with a mixed solvent of dichloromethane and isopropanol (v / v) = 10:1 (20 mL×3), and the organic phase was washed with a saturated sodium chloride aqueous solution (20 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was separated and purified by Prep-TLC to obtain compound 47 (20 mg, 6.72%).

[0948] Ms m / z(ESI):461.3[M / 2+H] +

[0949] 1H NMR(400MHz,CD3OD)δ8.71(s,1H),8.61(d,1H),8.01(dd,1H),7.95–7.89(m,2H),7.53(d,1H),7.02(s,1H),6.9 7–6.88(m,2H),6.67(d,1H),4.70(s,2H),3.80–3.74(d,1H),3.73–3.68(m,2H),3.67–3.60(m,2H),3.58–3.51(m ,2H),3.11–3.02(m,2H),3.01–2.94(m,1H),2.92–2.83(m,2H),2.82–2.75(m,3H),2.73–2.58(m,2H),2.53(s,3 H),2.37–2.28(m,1H),2.22–2.00(m,3H),1.98–1.91(m,1H),1.79–1.67(m,3H),1.66–1.55(m,5H),1.49(s,9H).

[0950] Example 48: Synthesis of Compound 48

[0951]

[0952] Referring to the synthesis method of compound 47, intermediate 2 was used to replace intermediate 1, and intermediate G was used to replace intermediate B to obtain compound 48 (12 mg, 4.06%).

[0953] Ms m / z(ESI):935.3[M+H] +

[0954] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.60(d,1H),8.00(dd,1H),7.96–7.89(m,2H),7.65(d,1H),7. 02(s,1H),6.92(dd,2H),6.66(d,1H),5.52(q,1H),3.79–3.68(m,3H),3.66–3.60(m,2H),3.58–3. 51(m,2H),3.11–2.99(m,2H),2.99–2.93(m,1H),2.90–2.75(m,4H),2.72–2.57(m,7H),2.34–2.24 (m,1H),2.16–2.08(m,2H),2.06–1.90(m,2H),1.79–1.67(m,3H),1.66–1.54(m,7H),1.42(s,9H).

[0955] Example 49: Synthesis of Compound 49

[0956]

[0957] Referring to the synthetic route and experimental operation method of compound 48, 33B was used to replace 31B to obtain compound 49 (19 mg).

[0958] Ms m / z(ESI):935.4[M+H] +

[0959] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.60(d,1H),7.99(dd,1H),7.96–7.89(m,2H),7.65(d,1H),7. 01(s,1H),6.91(dd,2H),6.65(d,1H),5.52(q,1H),3.77–3.67(m,3H),3.65–3.59(m,2H),3.57–3. 50(m,2H),3.10–2.97(m,2H),2.95–2.90(m,1H),2.89–2.75(m,4H),2.72–2.51(m,7H),2.29–2.20 (m,1H),2.14–2.06(m,2H),2.05–1.88(m,2H),1.77–1.66(m,3H),1.65–1.53(m,7H),1.41(s,9H).

[0960] Example 50: Synthesis of Compound 50

[0961]

[0962] Step 1: Synthesis of Compound 50A

[0963] Compound 47H (300 mg, 0.484 mmol), triphenylphosphine (317.4 mg, 1.21 mmol) and imidazole (165 mg, 7.42 mmol) were dissolved in 20 mL of ultra-dry tetrahydrofuran, stirred at room temperature for 15 min under nitrogen protection, and then iodine (307.1 mg, 1.21 mmol) was added and reacted at 50° C. for 5 h. After the raw materials were completely consumed, the mixture was concentrated and the residue was purified by column chromatography to obtain compound 50A (335 mg, 95%).

[0964] Ms m / z(ESI):731.2[M+H] +

[0965] Step 2: Synthesis of compound 50

[0966] Compound 50A (335 mg, 0.46 mmol), compound 33B (220 mg, 0.69 mmol) and potassium carbonate (127 mg, 0.92 mmol) were dissolved in 10 mL of ultra-dry DMF and heated to 80°C for 3 h under nitrogen protection. After cooling to room temperature, 100 mL of ethyl acetate was added to dilute the mixture, and the organic phase was washed with 30 mL of water for 3 times and 30 mL of saturated brine, respectively. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated to remove the solvent, and the residue was purified by column chromatography to obtain compound 50 (52 mg, 12%).

[0967] Ms m / z(ESI):921.4[M+H] +

[0968] 1 H NMR(400MHz,CD3OD)δ8.70(s,1H),8.60(d,1H),8.00(dd,1H),7.95–7.89(m,2H),7.53(d,1H),7.01( s,1H),6.92(dd,2H),6.66(d,1H),4.70(s,2H),3.78–3.67(m,3H),3.66–3.60(m,2H),3.57–3.50(m,2 H),3.10–2.98(m,2H),2.97–2.91(m,1H),2.89–2.75(m,4H),2.72–2.55(m,4H),2.53(s,3H),2.30–2 .20(m,1H),2.15–2.06(m,2H),2.03–1.89(m,2H),1.78–1.64(m,3H),1.63–1.54(m,4H),1.49(s,9H).

[0969] Example 51: Synthesis of Compound 51

[0970]

[0971] Step 1: Synthesis of compound 51B

[0972] Compound 51A (150 mg, 0.43 mmol) was dissolved in 3 mL of dichloromethane, and 3 mL of trifluoroacetic acid was added thereto. The mixture was stirred at room temperature for 30 min and then directly dried on a rotary evaporator to obtain a crude product of 51B (160 mg).

[0973] Step 2: Synthesis of compound 51C

[0974] To the crude product of 51B (160 mg), an appropriate amount of dichloromethane and two drops of triethylamine were added, and the resulting clear solution was then directly spun dry. The resulting solid was then dissolved in a mixed solution of 3 mL of 1,2-dichloroethane and 3 mL of methanol, and compound 20D (200 mg, 0.34 mmol) and two drops of glacial acetic acid were added thereto, followed by stirring at room temperature for one hour, and then sodium triacetoxyborohydride (217 mg, 1.02 mmol) was added to the reaction solution and stirred overnight. The reaction mixture was filtered, concentrated, and silica gel column chromatography was performed to obtain compound 51C (180 mg, 65%).

[0975] Ms m / z(ESI):827.4[M+H] +

[0976] Step 3: Synthesis of compound 51

[0977] Compound 51C (180 mg, 0.218 mmol) was added to a single-mouth bottle, dissolved with 5 mL of DMF, then HOBt (30 mg, 0.218 mmol), EDCI (42 mg, 0.218 mmol), and NMI (54 mg, 0.653 mmol) were added, stirred at room temperature for 1 h, and then compound 32D (72 mg, 0.436 mmol) was added, and stirring continued for 2 h. After the reaction was completed, the reaction solution was diluted with ethyl acetate, filtered, washed three times with saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to obtain a crude product of compound 51, which was further purified by preparative HPLC to obtain compound 51 (52 mg, 26%). (Instrument: WATERS AUTOP preparative liquid phase; chromatographic column: SunFire@PrepC18 (19×250nm); mobile phase A: acetonitrile; mobile phase B: water (containing 0.1% ammonium acetate); gradient elution: mobile phase A content is 10-70%; flow rate: 17mL / min; column temperature: room temperature; detection wavelength: 210nm; the sample is dissolved in DMF and filtered with a 0.45um filter to prepare a sample solution; elution time: 15min).

[0978] Ms m / z(ESI):937.5[M+H] +

[0979] 1H NMR(400MHz,DMSO-d6)δ12.53(s,1H),10.81(s,1H),9.91(d,1H),8.79(d,1H),8.75(s,1H),8.14(dd,1H),8 .08(d,1H),8.04(s,1H),7.93(t,1H),7.66(d,1H),7.36(d,1H),7.26(s,1H),6.94(d,1H),6.68(d,1H),5.4 4–5.34(m,1H),4.79–4.67(m,1H),4.40(d,2H),3.85(d,1H),3.17–3.08(m,1H),2.98–2.63(m,9H),2.53(s, 3H),2.24–1.94(m,6H),1.90–1.73(m,4H),1.65–1.58(m,1H),1.55(d,3H),1.37(s,9H),1.18–1.06(m,2H).

[0980] Example 52: Synthesis of Compound 52

[0981]

[0982] Step 1: Synthesis of Compound 52A

[0983] Compound Eb-1 (5.0 g, 12.98 mmol), biboronic acid pinacol ester (4.28 g, 116.87 mmol), potassium acetate (4.0 g, 40.76 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (1.06, 1.3 mmol) were dissolved in 100 mL of dioxane under nitrogen protection and reacted at 80°C for 12 h. After cooling to room temperature, 500 mL of water was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by column chromatography to obtain compound 52B (5.0 g, 88.66%).

[0984] Ms m / z(ESI):433.3[M+H] +

[0985] Step 2: Synthesis of compound 52B

[0986] Compound 52A (5.0 g, 11.56 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.94 g, 1.16 mmol), intermediate A (5.34 g, 12.72 mmol) and potassium carbonate (3.99 g, 28.90 mmol) were dissolved in 60 mL of 1,4-dioxane and 6 mL of water under nitrogen protection, and reacted at 80°C for 12 h. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 52B (4.5 g, 65.06%).

[0987] Ms m / z(ESI):598.1[M+H] +

[0988] Step 3: Synthesis of Compound 52C

[0989] Compound 52B (4.5 g, 7.52 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (0.61 g, 0.75 mmol), intermediate 1 (2.77 g, 9.78 mmol) and potassium carbonate (4.16 g, 30.08 mmol) were dissolved in 60 mL of 1,4-dioxane and 6 mL of water, and reacted at 100° C. for 2 hours. The residue was concentrated and purified by column chromatography to obtain compound 52C (3.0 g, 58.39%).

[0990] Step 4: Synthesis of Compound 52D

[0991] Intermediate B (1.49 g, 8.78 mmol) was dissolved in 30 mL of DCM, 1-chloro-N,N,2-trimethylpropyleneamine (3.70 g, 13.17 mmol) was slowly added at 0°C, the temperature was raised to room temperature and stirred for 30 minutes, the above liquid was slowly added to a mixed solution of 52C (3.0 g, 4.39 mmol) and N-methylimidazole (1.8 g, 21.95 mmol) in dichloromethane at room temperature, and the mixture was reacted for 2 hours. The reaction was extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 52D (1.5 g, 40.89%).

[0992] Ms m / z(ESI):835.5[M+H] +

[0993] Step 5: Synthesis of Compound 52E

[0994] Compound 52D (1.0 g, 1.2 mmol) was dissolved in 30 mL of 4% sodium hydroxide in methanol solution and stirred at room temperature for 2 hours. The mixture was concentrated and purified by column chromatography to obtain Compound 52E (0.5 g, 60.9%).

[0995] Step 6: Synthesis of Compound 52F

[0996] Compound 52E (0.1 g, 0.14 mmol) was dissolved in a mixture of 1 mL of dichloromethane and 1 mL of trifluoroacetic acid, reacted at room temperature for 2 hours, concentrated, and the crude product was directly used for the next reaction.

[0997] Ms m / z(ESI):595.2[M+H] +

[0998] Step 7: Synthesis of Compound 52

[0999] 52E was added to a 50 mL single-mouth bottle, and 5 mL of N,N-dimethylacetamide, intermediate C (84 mg, 0.28 mmol) and 0.1 mL of acetic acid were added. After stirring at room temperature for 4 h, sodium triacetoxyborohydride (89 mg, 0.42 mmol) was added and reacted at room temperature for 12 h. The reaction solution was concentrated and the residue was subjected to Pre-HPLC (instrument and preparation column: Waters 2767 was used for preparation of liquid phase, and the preparation column model was SunFire@Prep C18, 5 μm, inner diameter × length = 19 mm × 250 mm). Preparation method: The DMSO solution of the crude product was filtered with a 0.45 μm filter membrane to prepare a sample solution. Mobile phase system: water (containing 0.1% TFA) / acetonitrile. Gradient elution method: Acetonitrile was gradiently eluted from 10% to 50% (elution time 15 min). Lyophilization gave the trifluoroacetate salt of compound 52 (0.1 g, two-step yield 64.66%).

[1000] Ms m / z(ESI):880.4[M+H] +

[1001] 1 H NMR(400MHz,CD3OD)δ8.95(s,1H),7.92–7.85(m,2H),7.63(dd,2H),7.33–7.24(m,3H) ,7.17(d,2H),6.91(d,1H),4.76–4.70(m,2H),4.27–4.17(m,1H),3.87–3.67(m,6H),3 .60–3.50(m,1H),3.30–3.15(m,4H),3.07–2.84(m,5H),2.80(t,2H),2.58(s,3H),2.2 5–2.11(m,2H),2.07–1.96(m,2H),1.89–1.77(m,1H),1.65–1.53(m,2H),1.50(s,9H).

[1002] Example 53: Synthesis of Compound 53

[1003]

[1004] Referring to the synthesis, route and experimental operation method of compound 52, Ea-1 was used to replace Eb-1 to obtain the trifluoroacetate salt of compound 53 (19 mg). Pre-HPLC (Instrument and preparation column: Waters 2767 was used to prepare the liquid phase, and the preparation column model was SunFire@Prep C18, 5 μm, inner diameter × length = 19 mm × 250 mm). Preparation method: The DMSO solution of the crude product was filtered with a 0.45 μm filter membrane to prepare a sample solution. Mobile phase system: water (containing 0.1% TFA) / acetonitrile. Gradient elution method: Acetonitrile was gradient eluted from 10% to 50% (elution time 15 min).

[1005] Ms m / z(ESI):880.3[M+H] +

[1006] 1 H NMR(400MHz,CD3OD)δ8.95(s,1H),7.93–7.85(m,2H),7.63(dd,2H),7.34–7.14(m,5H) ,6.91(d,1H),4.73(s,2H),4.27–4.17(m,1H),3.88–3.67(m,6H),3.60–3.49(m,1H),3 .30–3.16(m,4H),3.08–2.96(m,3H),2.94–2.86(m,2H),2.80(t,2H),2.58(s,3H),2.2 8–2.13(m,2H),2.08–1.97(m,2H),1.88–1.76(m,1H),1.67–1.53(m,2H),1.50(s,9H).

[1007] Example 54: Synthesis of Compound 54

[1008]

[1009] Step 1: Synthesis of Compound 54A

[1010] Compound 6G (350 mg, 0.43 mmol) was dissolved in 15 mL of DCM, 5 mL of TFA was slowly added at room temperature, and the mixture was stirred for 2 hours. A saturated aqueous sodium bicarbonate solution was added to adjust the pH to about 8, and the mixture was concentrated and diluted with water. The mixture was extracted with DCM, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain the target compound 54A (300 mg, 97.69%).

[1011] Ms m / z(ESI):717.2[M+H]+

[1012] Step 2: Synthesis of compound 54C

[1013] Compound 54A (0.3 g, 0.42 mmol) and 54B (150 mg, 0.50 mmol) were dissolved in 15 mL of N,N-dimethylacetamide, and 0.3 mL of acetic acid was added. The mixture was stirred at room temperature for 1 hour, and sodium triacetylborohydride (0.18 g, 0.84 mmol) was slowly added. The mixture was reacted at room temperature overnight, and saturated aqueous sodium bicarbonate solution was added to adjust the pH to about 8. The mixture was concentrated and diluted with water. The mixture was extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain the target compound 54C (310 mg, 73.84%).

[1014] Ms m / z(ESI):502.2[M+H] +

[1015] Step 3: Synthesis of Compound 54

[1016] Compound 54C (250 mg, 0.25 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 2 hours, extracted with dichloromethane, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by column chromatography to obtain compound 54 (45 mg, 20.92%).

[1017] Ms m / z(ESI):863.1[M+H] +

[1018] 1 H NMR(400MHz,CD3OD)δ8.68(s,1H),8.10–8.05(m,1H),7.95–7.89(m,2H),7.62–7.57(m,1H),7. 55–7.51(m,2H),7.49–7.41(m,2H),6.98–6.91(m,2H),4.70(s,2H),4.01–3.96(m,2H),3.93–3. 86(m,1H),3.79–3.71(m,2H),3.19–3.11(m,1H),3.09–2.74(m,9H),2.53(s,3H),2.36–2.30(m ,2H),2.29–2.19(m,1H),2.04–1.90(m,4H),1.87–1.70(m,2H),1.49(s,9H),1.43–1.31(m,2H).

[1019] Example 55: Synthesis of Compound 55

[1020]

[1021] Synthesis of compound 55 Reference to the synthesis method of compound 54 (51 mg, 28.15%)

[1022] Ms m / z(ESI):880.3[M+H] +

[1023] 1 H NMR(400MHz,CD3OD)δ8.67(s,1H),7.95–7.87(m,2H),7.63–7.56(m,1H),7.56–7.49(m,2H),7.22–7 .15(m,1H),6.97–6.90(m,2H),6.82–6.73(m,2H),4.70(s,2H),3.94–3.85(m,1H),3.82–3.69(m,4H) ,3.16–3.10(m,1H),3.09–2.86(m,4H),2.86–2.72(m,5H),2.53(s,3H),2.38–2.31(m,2H),2.30–2. 20(m,1H),2.04–1.94(m,2H),1.94–1.86(m,2H),1.86–1.70(m,2H),1.49(s,9H),1.40–1.26(m,2H).

[1024] Example 56: Synthesis of Compound 56

[1025]

[1026] Synthesis of compound 56 Reference to the synthesis method of compound 54 (31 mg, 23.89%)

[1027] Ms m / z(ESI):898.3[M+H] +

[1028] 1H NMR (400MHz, CD3OD) δ8.67(s,1H),7.95–7.89(m,2H),7.62–7.57(m,1H),7.55–7.49(m,2H),6. 98–6.90(m,2H),6.65–6.57(m,2H),4.70(s,2H),3.93–3.85(m,1H),3.82–3.75(m,2H),3.74–3. 66(m,2H),3.18–3.09(m,1H),3.07–2.89(m,4H),2.88–2.76(m,5H),2.53(s,3H),2.34–2.28(m ,2H),2.27–2.18(m,1H),2.02–1.95(m,2H),1.93–1.69(m,4H),1.49(s,9H),1.37–1.21(m,2H).

[1029] Example 57: Synthesis of Compound 57

[1030]

[1031] Step 1: Synthesis of compound 57B

[1032] Compound 57A (1.0 g, 2.70 mmol), Pd(dppf)Cl2 (0.4 g, 0.54 mmol), biboronic acid pinacol ester (1.03 g, 4.05 mmol) and potassium acetate (0.54 g, 5.4 mmol) were dissolved in 30 mL of 1,4-dioxane and reacted at 90° C. overnight. The residue was concentrated and purified by column chromatography to obtain compound 57B (1.2 g, 99%).

[1033] Ms m / z(ESI):418.2[M+H] +

[1034] Step 2: Synthesis of compound 57C

[1035] Compound 57B (1.2 g, 2.70 mmol), Pd(dppf)Cl2 (0.4 g, 0.54 mmol), intermediate A (2.27 g, 5.4 mmol) and potassium carbonate (0.75 g, 5.40 mmol) were dissolved in 30 mL of 1,4-dioxane and 3 mL of water and reacted at 80° C. overnight. The residue was concentrated and purified by column chromatography to obtain compound 57C (0.9 g, 57%).

[1036] Ms m / z(ESI):583.1[M+H] +

[1037] Step 3: Synthesis of compound 57D

[1038] Compound 57C (0.45 g, 0.77 mmol), Pd(dppf)Cl2 (0.11 g, 0.15 mmol), intermediate 1 (0.44 g, 1.54 mmol) and potassium carbonate (0.21 g, 1.54 mmol) were dissolved in 20 mL of 1,4-dioxane and 2 mL of water and reacted at 100° C. for 4 h. The residue was concentrated and purified by column chromatography to obtain compound 57D (456 mg, 88%).

[1039] Ms m / z(ESI):668.2[M+H] +

[1040] Step 4: Synthesis of Compound 57E

[1041] The intermediate compound B (0.23 g, 1.37 mmol), TCFH (0.38 g, 1.37 mmol), and N-methylimidazole (0.23 g, 2.73 mmol) were dissolved in 5 mL of DCM, and 57D (0.46 g, 0.68 mmol) was slowly added at room temperature to react overnight. The residue was purified by column chromatography to obtain compound 57E (354 mg, 63%).

[1042] Ms m / z(ESI):820.3[M+H]+

[1043] Step 5: Synthesis of Compound 57F

[1044] Compound 57E (0.35 g, 0.43 mmol) was dissolved in 15 mL of 4% sodium hydroxide in methanol solution, stirred at room temperature for 1 hour, and concentrated to remove the solvent to obtain crude compound 57F, which was directly used for the next step.

[1045] Ms m / z(ESI):680.3[M+H]+

[1046] Step 6: Synthesis of Compound 57G

[1047] The crude compound 57F was dissolved in 15 mL of DCM, and 5 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature. The mixture was stirred for 2 hours, and a certain amount of sodium bicarbonate was added to adjust the pH to greater than 8. The mixture was concentrated and dissolved in 5% methanol in dichloromethane. The filtrate was collected by filtration and concentrated to obtain the crude compound 57G (380 mg), which was directly subjected to the next step without purification.

[1048] Ms m / z(ESI):580.2[M+H]+

[1049] Step 7: Synthesis of compound 57

[1050] Compound 57G (380 mg crude, 0.43 mmol) and intermediate C (195 mg, 0.64 mmol) were dissolved in 15 mL DMA, 0.1 mL acetic acid was added, stirred at room temperature for 2 hours, sodium triacetyl borohydride (272 mg, 1.29 mmol) was slowly added, concentrated, and the residue was purified by preparative HPLC. (Instrument and preparative column: SHIMADZU LC-20AP was used for preparative liquid phase, the preparative column model was Phenomenex C18, 5 μm, inner diameter * length = 19 mm * 150 mm). Preparation method: The reaction solution was filtered with a 0.45 μm filter membrane to prepare a sample solution. Mobile phase system: acetonitrile / water (containing 10 Mm ammonium carbonate). Gradient elution method: Acetonitrile was gradiently eluted from 32% to 62% (elution time 15 min). After freeze-drying, compound 57 (62 mg, 17%) was obtained.

[1051] Ms m / z(ESI):865.4[M+H] +

[1052] 1 H NMR(400MHz,DMSO-d6)δ12.64(s,1H),10.22(s,1H),9.45(t,1H),8.84(s,1H),8.24(d,1H),8 .05–7.97(m,2H),7.61(d,1H),7.47(d,1H),7.24–7.20(m,1H),7.13(d,2H),6.93(d,2H),4.56 (d,2H),4.20–4.12(m,2H),3.89–3.81(m,2H),3.76–3.65(m,4H),3.08–2.98(m,2H),2.78–2. 63(m,4H),2.53–2.48(m,2H),2.48(s,3H),1.90–1.77(m,3H),1.44(s,9H),1.33–1.19(m,3H).

[1053] Example 58: Synthesis of Compound 58

[1054]

[1055] Step 1: Synthesis of compound 58B

[1056] Compound 58A (3.8 g, 10.79 mmol) (synthesis reference patent US2012157462), Pd(dppf)Cl2 (0.88 g, 1.08 mmol), biboronic acid pinacol ester (5.48 g, 21.58 mmol) and potassium acetate (3.18 g, 32.37 mmol) were dissolved in 40 mL of 1,4-dioxane and reacted at 90°C overnight. Silica gel was directly added to the sample and purified by column chromatography to obtain compound 58B (3.2 g, 74.3%).

[1057] Ms m / z(ESI):400.3[M+H] +

[1058] Step 2: Synthesis of compound 58C

[1059] Compound 58B (3.2 g, 8.01 mmol), Pd(dppf)Cl2 (0.65 g, 0.8 mmol), intermediate A (4.03 g, 9.61 mmol) and potassium carbonate (2.21 g, 16.02 mmol) were dissolved in 40 mL of 1,4-dioxane and reacted at 80° C. overnight. Silica gel was directly added to stir the sample, and compound 58C (3.6 g, 79.5%) was obtained by column chromatography purification.

[1060] Ms m / z(ESI):565.2.1[M+H] +

[1061] Step 3: Synthesis of compound 58D

[1062] Compound 58C (1.2 g, 2.12 mmol), Pd(dppf)Cl2 (0.17 g, 0.21 mmol), intermediate 2 (0.83 g, 3.18 mmol) and potassium carbonate (0.88 g, 6.36 mmol) were dissolved in 20 mL of 1,4-dioxane and reacted overnight at 100° C. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to obtain compound 58D (0.89 g, 63.1%).

[1063] Ms m / z(ESI):664.3[M+H] +

[1064] Step 4: Synthesis of Compound 58E

[1065] Compound 58D (0.51 g, 0.77 mmol) and intermediate G (0.16 g, 0.92 mmol) were dissolved in 10 mL of dichloromethane, and N-methylimidazole (0.25 g, 3.08 mmol) was added. Then TCFH (0.43 g, 1.54 mmol) was added. After the addition was complete, the mixture was reacted at room temperature for 2 hours, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 58E (0.41 g, 65.4%).

[1066] Ms m / z(ESI):816.4[M+H] +

[1067] Step 5: Synthesis of Compound 58F

[1068] Compound 58E (0.10 g, 0.12 mmol) was dissolved in 1 ml of tetrahydrofuran, added to 1 mL of 4% sodium hydroxide methanol solution, stirred at room temperature for 1 hour, concentrated to remove the solvent, and the crude residue 58F was directly used in the next step.

[1069] Ms m / z(ESI):676.3[M+H] +

[1070] Step 6: Synthesis of Compound 58G

[1071] The crude compound 58F (0.083 g, 0.12 mmol) was dissolved in 3 mL of DCM, and 1 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature. The mixture was stirred for 2 hours, and a saturated sodium bicarbonate aqueous solution was added to adjust the pH to about 8. The mixture was concentrated, and a 5% methanol in dichloromethane solution was added to dissolve the mixture. The filtrate was collected by filtration and concentrated to obtain the crude compound 58G (65 mg), which was directly used for the next step.

[1072] Ms m / z(ESI):576.3[M+H] +

[1073] Step 7: Synthesis of Compound 58

[1074] Compound 58G (65 mg, 0.11 mmol) and intermediate C (50 mg, 0.17 mmol) were dissolved in 5 mL N,N-dimethylacetamide, glacial acetic acid (7 mg, 0.11 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Sodium triacetyl borohydride (47 mg, 0.22 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was purified by Pre-HPLC (instrument and preparation column: SHIMADZU LC-20AP was used to prepare the liquid phase, and the preparation column model was Phenomenex C18, 5 μm, inner diameter * length = 19 mm * 150 mm). Preparation method: The reaction solution was filtered with a 0.45 μm filter membrane to prepare a sample solution. Mobile phase system: acetonitrile / water (containing 10 Mm ammonium carbonate). Gradient elution method: Acetonitrile was gradiently eluted from 32% to 62% (elution time 15 min). After freeze-drying, compound 58 (6 mg, 6.17%) was obtained.

[1075] Ms m / z(ESI):861.9[M+H] +

[1076] 1 H NMR(400MHz,CD3OD)δ8.93(s,1H),8.30–8.25(m,1H),8.07–8.02(m,1H),8.00–7.95(m,1H),7.95– 7.91(m,1H),7.81–7.74(m,2H),7.48–7.45(m,1H),7.43–7.32(m,4H),5.52(q,1H),4.41–4.34(m, 2H),4.16–4.10(m,2H),3.90–3.82(m,2H),3.80–3.70(m,2H),3.28–3.19(m,4H),2.85–2.77(m,2H ),2.75–2.68(m,2H),2.65(s,3H),2.16–2.01(m,3H),1.65(d,3H),1.62–1.52(m,2H),1.42(s,9H).

[1077] Example 59: Synthesis of Compound 59

[1078]

[1079] Step 1: Synthesis of Compound 59A

[1080] Compound 58C (1.5 g, 2.65 mmol), Pd(dppf)Cl2 (0.22 g, 0.27 mmol), intermediate 1 (0.98 g, 3.97 mmol) and potassium carbonate (1.10 g, 7.95 mmol) were dissolved in 20 mL of 1,4-dioxane and reacted at 100° C. overnight. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to obtain compound 59A (0.63 g, 36.5%).

[1081] Ms m / z(ESI):650.2[M+H] +

[1082] Step 2: Synthesis of compound 59B

[1083] Compound 58D (0.60 g, 0.92 mmol) and intermediate B (0.19 g, 1.10 mmol) were dissolved in 10 mL of dichloromethane, and N-methylimidazole (0.30 g, 3.68 mmol) was added. Then TCFH (0.52 g, 1.84 mmol) was added. After the addition was complete, the mixture was reacted at room temperature for 2 hours, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound 59B (0.38 g, 51.3%).

[1084] Ms m / z(ESI):802.3[M+H] +

[1085] Step 3: Synthesis of Compound 59C

[1086] Compound 59B (0.20 g, 0.25 mmol) was dissolved in 2 ml of tetrahydrofuran, added to 2 mL of 4% sodium hydroxide methanol solution, stirred at room temperature for 1 hour, concentrated to remove the solvent, and the crude residue 59C was directly used in the next step.

[1087] Ms m / z(ESI):662.3[M+H] +

[1088] Step 4: Synthesis of compound 59D

[1089] The crude compound 59C (0.16 g, 0.24 mmol) was dissolved in 3 mL of DCM, and 2 mL of 1,4-dioxane hydrochloride solution was slowly added at room temperature, stirred for 2 hours, and saturated sodium bicarbonate aqueous solution was added to adjust the pH to about 8, concentrated, and 5% methanol in dichloromethane solution was added to dissolve, and the filtrate was collected by filtration. The filtrate was concentrated to obtain the crude compound 59D (100 mg), which was directly carried out to the next step.

[1090] Ms m / z(ESI):562.3[M+H] +

[1091] Step 5: Synthesis of compound 59

[1092] Compound 59D (100 mg, 0.18 mmol) and intermediate C (65 mg, 0.22 mmol) were dissolved in 5 mL N,N-dimethylacetamide, glacial acetic acid (11 mg, 0.18 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Sodium triacetyl borohydride (76 mg, 0.36 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was purified by Pre-HPLC (instrument and preparation column: SHIMADZU LC-20AP was used for preparation of liquid phase, and the preparation column model was Phenomenex C18, 5 μm, inner diameter * length = 19 mm * 150 mm). Preparation method: The reaction solution was filtered with a 0.45 μm filter membrane to prepare a sample solution. Mobile phase system: acetonitrile / water (containing 10 Mm ammonium carbonate). Gradient elution method: Acetonitrile was gradiently eluted from 27% to 55% (elution time 15 min). After freeze-drying, compound 59 (16 mg, 10.6%) was obtained.

[1093] Ms m / z(ESI):847.3[M+H] +

[1094] 1 H NMR(400MHz,DMSO-d6)δ12.68(s,1H),10.23(s,1H),9.48(t,1H),8.79(s,1H),8.35–8.30(m,1 H),8.14–8.08(m,2H),8.01–7.95(m,1H),7.66–7.60(m,1H),7.50–7.40(m,2H),7.17–7.11(m, 2H),6.99–6.91(m,2H),4.60–4.54(m,2H),4.29–4.14(m,2H),3.98–3.80(m,2H),3.75–3.64(m ,4H),3.11–2.97(m,2H),2.79–2.64(m,6H),1.90–1.79(m,3H),1.45(s,9H),1.36–1.22(m,2H).

[1095] Example 60: Synthesis of Compound 60

[1096]

[1097] Steps 1 to 4: Synthesis of intermediate 60D

[1098] Referring to the synthetic route and experimental operation method of compound 58, 200 mg of intermediate 60D was prepared.

[1099] Step 5: Synthesis of compound 9

[1100] Compound 60D (200 mg, 0.2 mmol) was dissolved in 3 ml of tetrahydrofuran, and 0.5 ml of tetrabutylammonium fluoride solution in tetrahydrofuran (1 M) was added thereto. The mixture was reacted at room temperature for 30 min. After the reaction solution was concentrated, the residue was purified twice by preparative HPLC to obtain compound 60 (64 mg, 37%).

[1101] Preparation method: Instrument: SHIMADZU LC-20AP; Chromatographic column: C18; Mobile phase: A is 10mmol / L ammonium bicarbonate aqueous solution; B is acetonitrile; Elution conditions: 50% to 70% B solution A gradient elution; Flow rate: 75mL / min; Column temperature: room temperature; Detection wavelength: 210&254nm;

[1102] LCMS m / z=879.4[M+H] +

[1103] 1 H NMR(400MHz,CD3OD)δ8.77(s,1H),8.06(d,1H),7.96–7.88(m,2H),7.67(d,1H),7.41(d,1H), 7.22–7.15(m,3H),7.01(d,2H),5.53(q,1H),4.22–4.13(m,2H),3.92–3.85(m,2H),3.83–3.76 (m,2H),3.75–3.67(m,2H),3.27–3.19(m,3H),3.10–3.03(m,2H),2.82–2.69(m,4H),2.59(s, 3H),2.57–2.51(m,2H),1.98–1.92(m,2H),1.90–1.78(m,1H),1.71–1.60(m,5H),1.41(s,9H).

[1104] Control compound 1:

[1105]

[1106] Biological test cases

[1107] 1. Cell proliferation inhibition experiment

[1108] When SU-DHL-4 cells grew to 5×10 6 Mino cells grew to 2×10 6When the number of cells is 20000 / mL, plate the cells. Use a pipette to mix the cells in the culture dish / bottle, transfer them to a 15mL (50mL) sterile centrifuge tube, centrifuge at 1500rpm for 3 minutes, take out the cells after centrifugation, and discard the supernatant. Add 5mL of culture medium to the centrifuge tube to resuspend the cells and count them. According to the counting results, dilute SU-DHL-4 cells to 20,000 / 90μL and Mino cells to 5,000 / 90μL, and plate the cells with a spray gun, 90μL per well. While plating, make sure to mix the cells in the sample slot evenly and mark the cell information on the 96-well plate.

[1109] SU-DHL-4 cells: P13I and test compound stock solution 10mM, initial dosing concentration 10000nM, 3-fold dilution 9 gradients. Compound concentrations: 10000, 3333.33, 1111.11, 370.37, 123.46, 41.15, 13.72, 4.57, 1.52nM. Dilution method: 5μL compound stock solution + 495μL culture medium in the first well, 80μL culture medium containing 1% DMSO + 40μL dilution solution in the previous well in the second to ninth wells.

[1110] Mino cells: P13I and test compound stock solution 10mM, initial dosing concentration 10000nM, 5-fold dilution 6 gradients. Dosing concentration: 10000, 2000, 400, 80, 16, 3.2nM. Dilution method: 5μL compound stock solution + 495μL culture medium in the first well, 80μL culture medium containing 1% DMSO + 20μL dilution solution in the previous well in the second to sixth wells.

[1111] Add 10 μL / well of compound to the 96-well plate with cells, set up 3 replicates for each concentration, and the last column is the DMSO solvent control group, and continue to culture at 37°C and 5% CO2 for 72 hours.

[1112] After 72 hours, 100 μL of detection reagent (Cell Viability Assay, Promega, G7573) was added to each well, mixed for 2 minutes, incubated at room temperature for 10 minutes, and the chemiluminescence readings were detected by a microplate reader.

[1113] Cell proliferation inhibition assay (IC 50 ): Use origin9.2 software to calculate the IC of the compound to inhibit cell proliferation 50 value.

[1114] Table 1 IC of Mino cell proliferation 50 value

[1115] Compound No. <![CDATA[IC 50 (nM)]]> Compound No. <![CDATA[IC 50 (nM)]]> Compound 1 A Compound 2 A Compound 3 A Compound 4 A Compound 5 A Compound 7 A Compound 8 A

[1116] A<1000nM

[1117] Conclusion: The compounds synthesized using the technology of the present invention, such as the compounds in the examples, have a good inhibitory effect on the proliferation of Mino cells (mantle cell lymphoma cells).

[1118] 2. TMD-8 cell proliferation inhibition activity test:

[1119] TMD-8 is a human lymphoma cell line that expresses BTK protein and is used to evaluate the efficacy of compounds. The culture medium of TMD-8 cells is RPMI-1640 + 10% FBS + 1% double antibody, and cultured in a 37°C, 5% CO2 incubator. Cells were plated in 96-well culture plates (Biosharp, BS-MP-96W), 3000 cells / well. After plating, different concentrations of compounds were added, with a final volume of 100 μL / well, and cultured in a 37°C, 5% CO2 incubator for 72 hours. After the culture was completed, 50 μL of detection solution ( Promega, G7573), mixed for 2 minutes, incubated at room temperature for 10 minutes, and the chemiluminescence reading was detected by an enzyme reader (Molecular Devices, SpectraMax Paradigm). The inhibition rate of the compound on cell proliferation was calculated according to formula (1), where RLU compound Read the compound wells, RLU control Read the value for the DMSO control well, RLU blank The data were analyzed using Graphpad Prism 8.0 software, and a 4-parameter equation was fitted to generate concentration response curves and calculate the IC of compounds for inhibiting cell proliferation. 50 value.

[1120] Inh%=100%-(RLU compound -RLU blank ) / (RLU control -RLU blank )*100% Formula (1)

[1121] Table 2 TMD8 cell proliferation inhibitory activity

[1122]

[1123]

[1124] A:<50nM

[1125] Conclusion: The compounds synthesized using the technology of the present invention, such as the compounds in the examples, have a good inhibitory effect on TMD-8 cell proliferation.

[1126] 3. Detection of BTK degradation in Mino cells

[1127] Mino is a human mantle cell lymphoma cell line purchased from ATCC. The culture conditions are: RPMI-1640 + 15% FBS + 1% double antibody, cultured at 37°C, 5% CO2 incubator. Cells were plated in 6-well plates, 5×10 5 / well. After plating, different concentrations of compounds were added and cultured in an incubator at 37°C and 5% CO2 for 6 hours. After the culture was completed, the cells were collected and lysed on ice for 15 minutes with RIPA lysis buffer (beyotime, Cat.P0013B). The cells were centrifuged at 12000 rpm and 4°C for 10 minutes to collect the supernatant protein samples. After protein quantification using a BCA kit (Beyotime, Cat.P0009), the protein was diluted to 0.2 mg / mL and the expression of BTK (CST, Cat.8547S) and the internal reference β-Actin (CST, Cat.3700S) was detected using an automatic protein blot quantitative analyzer (Proteinsimple). The relative peak area of ​​BTK was calculated using the "Compass for SW" software when the internal reference area was 10000. The degradation rate of BTK at different drug concentrations was calculated according to formula (1), where BTK treat is the relative peak area of ​​the drug-treated group, BTK solvent is the relative peak area of ​​the vehicle control group.

[1128] BTK Deg. % = 100% - (BTK treat / BTK solvent ×100%) Formula 2

[1129] Table 3 BTK degradation rate in Mino cells

[1130] Compound No. 100nM degradation rate 10nM degradation rate <![CDATA[DC 50 (nM)]]> Compound 1 A ND ND Compound 6 ND A A Compound 8 ND A ND Compound 22 A A A Compound 24 A A ND Compound 26 A A ND Compound 34 ND A A Compound 35 ND A ND Compound 37 A A A Compound 39 A A ND Compound 40 A ND ND Compound 41 ND A A Compound 44 ND A ND Compound 46 ND A ND Trifluoroacetate salt of compound 52 ND A ND Trifluoroacetate salt of compound 53 ND A ND Compound 54 ND A ND Compound 55 ND A ND Compound 57 ND A ND Compound 58 ND A ND Compound 59 ND A ND Compound 60 ND A ND

[1131] Degradation rate at 100nM: A>75%;

[1132] Degradation rate at 10 nM: A>50%;

[1133] DC50: A<10nM;

[1134] ND: Not detected.

[1135] Conclusion: The compounds synthesized using the technology of the present invention, such as the compounds in the examples, have good degradation activity on BTK protein in mino cells.

[1136] 4. Pharmacokinetics test in mice

[1137] Experimental animals: Male BALB / c mice, 20-25 g, 6 mice / compound, purchased from Chengdu Dashuo Experimental Animal Co., Ltd.

[1138] Experimental design: On the day of the experiment, 6 BALB / c mice / compounds were randomly divided into groups according to body weight. The mice were fasted but not watered for 12-14 hours one day before administration, and food was given 4 hours after administration.

[1139] Table 4 Dosage information

[1140]

[1141] Note: Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline;

[1142] Oral administration solvent: 5% DMSO + 5% Solutol + 10% PEG400 + 80% (20% SBE-CD)

[1143] (DMA: dimethylacetamide; DMSO: dimethyl sulfoxide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; PEG400: polyethylene glycol 400; SBE-β-CD: sulfobutyl-β-cyclodextrin;)

[1144] Before and after drug administration, 0.06 mL of blood was collected from the eye socket under isoflurane anesthesia, placed in an EDTAK2 centrifuge tube, and centrifuged at 5000 rpm at 4°C for 10 min to collect plasma. The blood collection time points for the intravenous group and the gavage group were: 0, 5, 15, 30 min, 1, 2, 4, 6, 8, 24 h. Before analysis and testing, all samples were stored at -80°C and quantitatively analyzed by LC-MS / MS.

[1145] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good oral absorption properties in mice.

[1146] 5. Pharmacokinetic Test in Rats

[1147] Experimental animals: Male SD rats, about 220 g, 6 to 8 weeks old, 6 rats / compound, purchased from Chengdu Dashuo Experimental Animal Co., Ltd.

[1148] Experimental design: On the day of the experiment, 6 SD rats / compound were randomly divided into groups according to body weight. The rats were fasted but not watered for 12-14 hours one day before administration, and were fed 4 hours after administration.

[1149] Table 5 Dosage information

[1150]

[1151] Note: Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline;

[1152] Oral administration solvent: 5% DMSO + 5% Solutol + 10% PEG400 + 80% (20% SBE-CD)

[1153] (DMA: dimethylacetamide; DMSO: dimethyl sulfoxide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; PEG400: polyethylene glycol 400; SBE-β-CD: sulfobutyl-β-cyclodextrin;)

[1154] Before and after drug administration, 0.10 mL of blood was collected from the eye socket under isoflurane anesthesia, placed in an EDTAK2 centrifuge tube, and centrifuged at 5000 rpm at 4°C for 10 min to collect plasma. The blood collection time points for the intravenous group and the gavage group were: 0, 5, 15, 30 min, 1, 2, 4, 6, 8, 24 h. Before analysis and testing, all samples were stored at -80°C and quantitatively analyzed by LC-MS / MS.

[1155] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good oral absorption properties in rats.

[1156] 6. Beagle dog pharmacokinetic test

[1157] Experimental animals: Male beagle dogs, about 8-11 kg, 5-6 per compound, purchased from Beijing Mas Biotechnology Co., Ltd.

[1158] Test method: On the test day, 5-6 beagle dogs / compound were randomly divided into groups according to body weight. The dogs were fasted but not watered for 12-14 hours one day before administration, and food was given 4 hours after administration.

[1159] Table 6 Dosage information

[1160]

[1161] Note: Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline;

[1162] Oral administration solvent: 5% DMSO + 5% Solutol + 10% PEG400 + 80% (20% SBE-CD)

[1163] (DMA: dimethylacetamide; DMSO: dimethyl sulfoxide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; PEG400: polyethylene glycol 400; SBE-β-CD: sulfobutyl-β-cyclodextrin;)

[1164] Before and after administration, 1 ml of blood was collected from the jugular vein or limb vein and placed in an EDTAK2 centrifuge tube. Centrifuge at 5000 rpm, 4°C for 10 min to collect plasma. The blood collection time points for the intravenous group and the gavage group in G1 and G2 groups were all: 0, 5, 15, 30 min, 1, 2, 4, 6, 8, 10, 12, 24 h, 48, 72 h. The blood collection time points for the intravenous group and the gavage group in G3 and G4 groups were all: 0, 5, 15, 30 min, 1, 2, 4, 6, 8, 10, 12, 24 h. Before analysis and testing, all samples were stored at -80°C and quantitatively analyzed by LC-MS / MS.

[1165] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good oral absorption properties in beagle dogs.

[1166] 7. Monkey Pharmacokinetic Test

[1167] Experimental animals: Male cynomolgus monkeys, 3-5 kg, 3-6 years old, 4-6 per compound. Purchased from Suzhou Xishan Biotechnology Co., Ltd.

[1168] Test method: On the test day, 4-6 monkeys / compound were randomly divided into groups according to body weight. The monkeys were fasted but not watered for 14-18 hours one day before administration and were fed 4 hours after administration.

[1169] Table 7 Dosage information

[1170]

[1171] Note: Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline;

[1172] Oral administration solvent: 5% DMSO + 5% Solutol + 10% PEG400 + 80% (20% SBE-CD)

[1173] (DMA: dimethylacetamide; DMSO: dimethyl sulfoxide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; PEG400: polyethylene glycol 400; SBE-β-CD: sulfobutyl-β-cyclodextrin;)

[1174] Before and after administration, 1.0 mL of blood was collected from the limb veins and placed in an EDTAK2 centrifuge tube. The blood was centrifuged at 5000 rpm and 4°C for 10 min to collect plasma. The blood collection time points for the intravenous group and the gavage group were: 0, 5 min, 15 min, 30 min, 1, 2, 4, 6, 8, 10, 12, 24 h. Before analysis and testing, all samples were stored at -80°C and quantitatively analyzed by LC-MS / MS.

[1175] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good oral absorption properties in monkeys.

[1176] 8. hERG potassium channel action test

[1177] Experimental platform: electrophysiological manual patch clamp system

[1178] Cell line: Chinese hamster ovary (CHO) cell line stably expressing hERG potassium channel

[1179] Experimental methods: CHO (Chinese Hamster Ovary) cells stably expressing hERG potassium channels were used to record hERG potassium channel currents using the whole-cell patch clamp technique at room temperature. The glass microelectrode was pulled from a glass electrode blank (BF150-86-10, Sutter) by a puller. The tip resistance after perfusion of the electrode solution was about 2-5 MΩ. The glass microelectrode was inserted into the amplifier probe to connect to the patch clamp amplifier. The clamping voltage and data recording were controlled and recorded by pClamp 10 software through a computer, with a sampling frequency of 10 kHz and a filter frequency of 2 kHz. After obtaining the whole-cell recording, the cell was clamped at -80 mV, and the step voltage to induce the hERG potassium current (I hERG) was given a 2-s depolarization voltage from -80 mV to +20 mV, then repolarized to -50 mV, and returned to -80 mV after 1 s. This voltage stimulus was given every 10 s, and the drug administration process was started after the hERG potassium current was determined to be stable (at least 1 minute). Compounds were administered for at least 1 min at each tested concentration, and at least 2 cells (n≥2) were tested at each concentration.

[1180] Data processing: pClamp 10, GraphPad Prism 5 and Excel software were used for data analysis. The degree of inhibition of hERG potassium current (peak value of hERG tail current induced at -50 mV) by different compound concentrations was calculated using the following formula:

[1181] Inhibition%=[1–(I / Io)]×100%

[1182] Wherein, Inhibition% represents the inhibition percentage of the compound on hERG potassium current, and I and Io represent the amplitude of hERG potassium current after and before drug addition, respectively.

[1183] Compound IC 50 The results were calculated using GraphPad Prism 5 software by fitting the following equation:

[1184] Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50-X)×HillSlope))

[1185] Among them, X is the Log value of the test sample detection concentration, Y is the inhibition percentage at the corresponding concentration, and Bottom and Top are the minimum and maximum inhibition percentages, respectively.

[1186] Conclusion: The compounds of the present invention, such as the compounds in the examples, have no significant hERG inhibitory activity.

[1187] 9. Human CD34+ hematopoietic stem cell proliferation inhibition experiment

[1188] Human CD34+Hematopoietic stem cells (TPCS, Cat.hmPB34-P-2CW) are CD34-positive stem cells obtained from human PBMC by immunomagnetic bead sorting. The culture conditions are: DPBS (Gibco, Cat.14190-144) + StemSpan SFEMII (STEMCELL, Cat.9655) + 1X StemSpan CD34+Expansion Supplement (STEMCELL, Cat.2691). First, 40nL of DMSO, positive reference Talazoparib or the compound to be tested were added to a 384-well plate (Corning, Cat.3764), and then the cell suspension was added, 400 cells / 40μl / well, so that the final concentration of each well was 0.1% DMSO, 3μM Talazoparib or different concentrations of compounds, centrifuged at room temperature for 1 minute at 1000rpm, and then cultured in a 37°C, 5% CO2 incubator for 7 days. After the incubation, 20 μL of CellTiter-Glo Reagent (Promega, Cat. G7573) was added directly to each well, centrifuged at 1000 rpm for 1 minute at room temperature, and then incubated in the dark for 20 minutes. After the incubation, the chemiluminescent signal CFU was read and recorded using the Envision multi-mode microplate reader (PerkinElmer, Cat. 2104). The cell proliferation inhibition rate of different concentrations of compounds was calculated according to formula (1), CFU high control is the average signal value of the DMSO group, CFU low control is the average signal value of the Talazoparib group, CFU compound The data processed according to formula (1) were used to fit the curve using XLfit or GraphPad Prism software with four parameters to calculate the concentration IC of the compound when the inhibition rate was 50%. 50 value.

[1189] Inhibiton % = (CFU high control-CFU compound ) / (CFU high control -CFU low control )×100%(Formula 1)

[1190] Table 8 Test results

[1191] Compound No. Inhibition rate % at 1uM drug concentration Compound 57 33.08% Compound 58 46.12% Compound 59 40.91% Compound 60 13.68% Control compound 1 87.71%

[1192] Conclusion: The compounds of the present invention, such as the example compounds, have a weaker inhibitory effect on the proliferation of human CD34+ hematopoietic stem cells. Compounds 57, 58, 59, and 60 have a weaker inhibitory effect on the proliferation of human CD34+ hematopoietic stem cells than the control compound 1 at a drug concentration of 1 uM.

Claims

1. A compound or a stereoisomer, tautomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, the compound being selected from the compounds represented by general formula (I), wherein: BLK(I); B is selected from L is selected from Its left side is connected to B and its right side is connected to K; K is selected from Q is selected from NR q CO、CONR q 、CO、NR q or key; B1 is selected from a 5-6 membered heterocyclic group; B4 is selected from phenyl, 5-6 membered heteroaryl, Benzo 5-membered heterocyclic group, benzo 6-membered heterocyclic group, pyrido 5-membered heterocyclic group, pyrido 6-membered heterocyclic group; Selected from aromatic or non-aromatic rings; W is selected from a 5-6 membered heterocyclic group; Z2 is selected from CH2, CH, NH or N; K1 is selected from phenyl, 5-6 membered heteroaryl, Benzo 5-membered heterocyclic group, benzo 6-membered heterocyclic group; Z3 is selected from CH2, CH, NH or N; L1 is selected from the group consisting of -Ak1-, -Cy1-, -Cy1-Ak1-, -Ak1-Cy1-, -Cy1-Ak1-Cy2-, -Cy1-Cy2-Ak1-, -Ak1-Cy1-Cy2-, -Cy1-Ak1-Cy2-Ak2-, -Ak1-Cy1-Ak2-Cy2-; Z1 is selected from N or CR k2 ; Ak1 and Ak2 are each independently selected from C 1-4 Alkylene, C 2-4 Alkenylene, C 2-4 Alkynylidene, O, NR L NR L CO, CO, wherein the alkylene, alkenylene, alkynylene is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group; R L is selected from H, methyl or ethyl; Cy1 and Cy2 are each independently selected from one of the following substituted or unsubstituted groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, phenyl, cyclopropyl-cyclopropyl, cyclopropyl-cyclobutyl, cyclopropyl-cyclopentyl, cyclopropyl-cyclohexyl, cyclobutyl-cyclobutyl, cyclobutyl-cyclopentyl, cyclobutyl-cyclohexyl, cyclopentyl-cyclopentyl, cyclopentyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclopentyl, cyclopentyl-cyclopentyl, cyclopentyl-cyclohexyl, cyclohex ...hexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohexyl-cyclohexyl, cyclohex cyclohexyl, cyclobutylspirocyclobutyl, cyclopropylspirocyclopentyl, cyclopropylspirocyclohexyl, cyclobutylspirocyclobutyl, cyclobutylspirocyclopentyl, cyclobutylspirocyclohexyl, cyclopentylspirocyclopentyl, cyclopentylspirocyclohexyl, cyclohexylspirocyclohexyl, cyclopropylazetidinyl, cyclopropylpyrrolidinyl, cyclopropylpiperidinyl, cyclobutylazetidinyl, cyclobutylpyrrolidinyl, cyclobutylpiperidinyl, cyclopentylazetidinyl, cyclopentyl ...propylazetidinyl, cyclopentylspirocyclohexyl, cyclopropylazetidinyl, cyclopropylpyrrolidinyl, cyclobutylpiperidinyl, cyclopentylazetidinyl, cyclopentylspirocyclohexyl, cyclopropylazetidinyl, cyclopropylpyrrolidinyl, cyclobutylpiperidinyl, cyclopentylazetidinyl, cyclopentylspirocyclohexyl, cyclopropylazetidinyl, cyclopropylpyrrolidinyl, cyclopropylpiperidinyl, cyclopropylspirocyclopentyl, cyclopentylspirocyclohexyl, cyclopropyl pyrrolidinyl, cyclopentylpiperidinyl, cyclohexylazetidinyl, cyclohexylpyrrolidinyl, cyclohexylpiperidinyl, azetidinylazetidinyl, azetidinylpyrrolidinyl, azetidinylpiperidinyl, pyrrolidinylazetidinyl, pyrrolidinylpyrrolidinyl, pyrrolidinylpiperidinyl, piperidinylazetidinyl, piperidinylpyrrolidinyl, piperidinylpiperidinyl, cyclobutylspiroazetidinyl, cyclobutylspiropyrrolidinyl, cyclo butylspiropiperidinyl, cyclopentylspiroazetidinyl, cyclopentylspiropyrrolidinyl, cyclopentylspiropiperidinyl, cyclohexylspiroazetidinyl, cyclohexylspiropyrrolidinyl, cyclohexylspiropiperidinyl, azetidinylspiroazetidinyl, azetidinylspiropyrrolidinyl, azetidinylspiropiperidinyl, pyrrolidinylspiroazetidinyl, pyrrolidinylspiropyrrolidinyl, pyrrolidinylspiropiperidinyl, piperidinylspiroazetidinyl, piperidinylspiropyrrolidinyl, piperidinylspiropiperidinyl, When substituted, it is optionally replaced by 1 to 4 atoms selected from deuterium, F, Cl, Br, I, OH, NH2, CONH2, COOH, CN, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group; R b1 , R b2 , R b3 , R b4 , R k1 , R k2 , R k3 , R bL , R q Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 4-6 membered carbocyclic group, 4-6 membered heterocyclic group, -OC 3-6 The alkyl and alkoxy, heterocyclic group, and carbocyclic group are optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 The alkylene group is substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group. b1 and b4 are each independently selected from 0, 1, 2, 3, 4, 5 or 6; b2 are each independently selected from 0, 1, 2, 3 or 4; b3 are each independently selected from 0, 1 or 2; p1 or p2 are each independently selected from 0, 1, 2, 3 or 4; The condition is, When K1 is selected from phenyl, pyridyl, benzopyrrolidinyl, B4 is selected from 8-10 membered bicyclic cycloalkyl or 12-15 membered tricyclic cycloalkyl; Alternatively, when B4 is selected from phenyl, pyridyl, pyrazolyl, thiazolyl, K1 is selected from 12-15 membered tricyclic annular groups.

2. The compound according to claim 1 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: B1 is selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl; B4 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, K1 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, Ak1 and Ak2 are each independently selected from methylene, ethylene, vinylene, and ethynylene, wherein the methylene, ethylene, vinylene, and ethynylene are optionally substituted by 1 to 4 selected from deuterium, F, Cl, Br, I, OH, NH2, COOH, CN, =O, 1 to 4 selected from deuterium, F, Cl, Br, I, OH, NH2, COOH, CN, =O, 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group; Cy1 and Cy2 are each independently selected from one of the following substituted or unsubstituted groups: When substituted, it is optionally replaced by 1 to 4 deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group; R b1 , R b2 , R b3 , R b4 , R k1 , R k2 , R k3 , R bL , R q each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl, cyclobutyl, phenyl, azetidinyl, oxetanyl, pyrrolidinyl, pyrrolyl, pyrazolyl, pyridinyl, -O-cyclopropyl, -O-cyclobutyl, -O-cyclopentyl, -O-cyclohexyl, -O-phenyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl, cyclobutyl, phenyl, azetidinyl, oxetanyl, pyrrolidinyl, pyrrolyl, pyrazolyl, pyridinyl is optionally substituted by 1 to 4 selected from deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 The alkylene group is substituted by a substituent of a 4- to 6-membered carbocyclic group or a 4- to 6-membered heterocyclic group.

3. The compound according to claim 2 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: L1 is selected from Q is selected from CONR q NR q CO、NR q or key; R b1 , R b2 , R b3 , R b4 , R k1 , R k2 Each is independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl; R k3 Each is independently selected from H, deuterium, and methyl; R q or R bL Each is independently selected from H, deuterium, and methyl.

4. The compound according to claim 3 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: B is selected from L is selected from one of the fragments shown in Table A; K is selected from 5. The compound according to claim 1 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: The compound of general formula (I) is selected from the compounds represented by general formula (III-1) or (III-2), B1 is selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl; B4 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, K1 is selected from phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, Z1 is selected from N or CH; L1 is selected from Q is selected from CONH, NHCO, NH or a bond; R b1 , R b2 , R b3 , R b4 , R k1 , R k2 Each is independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl; R bL Each is independently selected from H, deuterium, and methyl; b1, b4 are each independently selected from 0, 1, 2 or 3; b2 are each independently selected from 0, 1, 2 or 3; b3 are each independently selected from 0, 1 or 2; p1 and p2 are each independently selected from 0, 1, 2 or 3.

6. The compound according to claim 1 or its stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound represented by general formula (I), (II), (III-1) or (III-2) is selected from the compound represented by general formula (IV), wherein: R w Selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 4-membered carbocyclic group, 4-6-membered heterocyclic group; w is selected from 0, 1 or 2; s is selected from 0 or 1; B1, R b1 , R b2 , R b3 , R b4 , R k1 , R bL The definitions of , b1, b2, b3, b4, p1 or Z1 are the same as the corresponding definitions in any one of claims 1-5.

7. The compound according to claim 6 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: B1 is selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, furanyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl; R b1 , R b2 , R b3 , R b4 Each is independently selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropyloxy, cyclopropyl; R bL Each is independently selected from H, deuterium, and methyl; R w Selected from H, deuterium, F, Cl, Br, I, OH, =O, NH2, CN, CONH2, COOH, CF3, methyl, ethyl, methoxy, ethoxy, cyclopropyl; w is selected from 0, 1 or 2; s is selected from 0 or 1; b1, b4 are each independently selected from 0, 1 or 2; b2 are each independently selected from 0, 1 or 2; b3 are each independently selected from 0, 1 or 2; p1 is independently selected from 0, 1 or 2.

8. The compound according to claim 1 or its stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from the structures shown in Table E-1, Table E-1 9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition contains 1 to 1500 mg of a compound according to any one of claims 1 to 8 or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.

10. Use of the compound according to any one of claims 1 to 8 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal or the pharmaceutical composition according to claim 9 in the preparation of a medicament for inhibiting or degrading a disease associated with BTK, wherein the disease is preferably a tumor or an autoimmune disease, and the tumor is preferably a relapsed or refractory B-cell malignancy.

Citation Information

Cited By

  • BTK degrader and use thereof

    US12686684B2

  • Heteroaryl compound, preparation method therefor, and pharmaceutical use thereof

    WO2026012424A1

  • BTK degrader and use thereof

    WO2026021570A1

  • Heteroaryl compound, and preparation method therefor and pharmaceutical use thereof

    WO2026153486A1